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SUMMARY 
The  vast  majority  of  current  researches  involving  wound  healing  processes  have  been 
undertaken  utilising  animal  models  with  minimum  involvement  with  human  subjects. 
The  major  cellular  component  of  healing  after  neutrophils,  are  the  macrophages. 
This  thesis  examines  the  role  of  macrophages  in  wound  healing,  concentrating  on  the 
differences  in  the  subpopulation  of  wound  macrophages  in  acute  and  chronic  wounds. 
Examining  20  human  wound  bed  biopsies  (pilonidal  sinus  and  venous  leg  ulcers), 
significant  differences  were  observed  between  the  subpopulations  of  wound 
macrophages  in  acute  healing  and  chronic  non-healing  wounds.  The  results  exhibit 
that  within  the  acute  wound  there  is  an  accumulation  of  early  stage  macrophages 
(mean  20.8,  SD  8.6)  differentiating  from  monocytes  which  become  activated  and 
contribute  to  the  wound  healing  process.  There  being  few  early  stage  macrophages 
within  the  chronic  wound  (mean  10.4,  SD  6.7)  (p: 
50.01). 
Chronic  wounds  in 
comparison  demonstrated  a  significant  accumulation  of  tissue  macrophages  (mean 
34.0,  SD  10.5)  when  compared  to  acute  wounds  (mean  10.9,  SD  4.4)  with  limited 
wound  healing  (p<0.01). 
The  dermagraft  (DG)  study  comprising  of  53  patients,  showed  that  applying  a 
biologically  active  dressing  (1-12  dressings  over  12  weeks)  and  compression  to  the 
wound  bed,  exhibited  complete  closure  (76%)  or  reduction  in  the  size  of  the  wounds 
at  12  weeks,  compared  to  compression  alone.  Changes  in  the  extracelluar  components 
and  an  array  of  inflammatory  cells  and  cytokines  in  fifty  three  paired  wound  bed 
biopsies  (106)  with  and  without  DG  were  examined  at  week  0  and  week  6  of 
treatment. XVII 
On  histological  investigation,  DG  exhibited  an  increase  in  the  amount  of  collagen 
present  and  angiogenesis  in  the  wound  at  week  6  of  treatment. 
Although  there  were  no  significant  changes  in  the  lymphocyte  counts  in  response  to 
the  application  of  DG,  it  was  possible  to  demonstrate  a  significant  increase  in  the 
number  of  early  stage  macrophages  at  week  6  of  treatment  (p: 
50.05)  and  a  significant 
reduction  in  the  tissue  macrophage  counts,  at  week  6  of  treatment  (p_<0.05)  in  patients 
treated  with  4  pieces  of  DG. 
The  levels  of  different  cytokine  expression  within  the  wound  bed  at  week  6  exhibited 
some  changes  but  this  was  not  significant,  in  response  to  DG  treatment.  This  could  be 
to  the  possible  presence  of  proteinases  within  the  chronic  wound  bed  hydrolysing  the 
cytokines  produced  by  DG. 
From  the  results  attained,  it  was  able  to  conclude,  for  clinical  use  4  pieces  of  DG  at 
regular  dosing  intervals  were  sufficient  to  achieve  wound  contraction  or  closure.  This 
dose  regimen  has  now  been  taken  forward  for  further  pivotal  studies. 
This  thesis  thus  represents  some  of  the  first  evidence  in  human  tissue  that 
macrophages  may  play  a  role  in  wound  healing,  and  in  chronic  wounds,  a 
subpopulation  of  macrophages  can  be  modified  to  stimulate  these  wounds  towards 
healing. CHAPTER  ONE:  INTRODUCTION 2 
1.1  HISTORY  OF  WOUND  HEALING 
In  the  evolutionary  process,  humans  traded  the  slow  biological  sophistication  of 
regeneration,  seen  in  many  less  complex  organisms,  for  the  relatively  simple  and 
more  rapid  healing  of  wounds.  The  oldest  manuscripts  known  to  man  that  record  the 
care  and  treatment  of  wounds  dates  back  to  around  2200  BC,  in  the  form  of  clay 
tablets.  These  tablets  describe  the  three  healing  gestures  of  -  Washing  the  wound, 
Making  plasters,  and  Bandaging  the  wound. 
Throughout  the  ages,  a  variety  of  different  methods  and  substances  have  been  used  to 
treat  wounds.  Recipes  sometimes  consisted  of  dozens  of  different  ingredients,  mixed 
in  a  precise  manner,  and  often  requiring  the  assistance  of  a  priest,  magician  or 
apothecary. 
One  of  the  earliest  known  wound  care  products  was  beer!!  Wound  dressings,  often 
referred  to  as  plasters  were  designed  to  provide  protection  to  the  healing  wound  and  to 
absorb  exudates.  These  were  made  from  different  substances,  including  mud  or  clay, 
plants  and  herbs.  In  addition,  the  most  common  ingredient  used  in  plasters  was  oil. 
Ancient  Egyptians  were  the  first  to  document  wound  management  treatments.  (Sipos 
P  et  al.  2004)  From  the  Smith  and  Ebers  papyri,  dating  back  to  1650  BC  and  1550  BC, 
respectively,  it  can  be  shown  that  they  were  the  first  people  to  prepare  plasters  and 
apply  bandages,  including  the  application  of  more  ingenious  dressings  such  as  `goat 
dung  soaked  in  yeast  that  is  fermenting',  or  `a  frog  warmed  in  oil'!  However,  honey, 
grease,  resins  and  lint  were  the  more  common  components  of  Egyptian  plasters 
(Majno  G,  1975). 
The  Egyptians  were  also  known  to  use  meat  to  cover  wounds,  similar  to  the  way  pig 
skin,  or  allografts  are  used  today.  They  were  also  the  first  to  distinguish  between  what 3 
they  called  `bad'  or  `infected'  wounds,  and  `good'  or  `uninfected'  wounds.  The 
production  of  pus  was  considered  beneficial  to  healing  `sick'  wounds,  although  the 
scientific  basis  for  the  concept  of  infection  would  not  emerge  for  several  millennia. 
They  left  an  immense  influence  on  the  Greeks  and  Romans,  and  hence  the  Western 
world. 
The  Greeks  proceeded  to  improve  on  the  knowledge  of  the  Egyptians.  Hippocrates 
(460  -  375BC)  was  the  first  to  cleanse  the  wounds  with  wine  and  vinegar.  Wounds 
were  treated  with  applications  of  figs  and  brambles  in  an  attempt  to  alleviate  the 
symptoms  of  inflammation,  haemostasis  or gangrene.  The  Greeks  also  understood  the 
value  of  pressure  relief  at  the  ulcer  site  and  usually  recommended  that  the  patient 
stayed  off  their  feet  (Forrest  RD,  1982).  Hippocratic  physicians  believed  that  all 
diseases  including  wounds  could  be  cured  by  restoring  the  humoral  balance  or 
eliminating  the  `bad  humor'  by  blood  letting.  Blood  letting  in  an  attempt  to  heal 
wounds  was  practised  extensively,  as  the  physicians  believed  that  even  if  a  person 
died  during  blood  letting,  he  died  `healthy'.  They  also  developed  the  technique  of 
ligation  of  blood  vessels  and  hence  became  more  adventurous  in  blood  letting. 
The  cardinal  features  of  inflammation:  calor  (heat),  rubor  (redness),  tumour 
(swelling),  and  dolor  (pain),  was  not  described  until  Roman  times  by  Celsus.  (Rutkow 
IM,  1993,  Naylor  IL,  1999). 
With  the  fall  of  Rome,  the  Arabs  further  perfected  the  art  of  blood  letting,  but  it  was 
felt  that  as  the  sick  were  unclean,  blood  letting  should  be  performed  by  barbers  or 
surgeons  under  the  supervision  of  physicians. 
Wound  care  in  the  Middle  Ages  actually  regressed  with  the  loss  of  most  of  the  Greek 
and  Roman  writings. 4 
Theodoric  of  Bologna  (1205  -  1296),  who  trained  at  the  University  of  Bologna, 
believed  that  the  production  of  pus  in  a  wound  was  actually  deterimental  to  healing 
and  promoted  a  standardized  method  of  wound  healing  which  included  cleaning  the 
wound  with  acetic  acid,  removing  dead  tissue  by  debridement,  closing  the  wound  with 
stitches,  and  applying  a  bandage.  Unfortunately  this  practise  was  abandoned  after  the 
death  of  his  pupil,  the  French  surgeon  Henri  de  Mondeville.  This  was  mainly  due  to 
the  accusations  of  plagiarism  by  another  famous  French  surgeon,  Guy  de  Chauliac 
(Popp  AJ,  1995),  and  was  abandoned  for  700  years. 
The  next  milestone  in  wound  healing  occurred  during  the  time  of  Ambroise  Pare 
(1510  -  1590).  He  was  an  army  surgeon  during  the  reign  of  King  Henry  II  in  1552. 
He  developed  a  standard  method  of  managing  gunshot  wounds  which  involved 
treating  them  with  hot  oil  and  cauterisation.  During  a  particularly  bloody  battle  in 
1536,  Pare  ran  out  of  hot  oil  and  was  forced  to  find  and  alternative.  He  used  a  mixture 
of  turpentine,  rose  oil  and  egg  whites  to  treat  the  wounds  of  soldiers.  In  his  own  words 
he  wrote  " 
.... 
1  found  such  as  I  had  dressed  with  the  digestive  only,  free  from 
vehemence  of  pain  to  have  good  rest,  and  that  their  wounds  were  not  inflamed,  ... 
but 
on  the  contrary  the  others  that  were  burnt  with  scalding  oil  were  feverish,  tormented 
with  much  pain,  and  the  parts  about  their  wounds  were  swollen" 
From  then  on,  he  vowed  never  to  treat  injuries  with  hot  oil. 
Cle  de  Villars  in  1740,  noted  that  wounds  left  open  to  the  environment  healed  less 
effectively  than  wounds  that  were  closed.  This  resulted  in  the  birth  of  occlusive 
dressings.  John  Hunter  (1728  -  1793),  the  `Father  of  Modem  Surgery',  was  one  of  the 
dominant  personalities  in  medicine.  He  noted  that  wounds  were  able  to  heal  under  a 
scab  when  left  undressed  (Ellis  H.  2001).  He  was  also  the  first  surgeon  to  advocate 
the  laying  open  of  narrow  wounds  and  sinus  tracts,  which  subsequently  healed  by 5 
secondary  intention.  He  distinguished  `adhesive'  inflammation  which  was  amenable 
to  surgical  intervention,  from  `suppurative'  inflammation,  which  delayed  healing, 
demonstrating  this  was  related  to  infection  (Leaper  DJ,  1998). 
In  the  nineteenth  century  major  advances  in  wound  healing  were  developed.  The 
cause  of  infection  and  its  prevention  was  recognised.  Progress  was  made  towards  the 
greater  understanding  of  the  cellular  processes  that  contributed  to  the  inflammatory 
course  of  wound  healing.  Joseph  Lister  (1827  -  1912)  realised  that  bacteria  were  the 
cause  of  wound  sepsis.  However  he  realised  that  Louis  Pasteur's  (1822  -  1895) 
method  of  destroying  bacteria  by  heating  could  not  be  applied  to  living  tissue.  In  his 
search  to  find  an  antiseptic  he  tried  many  chemicals  and  discovered  that  carbolic  acid 
or  phenol  were  most  effective  (Toledo  -  Pereyra  LH  and  Toledo  MM.  1976).  The 
results  were  dramatic,  and  within  a  few  years,  the  antiseptic  techniques  of  soaking  the 
surgical  instruments,  sutures  and  lint  dressings,  and  spraying  the  operating  theatre 
with  carbolic  spray  became  standard  procedure.  Other  pioneers  in  the  evolution  of 
asepsis  were  Ernst  von  Berman  (1836  -  1907),  who  developed  the  method  of  steam 
sterilisation  of  instruments,  and  William  Stewart  Halsted  (1852  -  1922)  who  actively 
promoted  the  use  of  rubber  gloves  in  surgery  to  improve  wound  hygiene  (Rutkow  IM, 
1993). 
Understanding  the  biology  of  wound  healing  began  with  Virchow  when  he  published 
a  book  in  1860  -  `Cellular  pathology  as  based  on  physiological  and  pathological 
history'  and  Elie  Metchnikoff's  `The  identification  ofphagocytic  cells  in  the  process 
of  wound  healing',  in  1890.  With  the  invention  of  the  electron  microscope  in  1930, 
the  cellular  and  humoral  immunology  of  wound  healing  grew  rapidly. 
The  first  researcher  to  study  the  biology  of  wound  healing  in  humans  was  Shattuck  W 
Hartwell  in  1926,  who  presented  his  thesis,  entitled  `The  mechanism  of  healing  in 6 
human  wounds'  to  the  University  of  Minnesota  (Butterworth  RJ,  1992).  Hartwell 
suggested  that  human  wound  healing  differed  from  studies  performed  on  other  animal 
species. 
He  looked  at  850  sections  from  a  variety  of  wounds  in  experimental  animals  such  as 
rabbits,  dogs,  pigs,  pigeons  and  human. 
He  found  that  although  epithelialisation  was  similar  in  the  human  and  animal  wounds, 
the  fibrous  healing  differed  consistently  in  several  ways: 
-  There  were  more  mitoses  apparent  in  the  animal  wounds 
-  In  the  human,  fat  was  considered  the  main  locus  of  healing,  but  the  pattern 
of  subcutaneous  fat  in  animals  was  different 
-  Animal  wounds  had  larger  vessels  than  human 
-  The  morphology  of  cells  identified  by  Hartwell  as  macrophages  was 
different 
He  thus  concluded  that  `the  conception  of  healing  in  human  tissue  should  rightly  be 
built  up  from  observations  of  human  tissues.  The  fact  that  the  histological  findings  are 
different  in  animals  from  those  in  human  wounds  merely  emphasizes  this  fact.  The 
differences  serve  to  explain  why  the  description  of  wound  healing  in  human  surgical 
wound  does  not  correspond  more  closely  to  the  descriptions  of  healing  given  in  text 
books  which  are  based  on  experimental  wounds  in  animals.  (Hartwell  SW  1930, 
Hartwell  SW.  1955). 
The  last  few  years  have  seen  a  number  of  interesting  discoveries  in  the  understanding 
of  the  healing  process,  mostly  based  on  animal  wound  models.  From  being  merely 
scavenger  cells  to  `mop  up'  debris  in  wounded  tissue,  macrophages  have  been  shown 7 
to  play  an  integral  role  in  the  process  of  wound  healing,  ranging  from  wound 
debridement  to  matrix  formation  (Leibovitch  SJ  and  Ross  R,  1975).  Efforts  have  also 
been  made  to  stimulate  healing  in  recalcitrant  wounds  by  the  application  of  topical 
growth  factors  such  as  Platelet  Derived  Growth  Factor  (PDGF)  (Pierce  GF  et  al,  1995, 
Krupski  WC  et  al,  1991),  autografts  in  the  form  of  a  split  thickness  skin  graft,  and  the 
use  of  tissue  engineered  products  (Schonfield  WH  et  al,  2000,  Leigh  IM  and  Purkis 
PE,  1986). 
The  future  of  wound  healing  no  doubt  holds  exciting  new  discoveries. 8 
1.2  OVERVIEW  OF  WOUND  HEALING 
Cutaneous  injury  can  take  many  forms  -  surgical  trauma,  bums,  and  immunologically 
mediated  injury  are  just  a  few  in  a  long  list.  Despite  this,  the  general  sequence  of 
events  that  are  activated  in  response  to  injury  and  subsequent  wound  repair  show 
striking  similarity  irrespective  of  the  initial  insult.  Cutaneous  wound  healing  proceeds 
as  a  fibroproliferative  response  that  develops  into  a  fibrotic  scar.  Thus  the  organ  is 
patched  rather  than  restored.  Wound  repair  is  not  a  simple  linear  process  in  which 
growth  factors  released  by  physiologistic  events  activate  inflammation,  parenchymal 
cell  proliferation  and  migration,  but  rather  it  is  an  integration  of  dynamic  interactive 
processes  involving  soluble  mediators,  formed  blood  elements,  extracellular  matrix 
and  parenchymal  cells.  Alterations  in  the  normal  healing  processes  produce  less 
desirable  outcomes.  A  plethora  of  pathobiological  states  such  as  diabetes  (Falanga  V. 
2005),  venous  hypertension  (Trent  JT  et  al.  2005),  poor  arterial  perfusion  (Mogford 
JE  et  al.  2003),  or  persistent  infection  (Singer  AJ  and  McLain  SA.  2002)  can  lead  to 
non-healing  wounds  or excessive  scarring 
In  humans,  apart  from  in  the  foetus,  this  sequence  of  events  eventually  leads  to  the 
formation  of  scar  tissue  as  a  result  of  abundant  collagen  synthesis  by  fibroblasts  that 
proliferate  and  differentiate  within  the  provisional  matrix.  Only  hepatic  and  epithelial 
cells  (in  superficial  damage)  are  capable  of  complete  regeneration. 
The  wound  repair  processes  follow  a  specific  time  sequence  and  can  be  temporarily 
categorised  into  three  major  events:  Inflammation,  Tissue  formation,  and  Tissue 
remodelling  (Howes  EZ  et  al.,  1929).  The  three  phases  are  not  mutually  exclusive,  but 
overlap  in  the  time  sequence  of  wound  healing.  (Figure  1-1) 9 
Figure  1-1  Progression  of  Wound  Healing  -  key  events 
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In  chronic  non-healing  wounds  encountered  in  patients  with  venous  leg  ulcers,  this 
sequence  of  events  is  arrested  in  one  or  more  stages  of  this  progression  with  the 
development  of  a  `progression-regression'  pattern  of  healing.  Although  there  is 
significant  knowledge  of  the  processes  involved  in  normal  healing,  the  disordered 
processes  involved  in  the  biology  of  abnormal  wounds  are  more  difficult  to  explain. 
1.2.1  The  Inflammatory  Phase 
This  phase  commences  within  minutes  of  tissue  injury  resulting  in  the  arrest  of 
bleeding,  clearing  the  wounded  tissue  of  bacteria,  removal  of  non-viable  tissue  or 
debris,  and  the  formation  of  a  fibrin  rich  clot.  The  clot  has  a  dual  function  of  plugging 10 
severed  vessels  and  acting  as  a  scaffold  for  cells,  thus  preparing  the  wounded  tissue 
for  the  next  phase. 
1.2.1.1  Blood  Coagulation 
This  phase  is  stimulated  by  tissue  injury.  Damage  to  the  blood  vessels  causes 
extravasation  of  blood  constituents  into  the  injured  tissue,  which  stimulates  clotting. 
Blood  clotting  results  from  the  surface  activation  of  Hageman  factor,  tissue  pro- 
coagulant  factor  from  damaged  endothelial  cells,  surface  membrane  coagulation 
factors  and  phospholipids  expressed  on  activated  platelets  and  endothelial  cells  (Furie 
B  and  Furie  BC,  1988). 
The  critical  event  in  all  cases  is  the  availability  of  a  surface  of  damaged  blood  vessel 
wall,  with  its  exposed  collagen,  to  promote  adsorption  and  activation  of  coagulation 
pro-enzymes  such  as  fibinogen  and  prothrombin.  Minute  spontaneous  activation  of 
these  proenzymes  also  contribute  to  the  positive  feedback  loop  and  results  in  the 
amplification  of  the  physiological  response  of  coagulation. 
The  coagulation  cascade  ceases  with  the  production  of  prostacyclin,  which  inhibits 
platelet  aggregation,  antithombin  III  binding  to  thrombin  and  thus  inhibiting  its 
activity,  protein  Ca  potent  enzyme  that  degrades  coagulation  factors  V  and  VIII,  and 
the  release  of  plasminogen  activator  which  initiates  clot  lysis  by  converting 
plasminogen  to  plasmin  (Moncada  S  et  al.,  1976,  Stern  DM  et  al.,  1985,  Loedam  JA 
et  al.,  1988,  LoskutoffDJ  and  Edgington  TS,  1977). 
Haemostasis  is  the  main  function  of  blood  coagulation,  but  the  clot,  which  is  rich  in 
fibrin,  also  provides  a  matrix  scaffold  for  the  recruitment  of  cells  to  the  injured  area. 11 
Specifically  the  fibrin  acts  as  a  provisional  matrix  for  the  influx  of  monocytes  (Lanir 
N  et  al.,  1988)  and  fibroblasts  (Brown  LF  et  al.,  1993b) 
1.2.1.2  Platelets 
These  are  found  in  the  intravascular  space  in  an  inert  form.  Haemostasis  is  dependent 
on  platelet  adhesion  and  aggregation.  The  platelets  adhere  to  the  damaged  interstitial 
connective  tissue  and  then  aggregate.  During  aggregation,  they  become  activated 
secreting  multiple  mediators,  including  fibrinogen,  fibronectin,  thrombospondin  and 
von  Willebrand  factor  VIII,  amongst  others.  Fibrinogen,  fibronectin,  and 
thrombospondin  act  as  ligands  for  platelet  aggregration  and  platelet  fibrinogen  is  also 
converted  to  insoluble  fibrin  which  adds  to  the  fibrin  clot.  (Ginsberg  MH  et  al.,  1988). 
Platelets  also  release  chemotactic  factors  for  blood  leucocytes,  (Weksler  BB,  1992) 
growth  factors  such  as  platelet-derived  growth  factor  (PDGF),  (Ross  RR  and  Raines 
EW,  1990)  and  transforming  growth  factor-alpha  and  beta  (TGFa  and  ß)  (Demyk  R, 
1988,  Sporn  MB  and  Roberts  AM,  1992)  which  regulates  the  formation  of  new  tissue. 12 
1.2.1.3  Neutrophils 
Neutrophils  and  monocytes  enter  the  wounded  tissue  at  the  same  time  (usually  within 
hours  after  injury),  but  because  of  the  greater  number  of  neutrophils  in  the  general 
circulation,  they  tend  to  be  the  predominant  cell  type  in  the  early  phase  of 
inflammation.  They  are  chemotactically  attracted  to  the  injured  tissue  by  fibrin 
degradation  products,  such  as  fibrinopeptides  cleaved  from  fibringen,  C5a  from  the 
activated  classical  or  alternative  complement  cascades,  leukotriene  B4  released  from 
activated  neutrophils,  formyl  methionyl  peptides  from  bacterial  proteins  and  PDGF 
from  platelets  (Williams  TJ,  1988). 
Activated  neutrophils  also  release  elastase  and  collagenase,  which  facilitate  cell 
penetration  through  vessel  basement  membranes  (Tonnesen  MG  et  al,  1988).  At  the 
wound  site  they  destroy  contaminating  bacteria  by  phagocytosis  and  subsequent 
enzymatic  and  oxygen  radical  mechanism  (Klebanoff  SJ,  1992).  If  wound 
contamination  is  minimal,  neutrophil  infiltration  ceases  within  a  few  days.  Early  stage 
macrophages  are  also  armed  with  collagenases  which  facilitate  the  debridement  of 
non  -  viable  tissue  (Campbell  EJ  et  al.,  1987). 
1.2.1.4  Monocytes 
The  accumulation  of  monocytes  at  the  site  of  injury  persists  by  selective  monocyte 
chemoattractants.  These  include  fragments  of  collagen  (Postlethwaite  AE  and  Kang 
AH,  1976),  elastin  (Senior  RM  et  al.,  1980),  fibronectin  (Clark  RAF,  1988), 
enzymatically  active  thrombin  (Bar-Shavit  R  et  al.,  1983),  and  TGFß  (Wahl  SM  et  al., 13 
1987).  A  detailed  review  of  the  role  of  monocytes  and  macrophages  will  be  discussed 
in  later  chapters. 
1.2.2  The  Proliferative  Phase 
This  phase  commences  at  about  the  second  day  of  injury  and  lasts  about  four  weeks  in 
normal  healing  wounds.  During  this  phase,  there  is  a  marked  influx  of  macrophages 
and  fibroblasts  into  the  wound  along  the  fibrin  scaffold  laying  down  a  variety  of 
substances  including  hyaluronic  acid,  chronditin-4-sulphate,  dermatan  sulphate, 
heparan  sulphate  constituting  the  amorphous  ground  substance  within  the  wound. 
There  is  also  an  increased  synthesis  of  collagen.  This  increases  the  tensile  strength  of 
the  wound. 
1.2.2.1  Granulation  Tissue 
During  the  early  phase  of  cutaneous  wound  repair,  new  stroma,  often  called 
granulation  tissue,  begins  to  form  approximately  four  to  five  days  after  injury. 
Granulation  tissue  consists  of  a  dense  population  of  inflammatory  cells,  fibroblasts 
and  new  blood  vessels  embedded  in  a  loose  matrix  of  collagen,  fibronectin  and 
hyaluronic  acid.  The  large  number  of  new  capillary  loops  on  the  surface  of  the 
granulation  tissue  creates  a  granular  appearance,  hence  its  name. 
This  is  sometimes  referred  to  as  the  proliferative  phase  of  wound  healing.  In  this 
phase  the  formation  of  new  blood  vessels  -Angiogenesis,  and  the  laying  down  of  the 
extracellular  matrix  and  collagen-fibroplasia  are  the  major  events.  The  granulation 
tissue  restores  the  soft  tissue  defect  by  creating  new  connective  tissue  and  blood 14 
vessels,  which  forms  a  scaffolding  for  the  migration  of  epithelial  cells  (Martin  P, 
1997,  Witte  M  and  Barbul  A,  1997). 
In  healthy  wounds  granulation  tissue  appears  as  a  firm,  pink  tissue.  It  is  the 
prerequisite  to  re-epithelialisation.  Overgranulation  observed  in  patients  with  chronic 
wounds  is  thought  to  be  due  to  defective  signaling  or  a  result  of  infection,  thus 
preventing  re-epithelialisation. 
1.2.2.2  Angiogenesis 
This  term  was  first  used  by  Hertig  in  1935  to  describe  new  blood  vessel  formation  in 
the  placenta,  and  it  has  been  extensively  studied  in  chick  chorioallantoic  membrane 
and  the  cornea  by  Folkman  and  Shing  (Folkman  J  and  Shing  T,  1992).  Angiogenesis 
in  'the  healing  wound  usually  starts  at  the  same  time  as  fibroplasia  and  is  an  essential 
part  of  wound  healing.  A  number  of  experimental  systems,  such  as  the  rabbit  ear 
chamber,  corneal  and  chorioallantoic  models  (Folkman  J  and  Klagsburn  M,  1987), 
have  been  used  to  study  the  cellular  sequence  of  events  in  the  process  of 
neovascularisation,  but  the  regulators  of  these  processes  are  still  poorly  understood. 
The  process  begins  with  the  disruption  of  the  basement  membrane  of  the  parent  vessel 
by  specific  proteases  probably  released  by  endothelial  cells.  These  proteases  also 
breakdown  the  adjacent  extra  cellular  matrix  (Rifkin  BD  et  al.,  1982,  Magnatti  P  et 
al.,  1989).  This  creates  tissue  defects  that  facilitate  the  formation  of  capillary  sprouts 
that  form  the  basis  of  capillary  plexuses  (Folkman  J,  1982). 
Cellular  proliferation  occurs  in  the  endothelial  cells  remaining  within  the  parent 
vessel,  which  then  migrate  in  continuity  with  the  lead  cells.  The  capillary  sprouts  link 
up  to  form  loops  through  which  blood  begins  to  flow.  The  process  of  budding  repeats 15 
itself  from  the  new  vessels  forming  a  plexus,  supplying  nutrients  and  oxygen  to  the 
wounded  tissue. 
Angiogenesis  is  regulated  by  a  complex  interplay  between  the  hypoxic  environment, 
and  growth  factors  such  as  basic  fibroblast  growth  factor  (bFGF)  platelet  derived 
growth  factor  (PDGF),  vascular  endothelial  growth  factor  (VEGF).  (Tonnesen  MG  et 
al.,  2000) 
1.2.2.3  Fibroplasia  -  matrix  deposition  and  collagen  synthesis 
Clot  formation,  during  the  inflammatory  phase  provides  the  initial  fibrin  matrix  to 
support  cell  migration.  Under  the  influence  of  platelets  and  macrophages,  secreting 
PDGF  and  TGF(3  in  the  injured  tissue,  fibroblasts  enter  the  wound  environment  and 
undergo  a  series  of  changes  (Seppa  HEJ  et  al.,  1982,  Postlewaite  AE  et  al.,  1987). 
Moving  into  a  cross-linked  fibrin  blood  clot  needs  the  activity  of  a  proteolytic  system 
that  can  cleave  a  path  for  the  migration.  A  variety  of  fibroblast-derived  enzymes  and 
serum  derived  plasmin,  including  plasminogen  activator,  interstitial  collagenases 
[Matrix  metalloproteinase  1(MMP-1)],  gelatinises  [MMP-2]  and  stromelysin  [MMP- 
3]  aid  the  migrating  fibroblasts  (Grant  GA  et  at.,  1987,  Saus  J  et  al.,  1988,  Stetler- 
Stevenson  WG  et  al.,  1989).  The  endoplasmic  reticulum  and  golgi  apparatus  retract  to 
a  perinuclear  position  within  the  fibroblast.  This  is followed  by  the  formation  of  loose 
extra  cellular  matrix  composed  of  fibronectin.  (Grinnell  F  et  al.,  1981). 
Under  the  influence  of  TGF-ß  the  fibroblasts  change  their  phenotypic  composition 
and  increase  collagen  production  (Ignotz  RA  and  Massague  J,  1986).  Once  abundant 
collagen  matrix  is  deposited  into  the  wound,  fibroblasts  cease  collagen  production 
despite  the  continuing  expression  of  TGF-ß.  Grinnell  in  1994  has  demonstrated  that 16 
the  collagen  matrix  itself  can  suppress  both  fibroblast  proliferation  and  collagen 
production  (Grinnell  F,  1994).  It  has  been  found  that  many  fibroblasts  in  a  10-day 
healing  wound  develop  pyknotic  nuclei,  thus  resulting  in  apoptosis  (programmed  cell 
death),  but  the  triggers  for  wound  fibroblast  apoptosis  has  not  been  elucidated 
(Williams  GT,  1991).  This  converts  a  fibroblast-rich  granulation  tissue  to  a  relatively 
acellular  scar.  From  this  one  can  appreciate  that  fibroplasia  in  wound  repair  is  tightly 
regulated  and  when  this  regulation  is  disrupted,  excessive  scarring  may  occur  such  as 
in  keloid  formation  and  scleroderma. 
1.2.2.4  Epithelialisation 
Rapid  re-establishment  of  any  epithelial  barrier  decreases  significant  morbidity.  One 
or  two  days  after  injury,  epithelial  cells  at  the  wound  margin  begin  to  proliferate.  The 
epithelial  cells  undergo  marked  phenotypic  changes,  which  include  retraction  of  intra- 
cellular  tonofilaments,  dissolution  of  most  inter-cellular  desmosomes  and  the 
formation  of  peripheral  cytoplasmic  actin  filaments  which  aid  their  mobility 
(Gabbiani  G  et  al.,  1978).  Desmosomes  are  structures  that  interlink  epithelial  cells 
thus  providing  strength  to  the  epithelium.  The  binding  between  the  epidermis  and  the 
dermis  is  also  lost.  This  allows  wound  epidermal  cells  to  extend  pseudopodia  from 
their  free  basolateral  edge  and  move  into  the  wound.  Migrating  wound  epidermal  cells 
do  not  contain  the  keratin  proteins  that  are  found  in  mature  stratified  epidermis  or  the 
matrix  protein  flaggrin,  in  which  the  keratin  are  embedded.  Cells  in  all  layers  of  the 
migrating  tip  contain  the  type  of  keratin  that  is  normally  found  in  the  basal  layer  of 
the  stratified  epidermis  (Mansbridge  JN  and  Knapp  AM,  1987). 17 
The  stimulus  for  these  changes  are  unknown,  however  it  has  been  postulated  that  the 
lack  of  neighbouring  cell  contact  may  be  the  stimulus  for  both  epithelial  migration 
and  proliferation,  similar  to  the  way  re-endothelialisation  occurs  in  large  blood  vessels 
after  intimal  damage  (Heimark  RL  and  Schwartz  SM,  1988).  Growth  factors  such  as 
epidermal  growth  factor  family  [EGF],  transforming  growth  factor  a  [TGFa],  and 
fibroblast  growth  factor  family  [FGF]  may  also  play  a  role  in  the  migration  of 
keratinocytes  (Clark  RAF,  1996). 
Migrating  keratinocytes  dissect  through  the  wound,  breaking  down  slough  and  debris 
by  secreting  collagenases  and  plasminogen  activators  (Woodley  DT  et  al.,  1986, 
Grondahl-Hansen  J  et  al.,  1988). 
Once  keratinocytes  have  migrated  over  the  provisional  matrix,  there  is  re- 
establishment  of  the  elements  of  the  basement  membrane.  These  include  collagen  type 
IV,  heparan  sulphate  and  the  attachment  factor  laminin.  The  components  of  epidermal 
intracellular  junctions,  desmosomes  and  hemi-desmosomes  are  assembled,  and  the 
anchoring  fibrils  are  replaced.  The  epidermis  then  enters  a  regenerative  phase  in 
which  a  mature  stratum  corneum  is  produced  and  is  anchored  to  the  underlying 
neodermis  through  type  VII  collagen  (Gipson  IK  et  al.,  1988). 
If  the  wound  is  superficial,  there  is  preservation  of  epidermal  appendages  such  as 
eccrine  sweat  glands,  sebaceous  glands,  and  hair  follicles,  these  become  the  major 
source  of  epidermal  cells,  a  principle  utilised  in  the  healing  of  donor  sites  after 
harvesting  a  split  thickness  skin  graft  (Glat  PM  and  Longaker  MT,  1997). 18 
U.  3  The  Maturation  Phase 
1.2.3.1  Tissue  remodelling 
The  final  phase  of  wound  healing  is  an  ill-defined  overlapping  phase  that  begins  at  the 
time  of  matrix  deposition  in  the  wound  and  persists  for  many  years  after  wound 
closure  by  the  epithelium.  By  observing  the  strength  of  dermal  scars-  in  animal  models. 
with  time  from  injury,  it  can  be  seen  that  the  initial  deposition  of  collagen  fibres  are 
random,.,  but  soon  align  perpendicular  to  the  wound  providing  strength  to  the  scar 
tissue.  (Ehrlich  HP.,  1998).  There  is.  also  a  change  in  the  composition  of  the  collagen 
bundles  as  the  scar  tissue  matures.  Early  collagen,  known  as  type  III  collagen,  makes 
upr  30%  of  the-  granulation-  tissue;  and  contributes  little  to  the--wound's  tensile  strength 
(Kurkinen  M  et  al.,  1980).  As  the  collagen  matures,  type  III  collagen  is  replaced  by 
type  I  collagen.  Therefore  there  exists  a  simultaneous  process.  of  matrix  '  breakdown 
and  synthesis.  Fibroblasts  are  responsible  in  the  regulation  of  these  dual  processes,  by 
producing  the  extracellular  components  and  MMPs,  which  are  responsible  for  the 
degradation  of  the  matrix  (Mast  BA  and  Shultz  G.,  1996).  During  this  process  the  scar 
gains  tensile  strength,  but  only  approaches  80%  of  the  tensile  strength  of  unwounded 
tissue.  (Lindblad  WJ;  1998) 
Imbalance  in  matrix  synthesis  and  breakdown  results  in  abnormal  -wound  healing. 
This  is  seen  in  hypertrophic  scars,  keloid  formation,  and  non  healing  chronic  wounds. 19 
13  THE  EXTRACELLULAR  MATRIX  IN  WOUND  HEALING 
In  acute  wounds  granulation  tissue  forms  in  an  orderly  sequence,  initially  this  consists 
of  fibronectin,  hyaluronic  acid,  then  collagen  type  III  and  finally  collagen  type  I  as 
highlighted  in  the  previous  section. 
1.3.1  Fibronectin 
Fibronectin.  is.  a.  multidomain,  multifunctional  cell  adhesion  protein  found  in  blood 
and  in  a  variety  of  tissue  extracellular  matrices  (Hynes  RO,  1990).  It  fibrillar 
glycoprotein  of  440kDa  and  -is  -a  key  component  of  the  provisional  matrix  in  the  early 
stages  of  wound  repair.  Fibroblasts,  macrophages,  endothelial  cells  and  keratinocytes 
are  known  to  secrete  fibronectin  (Colvin  RB  et  al.,  1979,  Brown  LF  et  al.,  1993a, 
Kubo-M  et  al.,  1984) 
Fibronectin  is  present  in  the  initial  clot  with  fibrin  and  acts  as  a  stimulus  for  its  own 
production.  by  fibroblasts,,  macrophages,.  endothelial.  cells  and  keratinocytes,.  via  a 
positive  feedback  system.  It  has  several  roles  during  the  wound.  heal.  ing  process.  Jt 
acts  as  a  chemotactic  factor  for  peripheral  blood  monocytes,  as  a  non-specific  opsonic 
enhancer,  is  ehemotactic  for  cell  movement,  provides  a  substratum  for  cell  attachment 
and  new  matrix  deposition  (Brotchie  H  and  Wakefield  D,  1990). 
Monocytes,  are  attracted  to  fibronectin  or  proteolytic  fragments  of  fibronectin 
containing  `cell  binding'  domains  (Norris  DA  et  al.,  -1982,  Akiyama  SK-et-al.,  1994). 
This  results  in  an  accumulation  of  monocytes  at  the  site  of  wounding  (Senior  RM  et 
al.,  1980). 20 
Fibronectin  and  it's  fragments  also  stimulate  fibroblast  and  endothelial  cell 
-movement,  but  at  present.  it  is  unclear  whether  this  movement  is  secondary  to 
chemotaxis  (cells  migrating.  in.  response  to  a  fluid  phase  chemical  gradient)  or 
haptotaxis  (cells  migrating-  in-  response  to-  a  semi-solid  surface  -bound  chemical 
gradient  (Postlethwaite-AE  et  al.;  198  1,  -Bowersox  JC  and  Sorgente  N,  -1982). 
Tissue  debris,  such  denatured  collagen  in  wounds  when  coated  with  fibronectin 
appears  to  be  ingested  by  macrophages  (Martin  DE  et  al.,  1988,  Van  de  Water  III  L  et 
al.,  1981).  Here  fibronectin  functions  as  a  opsoniser  for  more  effective  clearance  of 
small  particles  from  the  wounded  tissue  by  macrophages,  fibroblasts  and  epidermal 
cells  (Gudewicz  PW  et  al.,  1980,  Grinnell  F  et  al.,  1981,  Takahima  A  and  Grinnell  F, 
1985). 
Fibronectin  provides  a  scaffold  for  the  assembly  of  collagen  matrix.  This  is  evidenced 
by  the  fact  that  its  appearance  in  the  wound  precedes  collagen  deposition,  and 
preventing  or  disrupting.  the  fibronectin  matrix  results  in  the  disruption  of  the  collagen 
matrix  (Welch  MP  et  al.,  1990,  Keski  Oja  T  et  al.,  1981). 
1.3.2  Hyaluronic  Acid  (HA) 
I 
Hyaluronic  acid  is  a  linear  polysaccharide  consisting  of  alternating  units  of  N-acetyl 
glucosamine  and  D-glucouronic  acid,  giving  a-molecular  weight  of  between  100  and 
5000  kDa  (Manuskiatti  W  and  Maibach  HI,  1996).  HA  is  synthesised  at  the  cell 
membrane  and  is  particularly  abundant  around  fibroblasts  and  other  mesenchymal 
cells,  where  HA  chain  elongation  occurs  by  membrane  linked  enzyme,  HA  synthase 
(Prehm  P,  1983),  unlike  other  polysaccharides-  which  are  synthesized  in  the  smooth 
endoplasmic  reticulum  of  cells. 21 
It  is  an  important  component  of  the  early  stages  of  wound  healing.  It  has  been 
demonstrated  that  wounded  tissues  express  higher  levels  of  _HA  . 
than  non-wounded 
tissues,  but  levels  fall  off  after  about  day  5  (Bronson  RE.  et  aL,.  t9&7).  Hk  levels-  are 
raised  in  foetal  wounds  and  it  has  been  suggested  that  these  high  levels  may  be  one  of 
the  mechanisms  for  scar  less  wound  healing-observed  in  foetuses  (Adzick  NS  et  al., 
1985b,  Boyce  DE  et  al.,  1997,  Krummel  TM  et  al.,  1987) 
HA  is  a  very  hydrophilic  molecule,  therefore  it  creates  a  highly  porous  network  into 
which  cells  such  as  fibroblasts  migrate.  The  cells.  then  degrade  the  matrix,  the 
degradation  products  of  HA  have  been  observed  to  be  potent  stimulators  of 
angiogenesis  -(Lees  VC  et  al.,  1995,  -Mast  BA  and  Haynes  JH  et  al.,  1992b). 
In  the  foetus,  the  less  resistant  HA-rich  matrix.  could  allow  faster.  cell  infiltration  into 
the  wound  site,  enhance  cell  proliferation,  and  influence,  the  amount  and  type  of 
collagen  deposited,  the  nature  of  the  fibrils  formed,  thus  resulting  in  a  more  reticular 
pattern  of  collagen  deposition.  This  may  result  in  the  scarless  wound  healing  observed 
in  the  foetus. 
In  the  -adult,  as  -the  wound  matures,  levels  of  HA  -declines,  -and  levels  of  other 
extracellular  matrix  proteoglycans  such  as  chrondrotin-4-sulphate  and  dermatan 
sulphate  increase  to  take  its  place  (McCallion  RL  and  Ferguson  MWJ,  1996). 22 
1.3.3  Collagen 
This  is  a  generic  term  for  a  family  of  closely  related  triple  helical  glycoproteins  found 
in  the  extracellular  matrix.  About  nineteen  distinct  collagen  types  have  so  far  been 
categorised,  and  additional  types  are  continuously  been  discovered  (Gordon  MK  et 
al.,  1992,  Myers  JC  et  al.,  1994).  They  make  up  25  -  30%  of  the  body  protein. 
Collagen  type  I  is  the  commonest,  constituting  90%  of  the  total  body  collagen.  Each 
collagen  type  is  made  up  of  three  polypeptide  a-chains,  coiled  into  a  left  hand  helix 
with  the  amino  acid  glycine  at  each  turn,  then  twisted  around  each  other  into  a  left 
hand  super  helix  (Stryer  L,  1981). 
There  are  nine  collagen  types,  which  are  known  to  be  important  in  the  reparative 
process  of  wound  healing:  type  I,  III,  IV,  V,  VI,  VII,  XII,  XIV,  XVII.  The  function  of 
the  more  recently  described  collagen  in  cutaneous  healing  remains  unclear.  The  more 
important  ones,  are  types  I,  III,  IV,  VII.. 
Type  I  collagen  is  the  major  constituent  of  fibrous  connective  tissue,  skin,  tendon 
ligaments  and  bone.  Early  wounds  however,  as  previously  stated,  contain  relatively 
more  type  III  collagen  (Kurkinen  M  et  al.,  1980),  which  is  replaced  by  type  I  collagen 
as  the  wound  matures.  Type  IV  collagen  forms  the  scaffolding  of  the  basement 
membrane,  and  Type  VII  collagen  forms  an  essential  component  of  the  anchoring 
fibrils  and  hemidesmosomes.  These  link  the  epithelium  to  the  underlying  connective 
tissue,  and  defects  in  type  VII  collagen  has  been  linked  to  the  blistering  skin  disease  - 
Epidermolysis  bullosa  (Burckner-Tuderman  L,  1993). 
Collagen  is  degraded  in  the  wound  environment  by  the  by-products  of  bacteria  and 
proteases  acting  as  chemotactic  agents  for  fibroblasts,  neutrophils,  and  granulocytes. 23 
These  cells  in  turn  release  proteases  and  cytokines  regulating  the  various  phases  of 
wound  healing  (Postlethwaite  AE  et  al.,  1978,  Werb  Z  and  Gordon  S,  1975). 
Thus  wound  repair,  in  the  extracellular  matrix  may  induce  changes  in  cell  phenotype 
that  in  turn  may  induce  matrix  modification,  creating  a  chain  reaction  until  tissue 
stabilisation  is  achieved. 
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1.4  CYTOKINES 
Cytokines  are  regulatory  proteins  and  encompasses  those  families  that  are  commonly 
referred  to  as  growth  factors,  colony  stimulating  factors,  interleukins,  lymphokines, 
monokines,  and  interferons.  The  array  of  names  for  cytokines  has  risen  because 
several  different  investigators  discovered  these  regulatory  proteins  in  different 
inflammatory  and  non-inflammatory  cells,  and  the  term  cytokine  is  the  most  general 
definition.  This  definition  is  not  restricted  to  the  immunohaemopoietic  system  (Cohen 
S  et  al.,  1974).  Cytokines  are  secreted  from  various  cells  in  the  tissue  and  act  locally 
in  an  autocrine  (affecting  the  same  cells  that  produce  them),  paracrine  (acting  on 
adjacent  cells)  or  endocrine  (acting  on  distant  cells)  way  to  control  cell  viability, 
proliferation,  differentiation  and  death  (Metcalf  D,  1992)  (Figure  1-2) 25 
Figure  1-2  Mechanism  of  Cytokine  Activity 
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Although  the  specific  pathways,  reactions,  and  functions  vary  for  each  cytokine,  these 
processes  are  similar  enough  to  be  generalised  in  the  following  way.  Activity  is 26 
initiated  when  a  cytokine  binds  to  specific,  high  affinity  receptors  on  the  cell 
membrane,  followed  by  signal  transduction  (Trippel  SB  et  al.,  1996).  (Figure  1-3) 
Figure  1-3  Cytokine  Signal  Transduction  Pathway 
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Most  growth  factors  are  associated  with  a  cytoplasmic  kinase,  which  initiates  a  series 
of  intracellular  alterations,  eventually  leading  to  phosphorylation  of  proteins  within 
the  nucleus  of  the  cell  necessary  for  gene  expression.  The  end  result  is  increased 27 
protein  synthesis,  changes  in  cellular  activity,  and/or  proliferation  of  cells 
(Greenhaigh  DG,  1996,  Bennett  NT  and  Schultz  GS,  1993). 
The  cell  surface  receptors  to  which  cytokines  bind  to  are  multimeric  complexes. 
Binding  activates  various  signal  transduction  pathways  within  the  cell  and  result  in  an 
appropriate  biological  response  in  the  target  tissue  (Dy  M  et  al.,  1999). 
Cytokines  are  secreted  in  very  small  quantities  and  often  directional  to  the  responder 
cells  i.  e  they  act  along  a  chemotactic  gradient  (Poo  WJ  et  al.,  1988).  Macrophages 
play  multiple  roles  in  both  the  degradative  and  reparative  phases  of  wound  healing. 
They  regulate  the  various  phases  of  wound  healing  by  producing  an  array  of 
cytokines. 
1.4.1  Tumour  Necrosis  factor  (TNFa) 
This  cytokine  has  been  called  Cachectin,  Macrophage  cytotoxin,  Necrosin,  Cytotoxin, 
Haemorrhagic  factor,  Macrophage  cytotoxic  factor,  and  Differentiating  inducing 
factors  (Aggarwal  BB,  1992). 
It  is  a  l7kDa  protein  with  157  amino  acids.  It  is  primarily  produced  by  macrophages 
in  response  to  bacteria,  viruses,  mycoplasma,  immune  complexes,  other  cytokines 
such  as  Interleukin  1,  Interleukin  2,  Interferon  y,  tumour  cells,  Complement  5a, 
protein  kinase  C  activators,  and  platelet  activating  factor  (Spriggs  DR  et  al.,  1992). 
The  production  of  this  cytokine  is  tightly  regulated,  being  suppressed  by 
Dexamethasone,  Prostaglandin  E2,  Transforming  growth  factor  ß,  Cyclosporin  A, 
Interleukin  4,  and  Interleukin  6. 
In  vitro,  TNFa  inhibits  the  proliferation  of  certain  tumour  cells,  stimulates  the 
proliferation  of  fibroblasts,  induces  endothelial  cell  adhesion  molecules,  induces  the 28 
production  of  plasminogen  activator  plasminogen  inhibitor,  activates  neutrophils, 
allows  differentiation  of  myeloid  cells,  and  induces  the  production  of  other 
cytokines.  (Nacy  CA  et  al.,  1991) 
In  vivo,  it  is  crucial  in  initiating  the  immune  cascade  during  the  host  response  to  injury 
or  bacteria.  TNFa  is  involved  in  the  recruitment  and  maturation  of  the  cellular 
component  of  inflammation,  which  includes  the  up-regulation  of  cell-surface  adhesion 
molecules  that  plays  a  vital  role  in  the  immune  cell  to  endothelium  interaction,  thus 
facilitating  neutrophil  chemotaxis  (Omann  GM  and  Hinshaw  DB,  1997,  Moser  R  et 
al.,  1989). 
Its  main  effects  include  haemostasis,  increased  vascular  permeability  and 
proliferation.  It  also  promotes  many  cellular  metabolic  events  that  increase  the  supply 
of  nutrient  substrates  and  acute-phase  protein  synthesis  essential  for  wound  healing 
(Fong  Y  and  Lowry  SF,  1996). 
1.4.2  Interleukin-1  (IL-1) 
This  family  of  cytokines  comprises  of  a,  and  ß,  subgroups.  They  have  been  referred 
to  as  Catabolin,  Endogenous  pyrogen,  Osteoclast  activating  factor,  Lymphocyte 
activating  factor,  Leucocyte  endogenous  mediator,  Fibroblast  activating  factor,  and  B 
cell  activating  factor. 
The  main  source  of  IL-I  production  are  cells  of  the  monocyte  -  macrophage  lineage, 
namely  activated  macrophages,  secreting  IL-1  ß,  and  human  keratinocytes 
predominantly  secretes  IL-la,  although  most  cell  types  have  the  potential  to  produce 
this  cytokine  (Mizutani  H  et  al.,  1991).  IL-la  is  a  l7kDa  protein  made  up  of  159 
amino  acids,  and  IL-10  is  a  17kDa  protein  made  up  of  153  amino  acids.  IL-1 29 
production  is  induced  by  a  wide  range  of  stimulants  including  bacterial  products 
(eg.  lipopolysaccarides  from  bacterial  cell  walls),  complement  components,  other 
cytokines  such  as  TNF,  IFNy,  GM-CSF,  and  IL-I  itself.  The  synthesis  of  IL-I  is 
inhibited  by  Prostaglandins,  and  Glucocorticoids  (Shaw  RJ  et  al.,  1990,  Shaw  RJ  et 
al.,  1991,  Muller  K  et  al.,  1988). 
IL-1  can  affect  a  wide  range  of  target  cells  and  organs.  It  has  been  described  as 
playing  a  central  role  in  the  effector  phase  of  the  immune  and  inflammatory  responses 
(Dower  SK  et  al.,  1992a,  Dinarello  CA,  1991,  Oppenheim  JJ  et  al.,  1986).  IL-1  also 
exerts  its  effects  by  inducing  the  production  of  secondary  cytokines  such  as  IL-6, 
Colony  stimulating  factors  and  other  chemokines  (Raines  EW  et  al.,  1989, 
Qwarnstrom  EE  et  al.,  1993). 
IL-I  activates  endothelial  cells  in  a  pro-inflammatory,  and  pro-thrombotic  way.  This 
induces  the  production  of  tissue  factor  and  platelet  activating  factor,  down  regulating 
the  proteins  C-dependent  anti-coagulation  pathway  and  the  inhibition  of  thrombus 
dissolution. 
In  the  acute  inflammatory  phase  of  wound  healing,  the  main  biological  activity  of  IL- 
1  is  to  stimulate  T-helper  cells  which  are  then  induced  to  secrete  IL-2  and  to  express 
IL-2  receptors  on  their  surface.  They  also  induce  the  production  of  acute  phase 
proteins  such  as  C-reactive  protein,  which  has  a  role  in  the  protection  and  antitoxic 
effects  of  the  invading  infection.  IL-i  also  acts  directly  on  B-cells  in  promoting  their 
proliferation  and  synthesis  of  immunogloblins  (West  MA,  1990).  The  production  of 
collagenase  and  metalloproteinases  is induced  by  IL-1,  which  also  stimulates 
fibrobaists  to  proliferate  and  synthesize  collagen.  Hence  IL-1  may  play  a  role  in  the 
remodeling  phase  of  wounds. 30 
1.4.3  Vascular  Endothelial  Growth  Factor  (VEGF) 
Vascular  endothelial  growth  factor  (VEGF)  is  an  endothelial  cell-specific  mitogen 
that  has  the  ability  to  promote  angiogenesis.  It  is  a  glycoprotein  weighing  45000  kDA 
and  exists  as  four  isomers  ranging  from  121  to  206  amino  acids  (Leung  DW  et  al., 
1989,  Houck  KA  et  al.,  1991). 
The  main  function  of  VEGF  is  to  promote  the  proliferation  of  vascular  endothelial 
cells  in  both  small  and  large  vessels  at  dosages  of  ED50  2-  110pM  (Ferrara  N  and 
Henzel  WJ,  1989,  Plouet  J  et  al,  1994).  In  higher  doses  (ED50  300  -  500pM),  VEGF 
seems  to  induce  monocyte  chemotaxis  by  increasing  the  permeability  of  blood 
vessels.  This  was  demonstrated  by  Connolly  et  al.  in  1989,  (Connolly  DT  et  al., 
1989,  ) 
1.4.4  Transforming  Growth  Factor  P  (TGFß) 
This  is  a  general  name  for  a  family  of  naturally  occurring  polypeptides,  which  have 
multiple  regulatory  effects  on  cell  proliferation  and  differentiation.  (Cox  D,  1995) 
Three  isoforms  exist  in  mammals  -  designated  TGF(31,  TGF02,  and  TGF03. 
TGF31  was  originally  purified  from  blood  platelets,  and  TGF02  was  purified  from 
bone  marrow.  The  biologically  active  TGFß  is  a  25  kDa  disulphide-linked  homodimer 
polypeptide  chain  (Gitelman  SE  and  Derynck  R,  1994). 
All  TGFßs  have  receptors  on  virtually  every  cell  in  the  body.  TGFß  is  chemotactic  for 
macrophages,  induces  procollagen  type  I  and  fibronectin,  and  inhibits 
metalloproteinases  (Overall  CM  et  al.,  1991).  The  presence  of  TGFf  results  in  an 31 
increased  deposition  of  collagen  in  cutaneous  wounds  (Pierce  GF  et  al.,  1992, 
Quaglino  D  et  al.,  1990)  and  has  been  shown  to  accelerate  normal  wound  healing  in  a 
rat  model  (Martin  P  et  al.,  1992).  Administration  of  TGF(31  prior  to  wounding  has 
also  been  demonstrated  to  accelerate  healing.  (Beck  LS  et  al.,  1993) 
Although  TGF03  has  similar  biological  activities  as  its  isoforms,  it  is  probably  more 
potent  than  TGFß  1  or  TGF02  in  stimulating  neovascularisation,  (Cox  D.  1995)  but 
unlike  the  other  forms,  TGF03  has  shown  to  reduce  scar  formation  in  rat  incisional 
model  and  may  have  a  role  in  the  management  of  hypertrophic  and  keloid  scars. 
(Shah  M  et  al.,  1992) 
1.4.5  Basic  Fibroblast  Growth  Factor  (bFGF) 
This  family  consists  of  at  least  nine  homologous  polypeptides.  The  most  researched  is 
the  basic  FGF  (bFGF)  which  is  a  18kDa  heparin-binding,  single  chain  polypeptide. 
However,  22  -  25kDa  bFGF  have  also  been  isolated,  but  their  functions  are  yet  to  be 
determined  (Prats  H,  et  al.,  1989).  It  exhibits  angiogenic  effects  by  stimulating 
endothelial  and  smooth  muscle  cells.  Inducing  proliferation  of  epithelial  cells  and 
fibroblasts  (Montansano  R  et  al.,  1994). 
bFGF  is  a  146  amino  acid  polypeptide.  An  important  characteristic  of  bFGF  is  its 
ability  to  bind  to  heparin  and  heparan  sulphate  which  protects  it  from  heat,  and 
proteolytic  degradation.  This  also  increases  the  affinity  of  FGFs  to  bind  to  receptors 
on  migrating  and  proliferating  epidermal  cells  and  hair  follicle  keratinocytes  adjacent 
to  the  wound  edge  by  2-3  fold.  (Rapraeger  AC  et  al.,  1991) 32 
It  has  been  demonstrated  that  bFGF  increases  granulation  tissue  in  excisional  wounds, 
but  is  sensitive  to  the  partial  pressure  of  02  in  the  wound  environment,  as  its  effects 
are  reduced  or  inhibited  in  ischaemic  wounds.  (Mustoe  TA  et  al.,  1991,  Pierce  GF  et 
al.,  1992,  Mustoe  TA  et  al.,  1994) 33 
1.5  MACROPHAGES  IN  WOUND  HEALING 
The  term  `Macrophage'  was  first  coined  by  Metchnikoff  in  1884,  which  literally 
means  big  eater,  when  he  demonstrated  that  rabbit  and  human  leukocytes  can  engulf 
various  bacteria,  a  process  he  called  phagocytosis.  In  contrast,  he  called  other 
phagocytic  cells  blood  microcytes,  later  to  be  called  polymorphonuclear  leukocytes 
and  granulocytes  (Van  Furth  R  et  al.,  1972).  The  role  of  humoral  factors  in  the 
phagocytic  process  was  not  appreciated  until  1903,  when  Almroth  Wright  first 
demonstrated  that  humoral  factors  called  opsonins  were  essential  for  phagocytosis  of 
bacteria  (Van  Furth  R,  1992). 
As  previously  described,  the  inflammatory  phase  of  wound  healing  begins  minutes 
after  injury.  The  first  type  of  cells  to  be  attracted  and  mobilised  at  the  site  of  injury  are 
the  neutrophils.  These  increase  rapidly  reaching  a  peak  at  24  -  48  hours.  It  has  been 
observed  that  depletion  of  circulating  neutrophils  in  guinea  pigs,  has  no  significant 
effect  on  healing  of  experimentally  induced  wounds,  and  thus  does  not  seem  to  play 
an  essential  role  in  the  process  of  wound  healing  (Simpson  DM  and  Ross  R,  1971, 
1972). 
Monocytes  emigrate  into  the  injured  tissue  at  about  the  same  time  as  neutrophils,  but 
as  neutrophils  are  abundant  in  the  circulation,  they  are  the  predominant  cell  type  for 
the  first  few  days  after  injury.  As  discussed  previously  in  1.2,  monocyte  influx  into 
the  wound  environment  is  stimulated  by  selective  chemoattractants,  such  as  fragments 
of  collagen,  elastin,  fibronectin,  enzymatically  active  thrombin  and  TGFß  There  they 
differentiate  into  macrophages.  It  used  to  be  thought  that  the  main  functions  of  these 
macrophages  are  to  remove  and  degrade  injured  tissue  debris.  However  in  1975, 
Leibovitch  and  Ross,  demonstrated  that  the  combined  depletion  of  circulating 34 
monocytes  and  tissue  macrophages  in  guinea  pigs,  resulted  in  severe  retardation  of 
tissue  debridement  and  a  marked  delay  in  fibroblast  proliferation  and  collagen 
deposition  (Leibovitch  SJ  and  Ross  R,  1975).  This  indicated  for  the  first  time  that 
macrophages  play  a  vital  role  in  the  orchestration  and  execution  of  both  the 
degradative  and  the  reparative  phase  of  wound  healing.  Hunt  et  at,  in  1984 
demonstrated  that  wound  inflammatory  cells  harvested  from  subcutaneous  wounds 
stimulated  angiogenesis,  fibroplasia,  and  collagen  synthesis  in  the  cornea  of  rabbits 
compared  to  controls  and  concluded  that  wound  macrophages  released  substances  that 
caused  these  responses  (Hunt  TK  et  al.,  1984).  Reduced  oxygen  tension  (hypoxia  of  5 
-  SOmmHg)  and  high  lactate  concentration  (10  -  15mM)  have  been  shown  to 
stimulate  macrophages  to  produce  growth  factors  that  result  in  angiogenesis,  thereby 
initiating  neovascularisation  in  the  wound  space  (Hunt  TK  et  al.,  2000). 
Macrophages  therefore  seem  to  regulate  the  inflammatory  and  the  reparative  phases 
of  wound  healing  in  animal  models.  The  understanding  of  the  role  of  macrophages  in 
human  wound  healing  will  be  discussed  in  this  thesis. 
1.5.1  The  monocyte  -Genesis  and  Differentiation 
Monocytes  are  derived  from  a  pleuripotential  stem  cell,  which  are  thought  to  reside  in 
the  bone  marrow  and  differentiate  into  lymphoid  stem  cells,  myeloid  stem  cells  or 
replicate  into  pleuripotential  stem  cells.  The  myeloid  cell  line  gives  rise  to  progenitor 
cells  of  the  of  the  megakaryocytic,  erythroid  and  the  granulo  -  monocytic  cell  lines  in 
response  to  Interleukin-1  (IL-1),  Interleukin-3  (IL-3)  and  Interleukin-6  (IL-6)  (Ogawa 
M,  1993).  In  response  to  specific  growth  factors  such  as  the  granulocyte-macrophage 
colony  stimulating  factor  (GM-CSF)  and  macrophage  colony  stimulating  factor(M- 35 
CSF)  the  granulo  -  monocytic  cells  give  rise  to  neutrophils  and  monoblasts 
(monocyte  precursor  cells).  The  first  cells  of  the  monocyte  -macrophage  system  that 
can  be  detected  in  the  blood  are  the  promonocytes.  The  maturation  of  these  cells  to 
monocytes  require  the  presence  of  M-CSF.  Monocytes  are  different  from  their 
precursors  due  to  their  inability  to  replicate,  and  develop  most  of  the  lysosomal 
system-which  enhances  phagocytic  activity  (Hamilton  JA,  1993). 
The  monocytes  then  leave  the  bone  marrow  and  travel  to  the  injured  tissue  via  the 
blood  stream.  They  move  into  the  injured  tissue  via  a  chemotactic  response  to  tissue 
hypoxia,  degradation  products  resulting  from  the  injured  tissue  and  neutrophils. 
(Postlethwaite  AE  and  Kang  AH,  1976.  Clark  RAF  et  al.,  1988,  Wolpe  SD  and 
Cerami  A,  1989)  Entering  the  tissue,  they  differentiate  to  macrophages.  They  undergo 
further  development  by  growing,  increasing  their  lysosomal  contents,  increasing  the 
number  and  size  of  their  mitochondria.  This  is  in  preparation  for  increased  energy 
expenditure,  production  of  various  cytokines  and  growth  factors.  However,  the 
mechanisms  responsible  for  driving  the  differentiation  remain  elusive.  Several  serum 
constituents  have  been  implicated,  including  la,  25-dihydroxyvitamin  D3  (Proveddini 
DM  et  al,  1986)  and  fibronectin  (Wright  SD  et  al,  1983).  The  fibronectin  theory  stems 
from  the  observation  that  circulating  blood  monocytes  have  a  fibronectin  receptor,  the 
P1  integrin.  Binding  of  fibronectin  stimulates  a  host  of  changes  within  the  monocyte 
including,  the  phagocytosis,  and  secretion  of  plasminogen  activator  and  elastase, 
functions  associaied  with  inflammatory  macrophages  (Hosein  B  et  al.,  1985).  The 
story  however  is  not  fully  understood,  as  it  is  possible  that  other  cytokines  in  the 
wound  environment  may  influence  monocyte  differentiation  in  an  autocrine  or 
paracrine  fashion.  It  may  therefore  be  the  result  of  a  combined  stimulation. 36 
1.5.2  Monocyte  Influx  vs.  Local  Production 
Several  investigations  have  shown  that  resident  tissue  macrophages  have  the  ability  to 
replicate  in  situ,  and  there  is  an  argument  that  circulating  blood  monocytes  may  not  be 
required  to  replenish  the  tissue  macrophages.  This  however  depends  on  the  type  of 
tissue.  Pulmonary  macrophages  for  example  have  been  shown  to  proliferate  locally. 
Systemic  hydrocortisone  administration  or  bone  marrow  irradiation  seems  to  have 
little  effect  on  the  concentration  of  the  alveolar  macrophage  population  and  local 
irradiation  of  the  thorax  seems  to  deplete  the  alveolar  macrophage  population  (Lin  H 
et  al.,  1982,  Sawyer  RT  et  al.,  1982,  Tarling  JD  and  Coggle  JE,  1982). 
Skin  contains  very  few  macrophages,  but  during  inflammmation,  the  numbers 
increase  dramatically.  Experiments  by  Leibovitch  and  Ross  in  1975,  seems  to  suggest 
that  macrophages  found  in  the  tissue  are  derived  from  blood  monocytes.  This 
suggestion  is  also  backed  up  observations  made  by  Stewart  et  al.,  in  1981.  By 
observing  the  sex  chromosome  markers  of  macrophages  emigrating  from  explants  of 
a  5-day  skin  wound  in  a  girl  who  recently  received  a  bone  graft  transplant  from  her 
brother,  it  was  found  that  the  macrophages  bore  the  karyotype  of  the  donor  ie.  The 
macrophages  had  the  male  XY  chromosomes  (Leibovitch  SJ  and  Ross  R,  1975, 
Stewart  RJ  et  al.,  1981). 
1.5.3  Phenotypic  Differentiation 
Macrophages  contribute  to  a  variety  of  functions  in  the  degradative  and  reparative 
phases  of  wound  healing  and  other  aspects  of  host  defences.  These  include  the 
recognition,  elimination  of  cells  infected  by  viruses,  intracellular  parasites,  and 37 
presentation  of  antigens  to  the  immune  system.  Two  general  hypotheses  have  been 
generated  to  explain  the  heterogenic  roles  exhibited  by  the  macrophages.  This  is 
depicted  in  figure  1-4. 
Figure  1-4  Two  Hypothesis  of  Macrophage  Phenotype  Differentiation 
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The  first  is  that  the  diversity  is  generated  by  functionally  distinct  and  committed  sub- 
populations  of  macrophages.  Although  this  is  an  attractive  concept  there  is  little 
experimental  data  to  support  it.  The  other  hypothesis  is  that  macrophages  are 
pleuripotential  cells  that  adapt  themselves  to  the  stimuli  or  conditions  that  prevail  at 
the  site  to  which  they  have  been  attracted.  Thus  the  precursor  cells  are  a  homogenous 
group  of  cells  (Gordon  S  et  al.,  1995). 
The  adaptation  theory  was  first  described  by  Russell  et  al  in  1977  and  Ruco  and 
Meltzer  in  1978.  They  demonstrated  that  peritoneal  macrophages  could  differentiate 
to  express  new  functional  activities  and  cytocidal  activities  in  response  to  various 
immune  and  bacterial  stimuli  in  vitro.  The  induced  macrophages  express  a  number  of' 
gene  products  that  collectively  contribute  to  the  altered  functional  activity  (Russell 
SW  et  al.,  1977,  Ruco  LP  and  Meltzer  MS,  1978). 39 
Some  of  these  macrophage  products  are  inducible  nitric  acid  synthase  (Ding  AH  et 
al.,  1988,  Lowenstein  CJ  et  al.,  1992),  complement  components  (Riches  DWH  and 
Stanworth  DR,  1982a)  and  interferon-0  (Riches  DWH  and  Underwood  GA,  1991). 
1.5.4  Surface  antigen  molecules 
Almost  20  years  ago,  it  was  shown  that  human  peripheral  blood  monocytes  and 
macrophages  were  not  a  homogenous  population,  but  differing  in  their  phenotype  and 
function. 
The  earliest  isolation  procedures  utilised  gradient  centrifugation  and  counterflow 
centifugation  techniques  (Figdor  CG  et  al.,  1982,  Weiner  RS  and  Mason  RR,  1984). 
These  separated  the  macrophage  subsets  by  size  and  density.  Akiyama  et  al.  defined 
these  as  a  major  population  of  regular  macrophages  and  a  minor  subset  of 
intermediate  macrophages  (Akiyama  Y  et  al.,  1983).  Regular  macrophages  were 
characterised  by  larger  size,  higher  expression  of  peroxidase  activity,  and  higher 
antibody-dependent  cell-mediated  cytotoxity.  The  intermediate  macrophages  on  the 
other  hand,  produced  less  peroxidase  activity,  but  could  be  more  easily  mobilized 
from  extracellular  reservoirs. 
More  recently,  macrophages  were  characterised  on  their  differences  in  the  surface 
marker  expression.  Monocytes  and  macrophages  express  several  well  known  surface 
molecules.  It  was  also  found  some  of  these  molecules  were  also  found  on  other 
haemopoietic  cells,  fibroblasts,  endothelial  and  epithelial  cells,  but  there  are  still  few 
examples  of  macrophage-specific  surface  markers  (Zhang  DE  et  al.,  1994,  Xie  Q-W 
et  al.,  1993,  Feinuran  R  et  al.,  1994). 40 
There  is  little  evidence  to  suggest  the  existence  of  specific  surface  markers  present  on 
monocytes  alone.  However,  there  are  certain  markers  of  high  restricted  specificity 
found  on  macrophages  at  different  differentiation  stages  in  the  local  environment  of 
acute  and  chronic  wounds.  With  the  use  of  specific  monoclonal  antibodies,  these 
membrane  molecules  function  as  excellent  markers  to  study  the  differentiation  and 
distribution  of  sub-population  of  macrophages.  Experiments  on  animals,  to  date,  have 
demonstrated  the  existence  of  an  array  of  macrophage  sub-population  in  murine  tissue 
models  (Gordon  S  et  al.,  1992). 
There  is  also  some  evidence  to  suggest  that  human  macrophages  also  exhibit  an  array 
of  surface  markers  at  different  differentiation  stages.  (Grage-Griebenow  E  et  al., 
2001)  (Figure  1-5) 41 
Figure  1-5  Proposed  Pathway  of  Macrophage  Differentiation 
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Schreiber  et  al  in  1991,  has  shown  that  as  monocytes  differentiate  into  macrophages, 
they  progressively  develop  phenotypic  and  functional  characteristics  pivotal  to  host 
defence.  At  the  same  time  they  also  express  specific  surface  markers.  This  could  he  a 
convenient  way  to  monitor  maturation  of  macrophages  in  wounded  tissue  (Schreiber 
Set  a].,  1991). 42 
1.5.5  Macrophage  Antigens 
1.5.5.1  The  pan-macrophage  marker  -  CD68 
This  is  a  110  kDa  glycoprotein  that  stains  macrophages  in  a  wide  variety  of  human 
tissues,  including  peripheral  blood  monocytes,  Kupffers  cells  and  macrophages  in  the 
red  pulp  of  the  spleen,  lamina  propria  of  the  gut,  lung  alveoli  and  bone  marrow 
(Pulford  KAF  et  al.,  1990,  Naksted  B  et  al.,  1989,  Athanasou  NA  et  al.,  1986).  It  is 
therefore  considered  as  a  pan-macrophage-marker  detecting  monocytes  and 
macrophages  at  all  stages  of  differentiation.  Therefore  it  can  function  as  a  valuable 
marker  for  monocytes  and  macrophages  in  wounded  tissues  which  are  composed  of  a 
variety  of  inflammatory  cells. 
1.5.5.2  The  early  macrophage  marker  -  27e10 
The  27e10  antigen  is  formed  from  two  non-covalently  linked  complexes  of  the 
migration  inhibition  factor  related  proteins  (NW)  8  and  14.  It  has  a  molecular  weight 
of  22kDa  (  MRP  8  has  a  molecular  weight  of  8kDA  and  MRP  14  has  a  molecular 
weight  of  l4kDa).  This  antigen  has  also  been  referred  to  as  the  Cystic  Fibrosis 
antigen,  CalgranulinA/B,  the  L1  antigen  and  calprotectin  to  name  but  a  few 
(Wilkinson  MM  et  al.,  1988,  Clark  BR  et  al.,  1990,  Dale  I,  Fagerhol  MK  and 
Naesgaard  I,  1983,  Steinbakk  M  et  al.,  1990).  The  27e10  antigen  belongs  to  a  group 
of  proteins  called  the  S  100  family  and  is  calcium  dependent  for  most  of  its  activities. 
Calcium  is  important  in  the  release  of  enzymes,  cytoskeleton  membrane  interactions, 
regulation  of  cell  differentiation  and  cell  cycle  progress  (Odink  K  et  al.,  1987, 43 
Kligman  D  and  Hilt  DC,  1988,  Heizmann  CW  and  Hunziker  W.  1991).  Calcium  ions 
seem  to  play  a  regulatory  role  in  the  transcriptional  stage  of  the  27e10  antigen 
synthesis.  Excess  Ca2+  switches  off  the  production  of  the  antigen  by  de-novo  synthesis 
of  suppressor  proteins.  Antigen  production  is  upregulated  by  vitamin  D3.  After 
synthesis,  the  27e10  antigen  is  extruded  to  the  cell  surface  via  a  novel  pathway 
requiring  an  intact  micro-tubule  network  following  the  activation  of  the  protein  kinase 
C  system  (Roth  J  et  al.,  1994,  Roth  J  et  al.,  1993,  Warner-Bartnicki  AL  et  al.,  1993. 
Rammes  A  et  al.,  1997). 
In  vitro,  IL-4  and  IL-10  has  been  shown  to  inhibit  the  expression  of  27e10  antigen  on 
the  surface  of  early  macrophages  (Lügering  N  et  al.,  1997). 
This  antigen  has  been  shown  to  be  present  in  pro-inflammatory,  early  macrophages 
which  are  found  in  acutely  inflamed  tissue  but  absent  in  mature  tissue  macrophages 
(Zwadlo  G  et  al.,  1988). 
27e10i"ecells  produce  large  amounts  of  inflammatory  mediators  such  as  prostaglandin 
E2,  Tumour  necrosis  factor  (TNF),  and  interleukin-1  (IL-1)  in  the  wounded  tissue, 
thus  perpetuating  the  stimulus  for  influx  of  other  inflammatory  cells  into  the  wound. 
(Zwadlo  G  et  al.,  1986). 
Hence  27e10  monoclonal  antibody  can  be  used  as  a  convenient  marker  to  identify 
early  inflammatory  macrophage  in  healing  and  non  healing  wounds. 44 
1.5.5.3  The  primed  macrophage  marker  -  Mannose  Receptor  (MR) 
The  macrophage  mannose  receptor  (also  known  as  the  mannose  -  fucose  receptor)  is 
a  175  kDa  membrane  glycoprotein  whose  presence  on  the  macrophage  membranes 
was  first  revealed  as  a  result  of  in  vivo  clearance  experiments  with  lysosomal 
hydrolases  (Stahl  PD,  1990).  This  receptor  recognises  glycosylated  molecules  with 
terminal  mannose,  fucose,  or  N-acetylglucosamine  moieties  and  efficiently 
internalises  soluble  and  particulate  ligands  through  endocytosis  and  phagocytosis, 
respectively  (Pontow  SE  et  al.,  1992).  The  expression  of  the  receptor  is  highly 
regulated  and  correlates  with  the  functional  state  of  the  monocyte/macrophage. 
Monocytes  do  not  express  mannose  receptors  and  it  has  been  shown  that  primed 
macrophages  express  higher  levels  than  activated  macrophages.  Increased  receptor 
expression  is  mediated  by  1,25  dihydroxyvitamin  D3  (Clohisy  DR  et  al.,  1987), 
Prostaglandin  E  (Schreiber  S  et  al.,  1990),  dexamethasone  (Shepherd  VL  et  al.,  1985), 
IL-4  (Stein  ML  et  al.,  1992),  LI-13  and  IgG2a  (Doyle  AG  et  al.,  1994,  Schreiber  S  et 
al.,  1991).  In  contrast,  MR  expression  is  down-regulated  by  interferon-y,  immune 
complexes  and  bacterial  lipopolysaccharides  (Noorman  F  et  al.,  1995,  Imber  MJ  et  al., 
1982,  Mokoena  T  and  Gordon  S,  1985,  Shepherd  VL  et  al.,  1990.  ). 
It  has  been  suggested  that  the  mannose  receptor  plays  a  role  in  the  uptake  of  antigen 
followed  by  antigen  presentation  by  dendritic  cells,  Langerhan  cells,  and  macrophages 
in  vitro  (Sousa  R  et  al.,  1993,  Muchmore  AV  et  al.,  1990).  However,  Noorman  et  al. 
in  1997  showed  that  there  are  no  MR+  dendritic  cell  families.  He  suggested  that 
macrophages  exist  in  two  stages  of  differentiation.  Primed  macrophages  exhibiting 
the  mannose  receptor  with  its  ability  to  capture  and  process  the  antigens,  once 45 
stimulated  become  activated  during  antigen  processing  lose  the  receptor  and  produce 
cytokines  to  stimulate  the  T  cells.  (Noorman  F  et  al.,  1997) 
In  summary,  MR+'  cells  identify  primed  macrophages. 
1.5.5.4  Tissue  macrophage  marker  -  Sialoadhesin  Receptor  (SR) 
Tissue  macrophages  are  distributed  throughout  the  organs  and  tissues  of  the  body, 
where  they  are  thought  to  play  a  central  role  in  both  innate  and  specific  immune 
responses  and  in  the  maintenance  of  normal  homeostatic  mechanisms.  The  precise 
function  of  macrophages  within  specific  microenvironments  such  as  the  bone  marrow 
is  poorly  understood.  It  appears  that  these  cells  maintain  a  discrete  population  of 
surface  receptors,  which  are  specific  for  their  particular  anatomical/functional  location 
and  which  appear  to  be  controlled  in  a  spatially  and  temporally  precise  manner.  The 
way  in  which  tissue  macrophages  interact  with  other  cells  and  with  components  of  the 
extracellular  matrix  is  believed  to  be  regulated  via  lectin-like  domains,  indicating  an 
important  role  for  carbohydrate  structures  in  cell  recognition  (Speert  DP  et  al.,  1988, 
Bevilacqua  MP  et  al.,  1989,  Johnston  GI  et  al.,  1989). 
Sialoadhesin  is  a  macrophage  restricted  plasma  membrane  receptor  of  185kDa,  and  is 
a  member  of  the  newly  recognised  family  of  sialic  acid  binding  lectins  called  siglecs. 
It  is  the  largest  member  of  the  sigelic  family.  Sialoadhesin  specifically  recognises  the 
oligosaccharide  sequences  NeuAca2,3Gal01,3  GaINAc  and 
NeuAca2,3Galß1,3(4)GIcNAc  in  either  glycoproteins  or  glycolipids.  This  may 
function  as  important  recognition  molecules  in  cellular  interactions  between  stromal 
tissue,  macrophages,  haematopoietic  and  lymphoid  tissues,  thus  playing  a  role  in 
wound  healing  (Crocker  PR  et  al.,  1991,  Kelm  S  et  al.,  1994). 46 
In  bone  marrow,  SR'  cells  are  localised  to  areas  of  contact  between  the  resident 
stromal  macrophages  and  the  developing  granulocytes.  In  the  spleen  these  cells  are 
found  in  the  marginal  zones,  in  the  subcapsular  sinus  and  medulla  of  lymph  nodes. 
During  T  cell-mediated  autoimmune  diseases  and  chronic  inflammation,  sialoadhesin 
is  also  expressed  by  the  infiltrated  macrophages  in  the  affected  tissues  (Dijkstra  CD  et 
al.,  1985,  Dijkstra  CD  et  al.,  1987,  Noble  B  et  al.,  1990). 
On  rat  macrophages,  sialoadhesin  expression  is  directly  induced  by  glucocorticoids 
and  the  glucocorticoid-dependent  sialoadhesin  expression  is  enhanced  by  interferon- 
ß,  interferon  -y,  IL-4and  LPS  (Van  den  Berg  TK  et  al.,  1996),  but  in  the  mouse,  IL-4 
has  been  described  to  selectively  inhibit  or  down  regulate  the  expression  of  SR.  This 
inhibitory  effect  can  be  modified  by  the  presence  of  other  cytokines  in  the  tissue 
microenvironment  (McWilliam  AS  et  al.,  1992).  This  is  opposite  to  the  expression  of 
the  MR  in  the  presence  of  IL-4,  where  it  has  a  stimulatory  effect  and  an  observable 
increase  in  MRS  cells  within  the  wounded  tissue.  The  effect  of  IL-4  in  human 
macrophages  is  not  yet  elucidated,  but  the  authors  believe  that  it  may  play  a  vital  role 
in  the  regulation  of  SR  '  tissue  macrophages  within  the  wounded  tissue. 
The  earliest  identified  function  of  SR+'  cells  was  the  ability  to  agglutinate 
unopsonized  sheep  and  human  erythrocytes  resulting  in  rosettes  (Crocker  PR  and 
Gordon  S,  1986).  More  recently  Crocker  et  al  have  demonstrated  a  cell-cell  binding 
hierarchy  with  a  strong  preference  for  cells  of  the  granulocytic  lineage.  In  rank  order, 
he  showed  that  of  SW'  cells  bound  to  neutrophils  with  the  greatest  avidity,  followed 
by  bone  marrow  cells,  then  blood  leukocytes,  then  lymphocytes  and  weakly  with 
thymocytes  (Crocker  PR  et  al.,  1995).  In  vivo,  the  adhesion  of  granulocytes  to  SR+"° 
cells  may  influence  the  function  of  the  granulocytes  and  their  turnover.  For  example, 
it  has  been  demonstrated  that  the  respiratory  burst  activity  of  granulocytes  can  be 47 
suppressed  by  the  binding  of  SR'  cells  to  granulocytes,  thus  preventing  the 
undesired  tissue  damage  caused  by  activated  granulocytes  (Cassidy  LF  et  al.,  1989).  It 
has  also  been  observed  that  senescent  neutrophils  are  cleared  from  the  circulation  by 
SR""  cells  in  the  reticuloendothelial  system  and  in  situ  at  sites  of  inflammation  (Perry 
VH  et  al.,  1992). 
Thus  SRC  macrophages,  through  their  direct  receptor-cell  interaction  with  other  cells 
of  the  inflammation  such  as  the  granulocytes,  lymphocytes  and  thymocytes,  may  play 
a  vital  role  in  influencing  the  behaviour  of  these  cells  in  chronic  inflammation.  This  is 
yet  another  distinct  function  of  a  specific  subset  of  macrophages  rather  than  secreting 
cytokines  when  the  macrophages  become  activated. 
In  this  study  SR  identifies  tissue  macrophages  in  wounds. 48 
1.6  HUMAN  WOUND  HEALING  MODELS 
Most  of  today's  understanding  of  the  mechanisms  of  wound  healing,  is  based  on 
animal  models.  It  is  known  that  human  skin  is  unique  and  highly  variable  according  to 
age,  sex,  race,  and  region  of  the  body.  There  is  no  single  model  that  can  be  utilised,  to 
represent  all  the  wound  types  seen  in  humans  (Montagna  W.  1971,  Butterworth  RJ, 
1992). 
Another  problem  is  that  there  are  currently  no  good  animal  models  to  represent 
chronic  wounds  such  as  venous  leg  ulcers,  diabetic  ulcers  or  pressure  sores.  Manna  et 
al  in  1982,  attempted  to  evaluate  guinea  pig  skin  as  a  chronic  wound  model,  eg.  a 
venous  leg  ulcer,  by  inducing  a  chemical  injury.  They  injected  sodium  tetradecyl 
sulphate  into  the  flank  skin  of  the  guinea  pig  to  mimic  a  sloughy  ulcer,  but  found  that 
these  wounds  healed  in  two  weeks.  This  was  quicker  than  venous  leg  ulcers,  as  they 
could  not  sustain  venous  hypertension  or  other  microvascular  abnormalities  that  are 
seen  in  venous  leg  ulcers  and  hence  severely  limited  its  value  as  a  chronic  wound 
model.  (Manna  V  et  al.,  1982) 
Another  problem  in  creating  chronic  animal  wound  models  is  the  definition  of  a 
'chronic'  wound.  There  is  no  definite  definition  of  a  chronic  wound,  but  in  humans 
this  has  been  defined  by  the  Wound  Healing  Society  as  a  wound  that  has  shown  no 
signs  towards  healing  in  8  weeks  (Franz  MG  et  al.  2000).  Despite  this,  animal  models 
do  allow  large  numbers  of  similar  wound  environments  to  be  studied.  It  is  possible,  on 
occasion  to  fill  gaps  in  our  knowledge  of  the  pathogenesis  of  human  disease  by  a 
close  study  of  morphologically  similar  ones  in  animals  (Scott  GBD,  1976).  An  ideal 
animal  species  suitable  for  predicting  response  in  humans  should  resemble  skin 
structure  and  react  similarly  to  a  wide  range  of  stimuli.  In  this  respect,  many  animal 49 
models  were  composed  of  `hairless'  strains  of  mammals,  such  as  bald  strains  of  rats, 
mice,  rabbits,  and  dogs. 
The  subject  of  using  animal  models  is  controversial  and  ethical  debates  continue  in 
every  continent.  Designing  experiments  requires  careful  forethought,  animal  models 
are  time  consuming,  expensive,  and  the  results  can  rarely  be  fully  extrapolated  to 
humans.  However,  animal  models  still  provide  invaluable  information  for  the  human 
wound  healing  response,  but  one  must  interpret  the  findings  with  caution 
(Chulakadabba  A  and  Sheraman  CP,  1999). 
Butterworth  studied  granulating  wound  tissue  in  26  patients  using  a  4mm  punch 
biopsy,  taken  under  local  anaesthetic,  and  concluded  that  human  tissue  provided  a 
more  accurate  and  clinically  relevant  model.  This  raised  fewer  ethical  objections  than 
work  on  animal  models.  Informed  consent  for  participation  into  study  is  also  easier  to 
obtain  from  individuals  (Butterworth  RJ,  1992). 
For  the  reasons  stated  above,  human  models  may  be  preferable  in  wound  healing 
research,  especially  if  it  is  directed  to  address  problems  in  clinical  practice. 
1.6.1  The  acute  wound  model:  The  pilonidal  sinus  (PNS)  excision  site 
The  term  pilonidal  sinus  originates  from  the  Latin  words  WAS  for  nest,  pilus  for  hair 
and  sinus  for  connections  to  the  skin  (Edwards  MH,  1977).  There  is  a  male 
preponderance  of  1.5:  1  especially  in  hirsute  men.  The  evidence  for  the  condition  as 
acquired  is  supported  by  its  rarity  in  children  and  its  similarity  to  the  condition  seen 
between  the  fingers  of  barbers,  due  to  repeated  contact  with  hair.  In  the  natal  cleft,  it 
is  postulated  that  the  skin  follicles  are  enlarged  due  to  the  shearing  action  of  the 50 
buttocks  and  it  is  the  implantation  of  foreign  hair  into  these  follicles  which 
subsequently  becomes  infected  (Brearly  R,  1955,  Bascom  J,  1980). 
The  infected  area  swells  and  occludes  the  follicular  opening,  rupturing  into  the 
subcutaneous  fat,  and  eventually  develops  a  sinus  track  to  the  skin  (Allen-Mersh  TC, 
1990) 
Numerous  treatments  exist,  but  none  are  perfect,  judged  by  the  outcomes  of  primary 
healing  and  recurrence  of  disease.  Methods  such  as  brushing  of  the  track,  laying  open 
of  track,  primary  closure,  and  asymmetrical  skin  incisions  in  an  attempt  to  flatten  the 
natal  cleft  to  reduce  buttock  friction  have  all  met  with  degrees  of  success  (Lord  PH, 
1965,  Clothier  PR  and  Haywood  IR,  1984,  Karydakis  GE,  1973) 
The  treatment  of  pilonidal  sinus  disease  at  the  University  Hospital  of  Wales, 
Department  of  Surgery,  has  been  to  widely  excise  the  affected  area,  allowing  the 
wound  to  heal  by  secondary  intention,  in  the  belief  that  this  will  lead  to  a  lower 
incidence  of  recurrence  of  the  disease  (Marks  J  et  al.,  1985). 
Thus  the  pilonidal  sinus  excision  site  forms  an  ideal  acute  wound  model  for  study. 
1.6.2  Chronic  wound  model:  The  chronic  venous  leg  ulcer  (IGLU) 
Chronic  wounds  as  is  their  nature  are  more  difficult  to  heal  and  sometimes  harder  to 
maintain  complete  closure.  Conditions  such  as  impaired  venous  drainage,  impaired 
arterial  supply,  metabolic  abnormalities,  persistent  mechanical  forces,  neurogenic 
defects  and  genetic  disorders  impairs  the  body's  ability  to  repair  tissue  damage 
(Margery  HD  et  al.,  1992). 
Venous  leg  ulcers  affect  about  1%  of  the  population,  increasing  to  around  3%  in  those 
65  years  or  older  (Callam  MJ,  1992). 51 
The  most  common  leg  ulcers  seen  in  UK  clinics  are  venous  (70-80%)  (Callam  MJ  et 
al.,  1987)  or  ischaemic  in  origin  (20-30%)  (Callam  MJ  et  al.,  1987) 
The  financial  cost  of  venous  leg  ulcer  in  Britain  has  been  estimated  to  be  between 
£294  -  650  million  per  year,  depending  on  the  variation  in  practice,  and  the  location 
of  provision  of  care  (eg.  Community  or  out-patient  clinic)  (Price  P  et  al.,  2000). 
1.6.2.1  Aetiology  of  Venous  Leg  Ulcers 
Venous  reflux  due  to  valvular  incompetence  is  the  main  trigger  for  local  changes  in 
the  microcirculation.  This  results  in  an  increase  in  the  ambulatory  venous  pressure  in 
the  subcutaneous  veins  of  the  lower  legs  and  ankles,  venous  hypertension  (Partsch  H, 
1995).  Incompetent  valves  result  in  the  failure  or  partial  failure  of  the  calf  muscle 
pump,  and  possibly  the  foot  pump  plexus  affecting  both  the  macro-  and  micro- 
circulation,  resulting  in  venous  hypertension  (Stemmer  R  et  a1.,  1980,  Creutzig  A  et 
al.,  1994).  There  are  three  major  theories  of  how  this  incompetence  results  in  venous 
ulceration. 
1.6.2.1.1  The  Fibrin  Cuff/  Growth  Factor  Entrapment  Theory 
When  the  sub-epidermal  capillary  bed  is  examined  histologically  in  patients  with 
venous  ulcers,  there  is  dilatation  of  the  horizontal  sub-capillary  venous  plexus  with 
grossly  coiled,  elongated  capillary  loops  and  a  reduction  in  the  number  of  capillaries 
supplying  the  epidermis  (Fagrell  B,  1973).  Fibrinogen,  a2  macroglobulins  and  other 
macromolecules  leaks  out  from  these  dilated  capillaries  into  the  dermis  of  the  wound, 
forming  a  peri-capillary  fibrin  cuff  and  this  is  thought  to  be  responsible  for  the 52 
reduced  diffusion  of  oxygenated  blood  to  the  tissues  (Burnand  KG  et  al.,  1982, 
Burnand  KG  and  Browse  NL,  1982,  Stacy  MC  et  al.,  1988).  Falanga  and  Eaglestein 
hypothesised  that  these  macromolecules  `trap'  growth  factors  or  other  homeostatic 
substances,  thus  rendering  them  unavailable  for  wound  healing  which  occurs  at  the 
wound  site  (Falanga  V  and  Eaglestein  WH,  1993). 
Their  hypothesis  stems  from  experiments  performed  by  Higley  et  al.  who 
characterised  fibrinogen  and  a2  macroglobulins  within  venous  leg  ulcers.  a2 
macroglobulins  are  also  known  to  be  a  binding  protein  for  growth  factors  (Higley  H  et 
al.,  1992). 
However,  the  trap  may  not  bind  all  the  growth  factors,  but  might  alter  the 
concentration  or  orderly  sequence  of  the  action  of  growth  factors.  The  excess  of 
macromolecular  burden  within  the  dermis  may  also  bind  to  normal  matrix 
components  and  interfere  with  their  function  in  healing. 
1.6.2.1.2  The  Leucocyte  Entrapment  Theory 
Venous  hypertension  due  the  failure  of  the  valves,  results  in  a  reduction  in  the 
pressure  gradient  between  the  arteriolar  and  venular  end  of  the  capillaries  in  the  leg. 
This  causes  a  reduction  in  the  velocity  of  the  blood  within  these  capillaries.  This  may 
lead  to  an  increase  in  the  adherence  of  blood  cells  to  the  endothelium  of  the  capillaries 
releasing  inflammatory  mediators  such  as  ICAM-1  and  VCAM-1(Coleridge  Smith  PD 
et  al.,  1988).  This  may result  in  the  obliteration  of  functioning  capillary  loops  in  the 
skin  aggravating  ischaemia  leading  to  ulceration  (Thomas  PRS  et  al.,  1998). 53 
1.6.2.1.3  The  Microangiopathy  Theory 
Using  intravital  capillaroscopy,  it  has  been  demonstrated  that  some  of  the  capillaries 
are  occluded  by  microthrombi  or  exhibit  long  intra-capillary  stasis.  This  can  in  turn 
reduces  nutrition  and  oxygenation  of  the  skin,  predisposing  to  ulceration.  Therefore 
the  functional  capillary  density  is  much  less  than  the  anatomical  density  (Steins  A  et 
al.,  1999) 
In  consideration,  probably  all  these  factors  play  a  role  in  the  pathogenesis  of  venous 
leg  ulcers. 
The  venous  leg  ulcer  is  therefore,  a  prime  example  of  a  chronic  wound  and  can  be 
used  as  a  convenient  chronic  wound  model. 
Clinically  these  patients  usually  exhibit  as  varicosities  in  the  lower  limb,  a  brownish 
flaky  appearance  to  the  skin  around  the  malleoli,  termed  lipodermatosclerosis,  and 
minor  trauma  to  this  area  results  in  a  superficial  ulcer  which  can  pose  a  challenge  to 
heal. S  54 
1.7  TISSUE  ENGINEERED  DERMAL  REPLACEMENT  - 
DERMAGRAFT® 
Chronic  wounds  like  venous  leg  ulcers  can  be  difficult  to  heal  within  an  acceptably 
short  time,  and  in  some  patients  are  harder  to  maintain  healed.  Many  of  these  patients 
are  elderly,  have  multiple  medical  problems,  poor  diet,  and  poor  social  circumstances. 
Therefore  effective  treatment  should  encompass  all  these  aspects.  When  possible, 
medical  problems  should  be  corrected,  nutrition  improved,  and  local  wound  care 
should  be  considered. 
Traditionally  the  treatment  of  venous  ulceration  has  been  conservative:  wound  care, 
surgical  correction,  elevation  and  compression  (Falanga  V,  1993).  Wound  care  in  the 
form  of  sharp  debridement  to  remove  any  dead  tissue  within  the  wound,  topical 
dressings  to  maintain  a  moist,  but  not  a  saturated  wound  environment,  and  a  balanced 
frequency  of  wound  dressing  changes,  which  will  prevent  saturation,  but  not  disturb 
the  healing  wound  un-necessarily  (Brem  H  et  al.,  2004).  Systemic  antibiotics  are  also 
sometimes  used  to  treat  significant  wound  infection.  Surgical  correction  of  the 
underlying  venous  insufficiency  in  a  small  number  of  patients  has  also  been  of  some 
benefit.  In  a  recent  study,  evaluating  surgical  correction  of  isolated  superficial  venous 
reflux  in  ulcerated  legs  reported  12  and  24  week  healing  rates  of  50%  and  72%  for 
operated  legs  and  62%  and  74%  for  non-operated  legs.  However,  these  authors  noted 
a  high  level  of  recurrence  of  28%,  30%,  and  44%  for  non-operated  legs  when 
compared  to  14%,  20%  and  26%  for  operated  legs  at  1,2,  and  3  years  respectively 
(Barwell  JR  et  al.,  2000). 
The  most  effective  treatment  intervention  for  venous  leg  ulcers  caused  by  venous 
hypertension  is  the  application  of  compression  bandages.  However  the  mode  of  action 55 
of  compression  therapy  is  still  unclear.  There  is  a  large  body  of  evidence  that 
associates  venous  ulceration  with  high  ambulatory  venous  pressures  in  the 
subcutaneous  veins  of  the  lower  legs  arising  from  valvular  incompetence.  This 
disrupts  the  local  blood  circulation,  both  the  macro  and  micro-circulation,  with  an 
increase  in  the  micro-circulation  (Anning  ST.  1952,  Creutzig  A  et  al.,  1994).  The 
application  of  compression  therapy  is  thought  to  correct  or  improve  this  incompetence 
(Christopoulos  DC  et  al.,  1995,  Krishnamoorthy  L  and  Melhuish  JM.  2000).  Even 
with  optimal  care  and  follow-up,  a  recurrence  of  venous  ulcers  occurs  in  29  -  59%  of 
patients  (Kowallek  DL  and  De  Palma  RG,  1997). 
Researchers  over  the  years  have  tried  numerous  methods  to  promote  healing.  These 
have  included  skin  grafting  (skin  transplant  from  one  region  to  another),  but  this 
carries  with  a  degree  of  morbidity,  especially  if  the  initial  wounds  are  large  (Eaglstein 
WH  and  Falanga  V,  1998).  Allografts,  (skin  transplant  between  two  unrelated 
individuals  of  the  same  species)  on  the  other  hand,  pose  ethical  consideration  and 
entails  problems  with  graft  rejection  (Navasaria  HA  et  al.,  1995).  The  problems 
associated  with  autogenic,  allogenic  and  xenogenic  (skin  transplant  between  two 
species)  skin  substitutes  have  prompted  the  search  for  alternatives  that  would  be 
widely  available,  and  have  properties  closely  resembling  that  of  normal  skin. 
Modern  attempts  to  develop  human  skin  replacements  began  in  the  early  1960s  with 
the  advancement  of  tissue  engineering  (Rooman  RP  and  Rosseuw  D,  1992). 
Rheinwald  and  Green  are  often  referred  to  as  the  pioneers  of  tissue  engineering.  They 
overcame  the  limitations  of  propagating  mammalian  cells  by  cultivating  human 
epidermal  cells  enabling  mass  culturing  of  these  cells  (Rheinwald  JG  and  Green  H, 
1975). 56 
Major  technical  advances  in  tissue  engineering  over  recent  years  have  made  it 
possible  to  culture  human  keratinocytes  in  laboratory  conditions.  One  of  the  major 
problems  with  the  use  of  cultured  keratinocytes  is  the  increase  in  wound  contracture. 
Their  have  however  been  more  promising  results  with  the  incorporation  of  dermal 
components  to  the  keratinocyte  cultures.  This  seems  to  improve  the  take  and  reduce 
contraction  of  the  grafts  (Couno  CB  et  al.,  1987,  Odessey  R,  1992).  Several 
commercially  available  dermal  substitutes  have  been  shown  to  increase  adherence  of 
cultured  keratinocytes  to  the  dermis.  Thes  include  ApligrafrM,  AllodermTm,  and 
Integra,  which  provide  the  dermal  component  to  increase  adherence  of  CEA 
(Falanga  V  et  al.,  1998,  Wainwright  D  et  al.,  1996,  Heimbach  D  et  al.,  1988, 
Freedlander  E,  1998,  Pomahac  B  et  al.,  1998,  Hansborough  JF  and  Franco  ES,  1998). 
More  recently,  a  living  human  dermal  replacement,  Denmagraft®  [DG]  has  been 
developed  (Advanced  Tissue  Sciences,  Inc.  USA,  La  Jolla  CA)  that  can  be 
permanently  implanted  to  mimic  the  patient's  damaged  dermis  thus  facilitating 
healing. 
DG  is  a  bioengineered  human  dermis,  consisting  of  neonatal  dermal  fibroblasts. 
Human  fibroblast  cells  are  harvested  from  neonatal  foreskins,  which  are  discarded 
after  circumcisiom.  The  fibroblast  cells  are  then  seeded  onto  a  three  dimensional 
bioabsorbable  scaffold  made  of  polyglactin.  As  the  fibroblasts  proliferate  within  the 
scaffold,  they  secrete  human  dermal  collagen,  fibronectin,  glycosaminoglycan,  growth 
factors  and  other  proteins,  producing  a  dermal  matrix.  This  results  in  a  metabolically 
active  dermal  tissue  with  the  structure  seen  in  the  papillary  dermis  of  newborn  skin.  It 
has  been  shown  that  a  single  donor  foreskin  can  provide  enough  cells  to  produce 
250,000  square  feet  of  DG  (Naughton  GK  et  al.,  1997). 57 
To  ensure  safety,  maternal  blood  and  cultured  cells  are  extensively  tested  throughout 
the  manufacturing  process  for  known  pathogenic  agents  such  as  Human 
Immunodeficiency  Virus  (HIV),  Human  T-cell  Lymphotrophic  Virus  (HTLV), 
Cytomegalovirus  (CMV),  Herpes  Simplex  Viruses  (HSV),  and  Hepatitis  viruses 
(Naughton  GK  et  al.,  1997). 
After  manufacture,  DG  is  stored  at  -70°C  until  used.  The  metabolic  activity  is 
assessed  before  and  after  cryopreservation  as  DG  is  designed  as  a  living  bioactive 
product  (Mansbridge  J  et  al.,  1988). 
DG  is  shipped  in  dry  ice  to  the  clinical  site.  Prior  to  implantation,  the  product  is 
thawed,  rinsed  in  sterile  saline  three  times,  cut  to  the  appropriate  wound  size  and 
placed  onto  the  wound  bed.  The  metabolically  active  fibroblasts  deliver  an  array  of 
growth  factors,  which  are  key  to  neovascularisation,  epithelial  migration,  and 
differentiation  and  facilitates  the  implantation  of  DG  into  the  patients'  wound  bed. 
It  has  been  shown  that  no  immunological  response,  in  the  form  of  tissue  rejection,  was 
demonstrated  when  evaluated  in  over  400  patients.  It  was  postulated  that  this  could  be 
due  to  the  lack  of  HLA-DR  surface  antigens  on  neonatal  fibroblasts,  compared  to 
other  skin  cells  which  generate  the  classic  allograft  rejection  (Couno  CB  et  al.,  1987). 
Clinical  studies  evaluating  the  efficacy  of  treating  human  diabetic  foot  ulcers  with  DG 
have  demonstrated  a  50%  increase  in  the  healing  rates  within  12  weeks,  and  more 
importantly,  a  much  delayed  recurrence  of  the  ulcer  in  the  treated  group.  It  has  been 
suggested  that  the  delay  could  be  due  to  a  more  normal  healing  pattern  with  DG 
(Gentzkow  GD  et  al.,  1996,  Naughton  GK  et  al.,  1997) 
Tissue  engineering  therefore  offers  the  ability  to  replace  damaged  or  destroyed  dermis 
with  a  manufactured  living  dermal  implant,  without  increasing  patient  morbidity. 58 
Dermagraft  may  be  able  to  `induce'  other  indolent  ulcers  such  as  venous  leg  ulcers  to 
heal. 
The  molecular  processes  of  wound  healing  and  clinical  progress  to  wound  closure  are 
the  main  topics  of  investigation  in  this  MD  thesis. 59 
2  CHAPTER  TWO:  AIM 60 
This  thesis  studies  the  influence  of  inflammatory  cells  on  human  wound  healing. 
After  the  initial  inflammatory  response  by  neutrophils,  the  majority  of  the  wound 
inflammatory  cells  are  mononuclear  cells.  As  previously  described,  macrophages 
seem  to  play  a  key  role  in  the  regulation  of  wound  healing,  in  both  degradative  and 
reparative  phases  of  wound  repair.  Consequently  this  work  concentrates  on  these 
cells. 
Much  of  the  work  into  the  role  of  the  macrophage  in  wound  healing  has  been  in 
animals  or  in  vitro  models.  Much  of  its  potential  role  in  human  wound  healing 
remains  unclear. 
Chronic  wound  healing  in  humans  may  be  characterised  by  a  reduction  of  total 
numbers  or  activation  of  wound  macrophages,  since  these  cells  are  essential  to  the 
healing  process.  This  thesis  aims  to  morphologically  characterise  the  numbers  and 
macrophage  activation  over  two  distinct  groups  of  wounds.  Macrophages  are  studied 
in  chronic  non-healing  wounds  and  following  two  weeks  of  normal  wound  healing  in 
PNS  wounds. 
Attempts  to  achieve  wound  closure  in  recalcitrant  wounds  have  also  been  conducted 
in  earnest  by  many  industries.  If  successful  these  may  reduce  the  yearly  health  service 
budgets  in  the  management  of  non-healing  wounds  and  their  associated  morbidity, 
both  in  the  UK  and  abroad  considerably.  Recently,  a  living  human  dermal 
replacement,  Dermagraft®(DG),  has  been  developed.  This  aims  to  be  permanently 
implanted  on  the  wounded  tissue  to  facilitate  healing.  The  hypothesis  suggested  was 
that  the  impaired  healing  observed  in  these  wound  may  be  due  to  an  abnormal  dermis, 
and  by  replacing  it  with  a  healthy  dermis,  one  could  `switch'  these  chronic  wounds 
into  acute  wounds.  Should  this  be  the  case  then  one  would  expect  to  find  changes  in 
the  inflammatory  profile  as  healing  or  wound  shrinkage  is  observed.  The  aim  here  is 61 
several-fold,  the  first  and  the  most  important  being  the  safety  of  the  product  in 
patients  with  venous  leg  ulcers,  the  effectiveness  of  DG  (when  used  in  conjunction 
with  multi-layer  compression  therapy)  in  the  promotion  of  healing,  to  determine  the 
optimal  treatment  application  frequency  to  achieve  a  clinical  benefit,  and  to  elucidate 
the  histological  changes  taking  place  within  the  wound  tissue  associated  with  DG 
treatment. 62 
3  CHAPTER  THREE:  METHOD 63 
3.1  PILOT  STUDY  METHOD 
3.1.1  Patient  group 
3.1.1.1  Acute  wound  healing  model 
It  is  common  practice  at  the  University  Hospital  of  Wales  and  Llandough  Hospital  in 
Cardiff,  that  following  excision  of  a  pilonidal  sinus  the  wound  is  left  to  granulate  and 
heal  by  secondary  intention.  This  forms  an  ideal  model  to  observe  acute  wound 
healing.  Following  ethical  approval  from  Bro  Taf  Ethics  Committee  and  with  the 
permission  of  all  surgeons,  patients  with  such  a  wound  were  recruited  from  surgical 
units  at  the  University  Hospital  of  Wales,  and  Liandough  Hospital  in  South 
Glamorgan.  Ten  patients  with  a  pilonidal  sinus  wound  were  recruited  for  the  study. 
The  patients  were  seen  within  a  week  of  the  operation  and  biopsied  around  14  days 
after  the  excision  of  the  pilonidal  sinus. 
3.1.1.2  Chronic  wound  healing  model 
Patients  with  venous  leg  ulcers  could  be  used  as  a  suitable  model  to  observe  the 
chronicity  of  non-healing  wounds.  Following  ethical  approval  from  Bro  Taf  Ethics 
Committee,  ten  venous  leg  ulcer  patients  were  recruited. 
A  detailed  medical  history  was  obtained  from  each  patient  to  identify  any  relevant 
past  or  current  factors  that  could  influence  their  wound  healing.  Patients  below  the 
age  of  eighteen,  pregnancy,  co-existing  illness,  chronic  renal  failure,  known 
malignancy,  or  on  steroid  or  immunosupression  treatment  were  excluded  from  the 64 
study.  Full  informed  consent  was  obtained  from  all  patients.  The  patients  underwent 
detailed  physical  examination  and  Doppler  ultrasound  examination  of  the  venous 
system  was  also  performed  to  confirm  venous  leg  ulcer  aetiology.  Those  selected 
demonstrated  no  progress  towards  healing  despite  the  use  of  graduated  compression 
therapy  for  at  least  twelve  weeks  prior  to  recruitment. 
3.1.2  Biopsy  Technique 
Biopsies  were  obtained  during  the  second  week  after  the  excision  of  a  pilonidal  sinus. 
They  were  usually  taken  at  1cm  below  the  wound  edge,  ensuring  true  representations 
of  the  wound  bed.  2mls  of  1%  Lignocaine  was  initially  injected  into  the  area.  A  6mm 
sterile  punch  (Stiefel  biopsy  punch,  SFM,  Wächtersbach,  W.  Germany)  was  then 
pushed  into  the  tissue  with  a  rotational  movement.  Once  the  full  length  of  the  blade  of 
the  punch  had  entered  the  tissue  the  tissue  was  `scooped'  out.  This  technique 
minimised  the  tissue  damage  that  may  occur  when  the  tissue  is handled  with  forceps. 
The  small  amount  of  bleeding  that  is  usually  seen  in  the  tissue  bed  following  biopsy 
was  cauterized  with  Silver  Nitrate  sticks  and  gentle  pressure  with  a  gauze  swab  for  a 
couple  of  minutes  until  the  bleeding  had  stopped. 65 
3.1.3  Specimen  preparation 
Prior  to  obtaining  the  biopsy,  a  skin  marker  was  used  to  mark  the  surface  of  the 
wound  bed  lightly,  and  this  mark  was  incorporated  into  the  biopsy  tissue.  Although, 
most  biopsies  were  cylindrical,  which  aided  in  the  orientation  of  the  tissue  during  the 
mounting  process,  and  enabled  a  longitudinal  section  through  all  layers  of  the  wound 
biopsy  could  be  obtained.  Occasionally  the  biopsy  was  in  the  shape  of  a  sphere  due 
the  scooping  action  when  using  the  punch.  Here  the  mark on  the  surface  of  the  wound 
aided  in  the  correct  orientation  of  the  tissue. 
A  small  amount  of  Cryo  -M  Bed  (Appendix  7.2)  embedding  medium  was  placed  on 
a  piece  of  cork  board  approximately  10  x5  millimetre,  at  room  temperature  on  a  small 
preparation  table  in  the  consulting  room.  The  preparation  table  contained  a  small 
beaker  of  N-Hexane  (20  -  30  mis),  a  pair  of  forceps,  tongs  and  a  dewar  flask 
containing  liquid  nitrogen. 
Within  one  minute  of  obtaining  the  biopsy,  it  was  mounted  on  its  side  on  the  prepared 
cork  board,  and  the  whole  specimen  was  covered  with  more  embedding  medium.  This 
ensures  a  longitudinal  representation  of  the  specimen  when  it  is  presented  for 
sectioning.  (Figure  3-1) 66 
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Mounting  the  Specimen 
Mounting  the  tissue  onto  a  cork  board 
The  beaker  of  N-Hexane  was  then  suspended  in  a  dewar  containing  liquid  nitrogen 
with  a  pair  of  tongs  and  the  prepared  specimen  on  the  cork  board  was  immersed  into 
the  beaker  with  a  pair  of  forceps.  The  specimen  was  completely  immersed  in  the  N- 
Hexane,  whilst  it  cooled  to  -  170°C.  This  was  to  avoid  the  formation  of  ice  crystals 
within  the  biopsy  during  the  freezing  process.  The  snap  freezing  of  the  tissue  sample 
was  completed  within  five  minutes  of  obtaining  the  specimen.  The  frozen  specimen 
was  then  placed  in  a  bijou  bottle,  labeled,  with  the  patient's  initials,  date  of  specimen 
preparation  and  stored  in  liquid  nitrogen  at  -170°C  until  use. 
During  sectioning,  the  specimen  was  placed  on  a  pre-cooled  chuck  (-20°C)  in  a 
cryostat  cutting  chamber.  The  tissue  was  supported  on  the  chuck  by  building  it  up 
with  the  embedding  medium  within  the  chamber.  6µm  sections  were  cut  and  mounted 
onto  Poly-L-Lysine  (Appendix  7.2)  coated  microscopy  slides.  Poly-L-Lysine  coated 
microscope  slides  enabled  the  thin  tissue  sections  to  be  picked  up  from  the  plattörm 67 
adjacent  to  the  cryostat  blade  with  minimal  distortion  to  the  architecture  of  the  tissue. 
The  slides  were  then  air  dried  for  about  an  hour  at  room  temperature,  wrapped 
sequentially  in  aluminium  foil,  and  stored  desiccated  at  -20°C  until  processed.  The 
slides  were  processed  within  two  weeks  of  cutting. 
3.1.4  Immunohistochemical  slide  processing 
The  slides  were  removed  from  the  freezer,  and  allowed  to  reach  room  temperature 
before  the  aluminium  foil  was  removed.  This  prevented  condensation  on  the  foil  from 
dissolving  any  soluble  antigens  on  the  sections. 
They  were  then  labeled  with  the  patient  initials  using  an  engraving  pen  and  were  fixed 
by  placing  in  dried  acetone  at  room  temperature  for  15  minutes. 
Most  of  the  sections  cut  from  the  biopsies  remained  stable  and  undamaged  throughout 
the  various  stages  of  the  staining  and  antibody  labelling  process. 
Excess  acetone  was  removed  by  air  drying  the  sections  for  10  minutes  at  room 
temperature.  The  slides  were  then  washed  three  times  for  five  minutes  in  Tris 
Buffered  Saline  (TBS)  at  a  pH  7.6.  The  sections  were  then  incubated  with  1%  normal 
bovine  serum  (ABC  Elite  Kit,  Appendix  7.2)  for  20  minutes  at  room  temperature  in  a 
humid  chamber.  (The  humid  chamber  was  prepared  each  morning  by  soaking  paper 
towels  in  water  and  placing  them  in  a  tupperware  container  with  a  lid,  and  the  slides 
placed  in  them  for  the  specific  incubation  period  at  room  temperature  approximately 
21  degrees  Celsius).  This  is  performed  to  block  any  non-specific  tissue  binding  of  the 
antibody  and  hence  reducing  the  background  staining  of  the  sections  during 
subsequent  development. 68 
After  20  minutes,  the  blocking  serum  was  drained  off  and  the  sections  were  incubated 
with  the  optimal  dilution  of  the  primary  antibody  for  30  minutes  in  a  humid  chamber 
at  room  temperature.  The  slides  were  washed  three  times  in  TBS  (five  minutes  each 
wash)  and  incubated  with  the  biotinylated  secondary  antibody  for  30  minutes  in  a 
humid  chamber  at  room  temperature.  Following  a  further  two  five  minute  washes  in 
TBS,  the  slides  were  once  again  incubated  in  a  humid  chamber  at  room  temperature 
with  the  ABC  Complex  histochemical  staining  reagent  (Appendix  7.2).  This  complex 
is  made  of  avidin  -a  large  glycoprotein  extracted  from  egg  white  (albumin)  and  a  low 
molecular  weight  vitamin  called  biotin.  It  is  usually  prepared  at  least  30  minutes 
before  incubation  to  allow  the  avidin  and  biotin  to  react  together  to  form  a  large 
labelled  complex  which  can  amplify  the  antigen-antibody  reaction  in  the  sections. 
The  sections  were  once  again  washed  twice  in  TBS  (five  minutes  each)  and  developed 
with  Diaminobenzidine  (DAB)  substrate  (0.005%)  (Appendix  7.2)  for  10  minutes  at 
room  temperature  (Appendix  7.1).  The  slides  were  rinsed  once  in  TBS  and 
counterstained  with  Erlichs'  Haematoxylin  for  30  seconds.  The  slides  were  rinsed  in 
tap  water  and  dehydrated  by  passing  through  70%  alcohol  (Appendix  7.2),  100% 
alcohol  twice,  alcohoUxylene  mixture,  and  xylene  twice  (Appendix  7.2).  Five  minutes 
were  spent  at  each  dehydration  stage.  Finally,  the  sections  were  mounted  under  cover 
slips  using  DPX  (Appendix  7.2). 
3.1.5  Monoclonal  antibody  panel. 
The  antibodies  used  and  their  relevant  dilutions  are  shown  in  table  3-1.  CD68  and 
27e10  were  available  commercially,  the  MR  antibody  was  a  kind  gift  from  P  Stahl, 69 
St.  Louis,  Missouri,  USA  and  the  SR  antibody  was  a  kind  gift  from  Dr  P  Crocker, 
Dundee,  UK  (Appendix  7.2) 
Table  3-1  Panel  of  Antibodies  used  in  the  Pilot  Study 
Monoclonal  Antibody  Target  Cell  Dilution 
CD68  (monoclonal  mouse)  Monocytes,  Macrophages  1.50 
27e10  (monoclonal  mouse)  Early  stage  Macrophages  1:  250 
Anti-mannose  (MR) 
(monoclonal  mouse) 
Primed  Macrophages  1:  500 
Anti-Sialoadhesin  (SR) 
(monoclonal  mouse) 
Tissue  Macrophages  1:  20 
The  final  dilutions  of  the  monoclonal  antibodies  were  determined  by  their  ability  to 
bind  specifically  to  the  antigen,  providing  a  clear  identification  of  the  cells  under 
study  without  flooding  or  bleaching  the  sections. 70 
3.1.6  Analysis 
3.1.6.1  Qualitative  Evaluation 
All  sections  were  examined  by  both  the  investigator  and  an  experienced 
immunologist,  Dr  Keith  Moore  (KM)  to  ensure  the  quality  of  the  sections  were 
adequate  for  analysis.  Instructions  on  the  identification  of  the  salient  features  of  the 
different  cells  were  established  at  the  start  of  the  assessment. 
The  features  that  helped  to  identify  the  different  types  of  cells  are  summarized  below. 
Polymorphonuclear  neutrophils  were  cells  with  multi  lobed  dark  nuclei  and  very  little 
cytoplasm. 
Macrophages  were  cells  with  eccentric  `kidney  shaped  nuclei,  containing  granules 
and  vacuoles  in  the  cytoplasm. 
Lymphocytes  were  small  round  cells  with  dark  round  nuclei  and  very  little  cytoplasm. 
Capillary  endothelial  cells  were  large  cells  with  elliptical  nuclei  encircling  vessel-like 
tubular  structures. 
Plasma  cells  were  medium  sized  cells  with  a  large  cytoplasm  and  eccentric  oval 
nuclei,  occasionally  looking  like  a  `clock  face'. 71 
3.1.6.2  Field  Selection 
The  use  of  a  single  section  to  obtain  histological  diagnosis  is  a  well-established 
procedure  in  routine  histopathology.  This  assumes  that  the  tissue  from  which  this 
biopsy  is  obtained,  and  the  subsequent  sections  are  homogenous  and  thus  represents 
the  whole  lesion.  This  may  be  adequate  to  generate  enough  baseline  data  to  allow 
clinical  decisions  to  be  made,  recognizing  that  the  lesion  may  be  heterogeneous,  e.  g. 
in  excluding  or  verifying  neoplastic  lesions  and  lymph  node  spread. 
Tissue  homogeneity  may  not  apply  to  acute  and  chronic  leg  ulcers,  where  one  area  of 
the  lesion  may  have  epithelised  and  in  the  case  of  the  chronic  wound,  another  area 
may  be  degenerating.  Previous  work  produced  from  this  unit,  demonstrated  that  when 
a  single  wound  biopsy  was  completely  sectioned  and  every  fifth  section  stained  for  a 
single  monoclonal  antibody  (in  this  case  CD3),  the  distribution  of  cells  in  the 
vascularised  area  of  a  single  section  were  95%  representative  to  those  found 
throughout  the  biopsy. 
Low  power  views  (x10  magnification)  of  the  wound  bed  sections  demonstrated  that 
the  wound  had  areas  of  vascularisation  with  abundant  cellular  infiltrate  and  avascular 
areas  with  sparse  cellular  infiltrate. 
The  macrophage  infiltrate  of  all  biopsies  was  quantified  within  the  vascularised  area 
of  the  section,  by  morphological  identification  and  counting  the  number  of  positively 
stained  cells  at  x40  magnification  view.  This  was  facilitated  by  transmitting  the 
microscope  image  of  the  section  on  a  visual  display  screen.  To  count  each  positively 
stained  cell  without  duplication,  a  computer  software  programme  developed  by  Dr 
Peter  Plassmann  (University  of  Glamorgan)  was  used.  This  highlighted  every  positive 
cell  counted  by  a  coloured  dot.  To  ensure  that  the  same  area  is  counted  for  the  various 72 
sub-populations  of  macrophages,  the  overall  shape  of  the  section  was  documented,  an 
area  was  randomly  selected  within  the  vascular  area  and  this  was  highlighted  in  the 
diagram.  This  was  performed  to  minimise  any  errors  that  may  occur  by  counting 
different  areas  for  the  different  antibody  positive  cells.  Having  identified  the  test  area 
the  number  of  positive  cells  for  the  different  monoclonal  antibody  was  counted  in 
twelve  sequential  fields  as  shown  in  figure  3-2. 
Figure  3-2  Field  Selection  within  Wound  Bed  Section 
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3.1.6.3  Reproducibility  of  Counting 
To  minimise  intra-observer  bias,  only  the  initials  of  the  patient  and  the  specific 
monoclonal  antibody,  prior  to  examination.  The  investigator  carried  out  all  counting 
several  weeks  after  the  staining  process.  The  type  of  wound  assessed  remained 
unknown  until  the  names  of  the  patients  were  matched  to  the  wound  type  at  the  end  of 
the  study. 
Intra-observer  counting  techniques  were  validated  by  carrying  out  duplicate  counts  by 
the  investigator  on  10  biopsies  for  a  single  antibody  twelve  months  after  the  initial 
counts.  The  slides  chosen  for  this  purpose  were  those  stained  by  the  tissue 
macrophage  surface  marker  Sialoadhesin  (SR). 
To  validate  inter-observer  variation  10  random  slides  for  the  same  monoclonal 
antibody,  stained  for  the  tissue  surface  macrophage  Sialoadhesin  (SR)  were  coded  (1 
to  10)  and  the  number  of  positively  stained  cells  was  counted  by  another  investigator, 
on  a  different  day. 74 
3.2  DERMAGRAFT  STUDY  METHOD 
The  main  body  of  this  thesis  consists  of  a  prospective,  randomised,  open-label 
feasibility  study  of  12  weeks  duration  conducted  at  6  centres,  3  in  the  UK  and  3  in 
Canada.  The  centres  that  participated  in  this  study  included,  Cardiff,  Cheltenham, 
Stockton-on-Tees  (Newcastle),  Toronto/  Mississauga,  Montreal,  and  Winnipeg.  It  is 
estimated  that  these  centres  would  provide  12  evaluable  patients  in  each  treatment 
arm.  The  different  arms  of  treatment  will  be  discussed  in  detail  in  the  following 
sections. 
The  primary  objective  of  the  study  was  to  assess  the  safety  and  effectiveness  of  DG  in 
conjunction  with  conventional  therapy,  in  the  promotion  of  healing  of  venous  leg 
ulcers,  compared  with  the  conventional  therapy  of  four  layer  compression 
(PROFORE)  only. 
The  secondary  objective  was  to  determine  the  optimal  treatment  application  frequency 
of  DG,  with  the  object  of  progressing  to  a  pivotal  study,  comparing  conventional  four 
layer  compression  bandaging  (PROFORE)  against  one  treatment  application  of  DG, 
in  conjunction  with  conventional  therapy,  with  suitable  patient  numbers. 
3.2.1  Patient  Population 
Sixty  three  venous  leg  ulcers  patients  were  screened  for  eligibility  prior  to  entry  into 
the  study  at  6  centres.  The  patient  had  to  fulfill  the  selection  criteria  at  the  screening 
visit,  and  give  written  informed  consent  to  participate  prior  to  study  enrolment. 75 
3.2.2  Patient  Selection  Criteria 
All  patients  entering  the  study  must  have  the  following  characteristics: 
1.  A  venous  leg  ulcer  without  exposure  of  muscle,  tendon  or  bone 
2.  Venous  reflux  demonstrated  by  appropriate  vascular  investigation  such  as  a 
duplex  or  a  venous  Doppler  scan  of  the  affected  limb,  or  the  patient  had  a  proven 
history  of  deep  vein  thrombosis  and/or  the  appearance  of  the  leg  is  typical  of  post- 
thrombotic  limb.  Typically  this  consists  of  varicosities,  a  brownish  flaky 
appearance  around  the  malleoli,  termed  lipodermatosclerosis,  and  a  superficial 
ulcer 
3.  Have  an  ulcer  present  for  at  least  2  months  but  not  more  than  60  months  prior  to 
screening  visit. 
4.  Have  an  ulcer  between  3cm2  and  25  cm  2 
5.  Have  an  ankle  Brachial  Pressure  Index  is  z  0.7 
6.  Patient's  ulcer  heals  less  than  50%  from  the  screening  visit  to  the  start  of 
treatment  (day  0  visit). 
Early  in  the  study,  it  was  identified  that  only  10%  of  the  patients  seen  in  the  6  centres 
were  eligible  for  study  as  the  target  ulcer  were  usually  less  5cm2.  This  was  revised  to 
incorporate  ulcers  of  3cm2  or  more.  The  length  of  time  the  target  ulcer  needed  to  be 
present  to  qualify  for  this  study  was  also  amended  from  24  months  to  5  years,  as  most 
of  the  patients  recruited  for  the  study  were  selected  from  a  sub-population  of  patients 
with  `harder  to  heal'  venous  leg  ulcers. 76 
3.2.3  Ethics 
The  study  protocol,  patient  information  sheet,  patient  consent  form,  and  information 
letter  to  the  General  Practitioner  (GP)  were  approved  by  an  Institutional  Review  Body 
(IRB)/Independent  Ethics  Committee  (IEC)  in  Canada  and  the  Local  Research  Ethics 
Committees  (LRECs),  in  the  UK. 
3.2.4  Screening  and  treatment  protocol 
A  screening  visit  to  assess  eligibility  to  enter  the  study  preceded  the  study  visit  by  a 
week.  All  eligible  patients  were  screened  for  inclusion  and  exclusion  criteria,  and 
signed  the  informed  consent  form  approved  by  IRB/IEC  or  LRECs  at  the  start  of  the 
study.  The  patients'  leg  ulcer  history  was  recorded,  and  if  the  patient  had  several 
ulcers,  one  target  venous  leg  ulcer  was  chosen  and  was  cleaned  according  to  standard 
practice  at  each  centre,  this  ranged  from  wiping  the  ulcer  with  a  saline  soaked  gauze, 
washing  the  leg  with  running  water  or  soaking  the  study  leg  in  a  bucket  of  water,  with 
or  without  emollients.  If  there  was  evidence  of  local  areas  of  necrosis  or slough  within 
the  ulcer  bed,  they  were  debrided  either  surgically  or  using  autolytic  agents,  at  the 
discretion  of  the  investigator  at  the  centre. 
After  debridement,  the  ulcer  was  photographed  and  traced  onto  a  transparent  ulcer 
grid  measurement  sheet,  so  that  its  area  could  be  determined.  Ulcer  tracings  and 
photographs  of  the  wound  site  were  carried  out  weekly  prior  to  the  application  of 
Dermagraft  (DG). 77 
Before  randomisation,  the  wound  was  dressed  according  to  the  standard  practice  of 
the  centre,  choosing  from  a  wide  range  of  non-adhesive  primary  dressings,  and  then 
bandaged  with  a  long  stretch  four-layer  bandaging  system  (PROFORETM) 
At  the  start  of  the  study,  (study  week  0),  the  inclusion  and  exclusion  criteria  were 
checked  again,  in  particular  the  criterion  which  stated  that  the  ulcer  must  have  not 
healed  by  more  than  50%  following  the  screening  visit. 
3.2.5  Selection  of  DG  doses  in  the  study 
Previous  studies  conducted  with  DG  in  the  treatment  of  diabetic  ulcers,  had  shown 
that  weekly  application  of  DG  for  eight  weeks  resulted  in  closure  of  the  wound. 
(Naughton  G  et  al.,  1997,  Pollack  RA  et  al.,  1997) 
In  this  study,  three  regimens  were  chosen  to  encompass  the  concept  that  a  chronic 
wound  needs  a  certain  amount  of  stimulation  before  the  process  of  wound  closure  will 
proceed.  Once  this  process  has  been  initiated  and  a  certain  rate  of  wound  closure 
maintained,  it  is  possible  that  no  further  treatment  will  be  necessary.  Consequently, 
two  extremes  of  treatment  were  chosen  to  determine  if  a  single  application  of  DG  at 
week  0  could  impact  on  venous  ulcer  healing,  or  whether  the  cumulative  effect  of 
repeated  applications  on  a  weekly  basis  (weeks  0-  11  i.  e.  total  of  12  pieces)  was 
important.  In  addition,  a  mid-ground  dosing  regimen  was  chosen  to  examine  the 
impact  of  repeat  applications  on  early  stimulation  of  the  wound  (weeks  0  and  1), 
followed  by  further  repeat  applications  evenly  spaced  during  the  course  of  treatment 
at  weeks  4  and  8,  i.  e  a  total  of  four  applications  (Weeks  0,1,4  and  8). 78 
3.2.6  Patient  Treatment  Randomisation 
Randomisation  occurred  according  to  a  pre-determined  code  list  for  each  centre.  All 
patients  attended  the  clinic  on  a  weekly  basis  even  if  they  did  not  require  DG 
application.  Patients  were  randomly  allocated  to  one  of  the  four  treatment  regimens  - 
Group  1:  Patients  received  one  piece  of  DG  from  week  0  up  to  and 
including  week  11,  at  each  weekly  visit  to  give  a  total  of  12 
applications 
Group  2:  Patients  received  a  piece  of  DG  at  weeks  0,1,4  and  8,  a  total  of 
4  applications 
Group  3:  Patients  received  only  1  piece  of  DG  at  week  0 
Group  4:  Patients  received  no  DG  (Control) 
Those  patients  allocated  to  the  control  group  had  their  ulcer  covered  with  a  piece  of 
non-adherent  Dermanet®,  and  a  four-layer  bandage  applied.  Dermanet  is  a  non- 
adhesive  dressing,  similar  to  many  other  proprietary  dressings  available  in  the 
community,  which  is  made  from  an  inactive  material  and  hence  exhibits  no  healing 
properties.  Patients  receiving  DG,  had  their  ulcer  covered  with  DG,  a  piece  of  non- 
adherent  Dermanet  and  four-layer  bandaging  system. 
As  previously  mentioned,  DG  was  shipped  to  the  various  centres  in  the  cryopreserved 
format  at  -70°C.  Prior  to  use,  DG  was  thawed  to  room  temperature  in  a  warm  water 79 
bath  of  37°C  for  about  3  minutes,  rinsed  in  sterile  physiological  saline  twice  for  five 
seconds  each,  cut  to  the  size  of  the  wound  bed,  and  applied  to  the  wound  bed.  This 
was  then  covered  by  a  piece  of  Dermanet,  and  the  four  layer  bandages. 
3.2.7  Biopsy  Procedure 
Biopsies  were  obtained  at  week  0  and  week  6  of  the  12  week  study,  from  the  centre  of 
the  ulcer  using  a  sterile  6mm-biopsy  punch  (Stiefel).  The  wound  was  infiltrated  with 
1%  plain  Lignocaine  and  the  biopsy  punch  was  inserted.  The  tissue  was  then 
`scooped'  out  of  the  wound  bed.  Haemostasis  was  achieved  by  gentle  pressure  with  an 
absorbent  dressing,  before  redressing  the  wound  as  per  standard  practice.  Experience 
from  numerous  previous  studies  has  shown  this  method  to  be  relatively  painless. 
The  first  time  scale  (Oweeks)  was  chosen  as  a  starting  point,  all  patients  up  until  that 
point  having  received  the  same  treatment  and  degree  of  monitoring.  Week  6  was 
chosen  as  the  point  for  the  second  biopsy  because  previous  work  from  this  unit  has 
demonstrated  that  the  maximal  immunological  and  cellular  activity,  in  response  to 
wound  manipulation,  occurs  at  this  time. 
3.2.8  Tissue  Preparation 
The  sample  tissue  was  bisected  longitudinally  by  placing  a  scalpel  over  the  mid-point 
of  the  tissue  and  pressed  firmly  with  one  smooth  movement.  One  half  of  the  biopsy 
was  placed  in  10%  buffered  formal  saline  and  transferred  24  hours  later  into  50% 
ethanol  for  transportation  and  long-term  storage,  at  room  temperature.  The  other  half 
was  snap  frozen  in  liquid  nitrogen,  as  described  in  section  3.1.3 80 
3.2.9  Assessment  of  Healing 
Photographs  and  ulcer  tracings  were  carried  out  weekly  in  the  clinic  over  the  12  week 
study  period  to  assess  the  progression  of  wound  healing.  Complete  wound  closure 
was  defined  as  full  epithelisation  of  the  wound  with  no  drainage.  Because  initial 
closure  can  be  difficult  to  judge  due  to  the  thin  neoepithelium,  complete  healing 
during  the  primary  efficacy  period  had  to  be  confirmed  at  the  next  consecutive  visit. 
Therefore  a  wound  judged  to  be  healed  at  one  visit  but  open  at  the  next  was 
considered  to  have  not  healed. 
Although  weekly  photographs  of  the  target  ulcer  were  taken,  for  the  duration  of  the 
study  period,  some  of  the  photographs  were  of  poor  quality,  being  too  dark  or 
overexposed,  making  the  assessment  of  the  progression  to  wound  closure  difficult. 
Ulcer  tracings  were  however  a  more  reproducible  way  of  assessing  progression. 
In  those  wounds  that  remained  unhealed  at  the  end  of  the  study  period,  the  area  of 
reduction  in  the  ulcer  size  was  expressed  as  a  percentage  for  ease  of  comparison 
between  the  groups,  this  was  calculated  as:  - 
Equation  1.  Percentage  Reduction  in  Ulcer  Size 
Percentage  Reduction  =  Week  0  area  -  Final  area  x  100 
Week  0  area 81 
Any  adverse  events  during  the  study  period  were  documented. 
The  wound  was  said  to  be  infected  if  it  demonstrated  at  least  two  of  the  following: 
Abnormal  purplish  granulation  tissue  with  contact  bleeding, 
Exudate 
Pain 
Superficial  Bridging 
Smell 
Lack  of  progress  to  healing  as  documented  by  an  increase  in  the  size  of  a 
wound 
This  criteria  of  wound  infection  classification  was  first  described  by  Cutting  and 
Harding  (Cutting  K  and  Harding  KG,  1994) 
3.2.10  Histology 
Each  fixed  biopsy  was  placed  in  a  capsule  and  passed  through  seven  serial 
concentrations  of  alcohol  and  xylene.  The  specimens  were  then  carefully  embedded  in 
paraffin  wax  and  orientated  so  that  sections  could  be  cut  vertically  through  the 
thickness  of  the  wound  biopsy.  After  solidification,  51im  sections  were  cut  and 
mounted  onto  poly-L-lysine  coated  slides  and  left  overnight  to  dry  at  60°C  in  an  oven. 
The  sections  on  the  slides  were  then  rehydrated  by  passing  the  slides  through  xylene 
for  5  minutes,  followed  by  two  passes  through  100%  alcohol  for  3  minutes.  They 
were  then  stained  with  Haematoxylin  and  Eosin  (H&E). 
The  other  half  of  the  biopsy  that  was  snap  frozen  was  cut  into  6µm  thick  sections 
using  a  microtome  and  mounted  on  poly-L-lysine  coated  slides. 82 
Using  the  immunohistochemical  processing  method  previously  described  in  3.1.4, 
sequential  sections  were  stained  by  a  panel  of  monoclonal  antibodies  to  demonstrate 
the  various  inflammatory  cell  types  involved  in  wound  healing.  The  antibodies  used, 
their  relevant  dilutions,  and  the  order  of  staining  is  shown  in  Table  3-2  and  Appendix 
7.2.  The  order  of  staining  was  important  because  it  ensured  that  the  macrophage  sub- 
populations,  the  lymphocytes,  and  cytokines  were  on  adjacent  sequential  sections,  and 
thus  aided  in  the  subsequent  immunohistochemical  analysis  of  the  tissues.  To 
minimise  any  aberrant  antigen-antibody  reaction  and  staining  patterns  due  to 
environmental  factors  such  as  the  humidity  and  ambient  temperature  of  the  laboratory, 
week  0  and  week  6  sections  for  one  patient  were  processed  in  one  sitting. 
Neutrophils,  which  are  the  first  inflammatory  cells  to  be  encountered  in  wounded 
tissue  were  stained  in  further  cut  wax  sections.  Cryostat  sections  were  abandoned  for 
this  antibody  because  the  antigen  diffused  out  of  the  cells  and  the  cells  were 
surrounded  by  a  `cloud'  of  labeling.  Wax  sections  however  yielded  specific  cellular 
staining.  The  wax  sections  were  brought  to  water  as  described  above,  and  stained  for 
neutrophils  using  the  Avidin-Biotin  peroxidase  technique,  as  previously  described, 
and  developed  with  DAB  substrate. 83 
Table  3-2  Antibody  Panel  used  in  the  Assessment  of  Frozen  sections  in  the  Main 
Study  (Appendix  7.2) 
Monoclonal 
Antibody 
Target  Cell  Dilution 
TNFa  (mouse)  Macrophage  Cytokine  Neat 
IL  1  ß(mouse)  Macrophage  Cytokine  1:  25 
CD68  (mouse)  All  Monocytes  and  Macrophages  1:  50 
27e10  (mouse)  Early  stage  Macrophages  1:  250 
Mannose  (mouse)  Primed  Macrophages  1:  500 
Sialoadhesin  (mouse)  Tissue  Macrophages  1:  20 
CD3  (mouse)  All  T  Lymphocytes  1:  50 
CD4(mouse)  Thelfvr  Lymphocytes  1:  10 
CD8  (mouse)  Tsupp«￿oi  Lymphocytes  1:  30 
CDI9(mouse)  B  Lymphocytes  1:  25 
CD45  (mouse)  All  Leucocytes'  1:  20 
Von  Williebrand 
Antigen  (rabbit) 
Factor  VIII  related  antigen  on 
Endothelial  cells 
1:  150 
VEGF  (mouse)  Endothelial  Cytokine  1:  100 
bFGF  (mouse)  Macrophage  Cytokine  1:  150 
TGFI3  (rat)  Macrophage  Cytokine  1:  400 
Neutrophil  Elastase 
(mouse) 
Neutrophils  1:  200 84 
3.2.11  Analysis 
3.2.11.1  Clinical 
The  primary  end  point  in  the  clinical  assessment  was  complete  wound  closure  by 
week  12.  The  secondary  end  point  was  to  assess  the  reduction  in  the  ulcer  area  at  the 
end  of  the  12  week  study  even  if  complete  closure  was  not  achieved.  Finally,  and 
most  importantly,  the  safety  of  DG  was  assessed  by  documenting  all  the  adverse 
events  that  occurred  to  the  study  patients  during  their  trial  period,  even  when  the 
adverse  event  was  not  directly  related  to  the  application  of  DG. 
3.2.11.2  Histological 
3.2.11.2.1  Wax  sections 
Each  patient  was  assigned  a  random  number.  Week  0  and  week  6  biopsies  were 
randomly  assigned  letters  a  and  b.  The  sections  were  analysed  as  a  pair  by  two 
assessors  who  were  blinded  as  to  which  biopsy  was  week  0  and  which  was  week  6. 85 
Both  assessors  analysed  the  sections  for  the  following 
1.  Thickness  of  granulation  tissue  (µm) 
2.  Pattern  of  collagen  and  the  distribution  of  extracellular  matrix 
3.  Blood  vessel  volume  and  distribution 
4.  Percentage  of  blood  vessel  cuffing 
5.  Cell  profile  -  polymorphonuclear  cell  levels,  lymphocyte  cell  levels 
6.  The  degree  of  fibrosis  at  the  base  of  the  sections 
Histological  examination  of  the  changes  between  week  0  and  6  biopsy  sections 
concentrated  on  three  areas 
1.  The  extracellular  matrix  and  collagen  distribution 
2.  The  nature  and  distribution  of  the  blood  vessels 
3.  The  types  of  cells  present  in  the  wound  tissue. 
Extracellular  matrix  and  collagen  distribution 
The  measurements  were  mostly  semi-quantitative,  but  as  the  biopsies  were  assessed  in 
pairs,  a  and  b,  the  findings  were  sufficiently  robust  to  detect  any  gross  differences. 
The  amount  of  extracellular  matrix  present  was  graded  as  none,  low,  medium,  high  or 
full  and  its  distribution  was  evaluated  as  patchy  or  even  on  photomicrograph  images 
captured  using  Photonics  Science  digital  camera  and  Image  Proplus  4  software. 86 
The  thickness  of  the  granulation  tissue  was  measured  from  the  junction  between  the 
exudate  and  granulation  tissue  to  the  junction  of  the  granulation  tissue  and  the 
underlying  scar  or  dermis  using  an  eye-piece  with  a  micrometer. 
The  pattern  of  the  collagen  I  mm.  from  the  wound  surface  was  classified  as  broad 
mature  bundles,  intermediate  bundles,  fine  fibres,  or  purely  myxoid. 
The  degree  of  fibrosis  at  the  base  of  the  biopsy  specimens  was  semi-quantatively 
graded  as  Normal  (basket  weave  pattern  composed  of  normal  thickness  fibres), 
Medium  (orientated  fibres  composed  of  normal  thickness  fibres),  and  Dense 
(orientated  fibres  composed  of  densely  packed  fine  collagen) 
The  nature  and  distribution  of  the  blood  vessels 
The  number  of  vascular  units  seen  per  mm2  was  counted  in  all  sections.  These  were 
usually  arranged  in  lobules  as  clusters  of  proliferating  capiillaries  similar  to  an 
angioma  that  is  being  fed  by  a  vessel  from  the  deep  dermis. 
The  orientation  of  the  vessels  to  the  surface  of  the  biopsy  was  also  recorded,  and  this 
was  classified  as  random  or  perpendicular  to  the  wound  surface.  The  percentage  of 
vessels  with  fibrin  cuffs  in  the  granulation  tissue  were  estimated  by  observing  the 
degree  of  cuffing  and  described  as  none,  medium  or  high.  From  this  the  approximate 
percentage  of  blood  vessels  in  the  ulcer  with  any  degree  of  fibrin  cuffing  was 
calculated. 87 
Cellular  pattern  and  distribution 
The  type  and  distribution  of  the  cells  present  were  evaluated.  The  cellular  infiltration 
within  the  granulation  tissue  was  assessed  separately  for  the  polymorphs  and  the 
lymphocytes,  using  a  grading  scale 
1.  No  significant  infiltrate  -  0% 
2.  Intermediate  between  1  and  3 
3.  Occasional  aggregates  -  25  % 
4.  Intermediate  between  3  and  5 
5.  Several  aggregates  or  moderately  diffuse  infiltration  -  75% 
6.  Intermediate  between  5  and  7 
7.  Confluent  aggregates  -100% 
Values  2,4  and  6  were  usually  used  for  adjustment  when  the  two  paired  biopsies  were 
compared  directly 
3.2.11.2.2  Frozen  sections 
Field  Selection 
Low  power  views  of  the  tissue  quickly  demonstrated  that  the  sections  were  made  up 
vascular  and  avascular  areas.  As  in  the  pilot  study,  the  overall  shape  of  the  section 
was  documented  and  the  area  counted  was  highlighted  in  the  in  the  diagram.  This  was 
performed  to  ensure  that  the  same  area  was  counted  for  the  various  inflammatory 
cells,  thus  minimising  any  errors  by  counting  different  areas  for  different  cells.  Once 88 
the  test  area  was  identified,  the  number  of  positive  cells  was  counted  in  12  sequential 
fields. 
The  inflammatory  cells  were  quantified  by  morphological  identification  and  counting 
at  x40  magnification.  This  was  performed  as  before  by  projecting  the  microscopic 
image  onto  a  computer  screen  and  each  positively  stained  cell  was  counted  without 
duplication  using  the  software  programme  as  in  the  pilot  study. 
The  number  of  blood  vessels  was  counted  for  the  whole  section,  and  was  standardised 
by  representing  the  data  as  the  number  of  blood  vessels  per  unit  area. 
Cytokine  expression  within  the  wound  bed  sections  were  graded  on  a1  to  4  basis, 
where 
1=  0-  24%  of  the  cells  positive 
2=  25  -  49%  of  the  cells  positive 
3=  50  -  74%  of  the  cells  positive 
4=  75  -  100%  of  the  cells  positive. 
3.2.12  Statistical  Analysis 
3.2.12.1  Statistical  analysis  of  clinical  outcomes  in  the  DG  study 
The  primary  endpoint  in  this  study  was  complete  healing.  This  study  was  not  powered 
to  detect  a  difference  in  the  proportion  of  patients  who  healed  by  week  12,  but  it  was 
planned  to  conduct  pair  wise  comparisons  as  descriptive  summary  statistics.  Fisher's 
exact  test  was  used  for  the  pair  wise  comparisons  as  the  sample  size  and  numbers 
healed  were  low. 89 
The  secondary  efficacy  endpoint  was  time to  wound  closure  and  this  was  represented 
as  the  median  closure  time.  No  formal  hypothesis  testing  was  conducted  owing  to  the 
low  number  of  patient  healing  in  each  treatment  group. 
3.2.12.2  Statistical  analysis  of  wax  sections  in  the  DG  study 
The  relationships  of  the  treatment  regimen  to  histological  changes  were  examined. 
For  each  of  the  DG  treatment  groups  compared  with  control,  any  changes  from  week 
0  to  week  6  in  histology  measures  were  assessed.  Fisher's  exact  test  was  applied  to 
the  binary  histology  measures  at  week  0  and  week  6  (i.  e.  two  by  two  tables)  and  the 
Mann-Whitney  U  test  was  used  for  all  other  comparisons. 
3.2.12.3  Statistical  analysis  of  the  frozen  sections  in  the  Pilot  and  DG 
study 
The  cell  type  distributions  in  the  sections  for  the  pilot  study  and  the  DG  study  were 
compared  using  the  Mann-Whitney  U  test. 
Differences  in  the  cytokines  for  the  different  treatment  times  and  groups  were 
compared  using  a  simple  comparative  analysis  based  on  an  increase  or  decrease  in  the 
intensity  of  the  staining. 90 
4  CHAPTER  FOUR:  RESULTS 91 
4.1  PILOT  STUDY 
4.1.1  Patient  group 
Ten  patients  with  clinically  non-infected  pilonidal  sinus  wounds  and  ten  patients  with 
clinically  non-infected  venous  leg  ulcers  were  recruited  into  the  pilot  study.  All 
twenty  patients  matched  the  inclusion  criteria  outlined  in  section  3.1.1.  Patient 
compliance  was  100%  for  this  part  of  the  study. 
4.1.2  Biopsies 
All  biopsies  were  easily  obtained  with  minimal  discomfort  to  the  patient  following 
infiltration  of  1%  plain  Lignocaine  into  the  wound  bed.  The  use  of  a  6mm  punch 
resulted  in  a  good  sample  yield.  The  biopsy  was  robust  and  withstood  handling  during 
the  freezing  process.  Although  minimal  bleeding  was  anticipated  and  encountered  in 
most  patients  of  both  groups,  two  patients  in  the  venous  leg  ulcer  group  needed 
prolonged  compression  and  a  review  of  the  wound  two  days  after  the  biopsy.  In  these 
patients,  the  biopsy  was  carried  out  near  a  blood  vessel,  which  was  partially 
transected  in  the  process.  However  there  were  no  long-term  sequelae  as  a  result  of 
this.  Therefore  a  total  of  20  biopsies  were  available  for  the  pilot  study. 92 
4.1.3  Specimen  preparation 
Microtome  sections  of  6µm  in  thickness  were  found  to  give  the  most  stable  slice  with 
minimal  distortion  and  disintegration  of  the  tissue  whilst  cutting  and  mounting  onto 
poly-L-lysine  coated  slides. 
4.1.4  Analysis 
4.1.4.1  Microscopic  Analysis 
Identification  of  the  inflammatory  cell  groups  was  accomplished  morphologically, 
and  by  staining  for  expression  of  subset-specific  antigens.  Positively  stained  cells 
were  brown  in  colour  and  the  negatively  stained  cells  were  blue.  Cell  populations 
were  quantitatively  assessed  using  the  counting  methods  described  in  section  3.1.6.2 
4.1.4.2  Qualitative  Evaluation 
The  salient  features  of  individual  cells  in  addition  to  those  cells  positively  stained  by 
DAB  were  identified  and  the  criteria  for  assessing  the  sections  were  established  as 
previously  described  in  section  3.1.6.1. 93 
4.1.4.3  Field  selection 
Low  power  views  (x10  magnification)  of  the  wound  bed  sections  quickly 
demonstrated  that  the  wound  had  areas  of  vascularisation  with  abundant  cellular 
infiltrate  and  avascular  areas  with  sparse  cellular  infiltrate. 
The  macrophage  infiltrate  of  all  biopsies  was  quantified  within  the  vascularised  area 
of  the  section,  by  morphological  identification  and  counting  the  number  of  positively 
stained  cells  at  x40  magnification  view.  The  overall  shape  of  the  section  was 
documented  to  minimise  any  errors  that  may  occur  by  counting  different  areas  for  the 
different  antibody  positive  cells.  (Figure  4-1) 94 
Figure  4-1  Low  power  photomicrograph  depicting  the  salient  features  of  a 
wound  bed  biopsy 
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The  vascular  area  contained  the  abundant  cells  and  the  avascular  area  was  predominanth 
made  up  of  connective  tissue  with  little  cellular  infiltrate. 95 
4.1.4.4  Reproducibility  of  counting 
A  more  useful  indication  of  the  reproducibility  of  counts  is  the  standard  deviation  of 
the  differences  between  the  first  and  second  counts,  and  between  investigator  1  and 
investigator  2.  This  allows  for  the  assessment  of  the  differences  between  the  counts, 
whilst  excluding  differences  between  separate  biopsies.  By  comparing  this  figure  with 
the  magnitude  of  the  counts,  a  degree  of  reproducibility  can  be  appreciated.  This 
method  can  be  further  verified  by  plotting  the  difference  between  the  two  counts 
against  the  mean,  as  described  by  Bland  and  Altman  (Bland  JM  and  Altman  DG, 
1986). 
Table  4-1  summarises  the  mean  positive  cell/field  of  12  fields  of  two  separate  blind 
counts  by  the  investigator  for  the  monoclonal  antibody  SR  stained  cells.  It  can  be  seen 
that  the  mean  values  for  the  two  counts  were  34.0  and  33.5  respectively.  The 
Pearson's  correlation  coefficient  for  this  set  of  data  was  0.97.  The  standard  deviation 
of  the  differences  between  the  counts  was  4.2,  which  was  small  compared  to  the 
standard  deviation  of  the  counts  themselves,  which  were  10.4  and  9.6  respectively. 
When  the  differences  between  the  two  counts  for  SW'  macrophages  is  plotted  against 
the  mean  of  both  counts  (Figure  4-2),  the  counts  displayed  a  pattern  distributed  evenly 
around  the  0  level.  80%  of  the  counts  were  within  ±5  of  the  differences  demonstrating 
reasonable  agreement  between  the  groups.  Hence  there  is  a  good  degree  of 
reproducibility  between  the  two  counts. 96 
Table  4-1  Results  of  two  separate  blind  counts  of  SR  monoclonal  antibody 
stain  in  ten  chronic  wound  sections 
Patient  No  1'`  Count  (SD)  2°d  Count  (SD)  Mean  Difference 
1  10.3  (5.3)  17.5  (8.4)  13.9  -7.2 
2  39.7  (11.5)  37.1  (8.5)  38.4  2.6 
3  27.7  (7.6)  25.4  (7.4)  26.6  2.3 
4  63.3  (13.8)  60.9  (12.8)  62.1  2.4 
5  78.9  (23.4)  64  (20.4)  71.5  14.9 
6  34.4  (14)  41.7  (10.7)  38.1  -7.3 
7  23.9  (7.6)  27(7.8)  25.5  -3.1 
8  4.3  (2.9)  4.5  (3.9)  4.4  -0.2 
9  34  (14)  37.6  (10.9)  35.8  -3.6 
10  23.2  (4.1)  18.9  (5)  21.1  4.3 
MEAN  34.0(10.4)  33.5  (9.6)  SD  4.2 97 
Figure  4-2  Differences  between  two  separate  blind  counts  of  SR+''` 
macrophages  plotted  against  their  mean  demonstrating  reasonable  agreement 
between  the  groups 
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Table  4-2  summarises  the  mean  counts  two  blind  counts  by  two  investigators  of  the 
SR  monoclonal  antibody  stain  for  five  acute  and  five  chronic  wound  sections. 
The  mean  for  the  first  investigator  was  22  and  for  the  second  was  19.  The  Pearson's 
correlation  coefficient  for  the  investigators  is  0.94.  The  standard  deviation  of  the 
difference  between  the  counts  was  4.9,  this  value  is  smaller  when  compared  to  the 
standard  deviation  of  the  two  counts  themselves,  which  were  7.1  and  8.8  respectively. 
Figure  4-3  is  a  plot  of  the  differences  between  the  counts  of  two  investigators  of  SR*Ve 
macrophages.  For  lower  mean  values  the  differences  are  small,  but  for  the  larger 
means,  there  tended  to  be  a  splay.  There  was  also  a  tendency  for  investigator  1  to  have 98 
higher  counts  for  the  larger  means.  However,  it  can  be  shown  that  there  seems  to  be 
an  acceptable  degree  of  reproducibility  between  the  two  investigators. 
Table  4-2  Results  of  two  separate  blind  counts  by  two  investigators  of  SR 
monoclonal  antibody  stain 
Patient 
No 
1'`  Investigator 
Mean  (SD) 
2"d  Investigator 
Mean  (SD)  Mean  Difference 
1  10.3  (4.5)  10.6  (8.1)  10.4  -0.3 
2  8.9  (3.9)  10.1  (5.2)  9.5  -1.2 
3  10.9  (3.2)  11.9  (10)  11.4  -1 
4  19.6  (9.0)  8.4  (5.5)  14  11.2 
5  11.1  (3.0)  11.8  (10.3)  11.5  -0.7 
6  10.3  (5.3)  9.5  (4.6)  9.9  0.8 
7  23.9  (7.6)  14.9  (5.9)  19.4  9 
8  27.7  (7.6)  14.4  (6.7)  21.1  13.3 
9  63.3  (13.8)  67.5  (18.2)  65.4  -4.2 
10  34.4  (14.0)  30.9  (13.8)  32.7  3.5 
MEAN  22.0  (7.1)  19.0  (8.8)  SD  4.9 99 
Figure  4-3  Difference  between  two  different  investigator  counts  of  SR' 
macrophages  plotted  against  their  mean  demonstrating  an  acceptable  degree  of 
reproducibility  between  the  two  investigators 
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In  summary,  it  was  possible  to  demonstrate  reproducibility  of  the  counts  by  the 
investigator  on  two  separate  occasions,  and  correlation  in  the  counts  between 
investigators  1  and  2. 100 
4.1.4.5  Macrophage  sub-population  distribution  in  acute  and  chronic 
wounds 
4.1.4.5.1  Pan  Macrophage  Marker  CD68 
Both  wound  types  demonstrated  an  abundance  of  monocytes  and  macrophages  within 
the  sectioned  biopsy  from  the  wound  bed,  stained  by  the  pan-macrophage  surface 
antigen  CD68.  The  maximal  concentration  of  macrophages  could  be  seen  around  the 
blood  vessels.  As  previously  stated,  due  to  the  abundance  of  macrophages  identified 
by  the  CD68  antibody,  it  was  impossible  to  obtain  a  numerical  count  of  this  antigen. 
Hence  a  scoring  system  was  introduced  to  standardise  the  evaluation  of  these  slides.  A 
score  of  grade  3  denotes  50  -  74%  of  all  cells  within  the  section  staining  positive  for 
the  CD68  antigen,  and  a  score  of  grade  4  denotes  75  -  100%  of  all  cells  staining 
positive  for  the  CD68  antigen.  (Table.  4-3) 
For  the  other  macrophage  sub-population  markers  the  mean  count  of  positively 
stained  cells  (and  the  standard  deviation)  was  calculated. 101 
Table  4-3  Distribution  of  the  Pan-Macrophage  MarkerCD68  in  Acute  and 
Chronic  Wounds  (Grades) 
Patient  No.  Acute  Wounds  Chronic  Wounds 
1  3  4 
2  4  3 
3  4  4 
4  3  3 
5  4  4 
6  4  4 
7  4  4 
8  3  3 
9  3  3 
10  3  4 
From  the  above  table  it  can  be  seen  there  is  an  abundance  of  monocytes  and 
macrophages  within  the  acute  and  chronic  wound  beds.  This  suggests  that  both 
healing  and  non-healing  wounds  have  large  numbers  of  macrophages  and  given  the 
right  condition  all  wounds  should  heal.  The  photomicrographs  of  the  two  wound  types 
also  exhibit  these  observations.  (Figure.  4-4) 102 
Figure  4-4  Distribution  of  CD68+`  Cells  in  the  Beds  of  Acute  and  Chronic 
Wounds 
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This  shows  that  both  healing  and  non-healing  wounds  have  large  numbers  of 
macrophages 
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4.1.4.5.2  Early  Macrophage  Marker-  27e10 
The  mean  count  of  the  early  stage  macrophages  within  the  acute  wound  is  20.8  (8.6) 
and  within  the  chronic  wound  is  10.4  (6.7).  These  are  significantly  different 
(p<0.01).  (Table.  4-4)  The  higher  mean  count  of  27e  10+"  cells  within  the  acute  wound 
when  compared  to  the  chronic  wound  can  also  be  seen  in  (Figure  4-5) 
Table  4-4  The  Mean  Distribution  (and  Standard  Deviation)  of  Early 
Macrophages  27e10+Ve  Cells  Within  Acute  and  Chronic  Wounds 
Patient  No.  Mean  (SD)  cells  in 
acute  wounds 
Mean  (SD)  cells  in 
chronic  wounds 
1  16.1  (10.4)  9.5  (3.8) 
2  19.1  (7.9)  10.4  (3.1) 
3  22.2  (4.3)  13.0  (6.6) 
4  27.1  (11.7)  13.2  (16.9) 
5  21.7  (5.7)  4.7  (4.3) 
6  40.3  (20.4)  5.9  (4.4) 
7  17.9  (5.3)  11.3  (11.2) 
8  21.3  (8.2)  25.9  (9.3) 
9  29.0  (7.4)  4.2  (3.0) 
10  14.6  (4.8)  6.3  (5.1) 
Mean  (SD)  20.8  (8.6)  10.4  (6.7) 
Statistical  Test:  Mann-Whitney  U  p5  0.01 104 
Figure  4-5  Distribution  of  27e10+"  Cells  in  the  Beds  of  Acute  and  Chronic 
Wounds 
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This  shows  that  there  are  more  27e  1  Ve  cells  in  acute  wounds  than  in  chronic  wounds 
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4.1.4.5.3  Primed  Macrophage  Marker  -  MR 
The  mean  count  of  primed  macrophages  within  the  acute  wound  was  55.4  (15.2).  This 
was  similar  to  the  mean  count  seen  in  the  chronic  wound  of  54.3  (19.2)  and  was  not 
statistically  significant  (p=0.82).  This  implies  that  the  distributions  of  primed 
macrophages  within  the  acute  and  chronic  wound  types  were  of  similar  magnitude. 
This  suggests  that  until  these  macrophages  are  activated  both  wounds  behave  in  a 
similar  manner  in  response  to  injury.  (Table  4-5)(Figure  4-6) 
Table  4-5  The  mean  (and  standard  deviation)  of  the  primed  surface  antigen 
marker  MR+`  cells  within  acute  and  chronic  wounds 
Patient  No.  Mean  (SD)  cells  in 
acute  wound 
Mean  (SD)  cells  in 
chronic  wounds 
1  64.2  (19.8)  28.7  (7.1) 
2  54.8  (13.3)  68.8  (20.9) 
3  78.3  (23.7)  50.3  (22.7) 
4  36.1  (8.4)  76  (32.9) 
5  59.2  (12.8)  82.2  (37.3) 
6  43.7  (13.6)  67.7  (19.8) 
7  72.1  (20.2)  45.3  (17.2) 
8  50.7  (11.0)  32.2  (10.0) 
9  47.6  (15.8)  53.3  (10.4) 
10  47.7  (13.4)  39.0  (13.7) 
Mean  (SD)  55.4  (15.2)  54.3  (19.2) 
Statistical  test  Mann-Whitney  Up=0.82 106 
Figure  4-6  The  Distribution  of  MR+`Cells  in  the  Beds  of  Acute  and  Chronic 
Wounds 
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4.1.4.5.4  Tissue  Macrophage  Marker  -  SR 
The  mean  count  of  the  tissue  macrophage  marker  SR+"  cells  for  the  acute  wound  was 
10.9  (4.4)  and  for  the  chronic  wound  was  34.0  (10.5),  which  was  statistically 
significant  (p<0.01).  (Table  4-6)  This  suggests  that  there  were  a  greater  proportion  of 
tissue  macrophages  within  the  chronic  wounds,  when  compared  to  acute  wounds. 
(Figure  4-7) 
Table  4-6  The  mean  distribution  (standard  deviation)  of  tissue  macrophages 
SR+`e  cells  within  acute  and  chronic  wounds 
Patient  No.  Mean  (SD)  cells  in 
acute  wounds 
Mean  (SD)  cells  in 
chronic  wounds 
1  8.9  (3.9)  10.3  (5.3) 
2  10.2  (4.5)  39.7  (11.5) 
3  7.7  (4.7)  27.7  (7.6) 
4  6.8  (2.3)  63.3  (13.8) 
5  9.0  (4.0)  78.9  (23.4) 
6  19.6  ((9.0)  34.4  (14.0) 
7  14.8  (5.8)  23.9  (7.6) 
8  11.1  (3.0)  4.3  (4.1) 
9  10.9  (3.2)  23.2  (4.1) 
10  9.9  (3.1)  34.0  (14.0) 
Mean  (SD)  10.9  (4.4)  34.0  (10.5) 
Statistical  TestMann-Whitney  U  p<0.01 108 
Figure  4-7  The  Distribution  of  SR+`e  Cells  in  the  Beds  of  Acute  and  Chronic 
Wounds 
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In  summary,  both  acute  and  chronic  wounds  exhibit  similar  magnitude  of  the  pan- 
macrophage  marker  CD68+Ve  cells  and  the  primed  macrophage  marker  MRS"  cells. 
However,  acute  wounds  demonstrate  a  significantly  larger  mean  count  of  the  early 
macrophage  marker  27e10+`e  cells  than  chronic  wounds,  and  chronic  wounds 
demonstrate  a  significantly  larger  mean  count  of  the  tissue  macrophage  marker  SR  +" 
cells  than  the  acute  wounds.  This  is  summarized  in  Table  4-7. 
Table  4-7  Cumulative  mean  distribution  of  the  sub-population  of 
macrophage  within  acute  and  chronic  wounds. 
Macrophage 
Antigens 
Mean  (SD)  cells  in 
acute  wounds 
Mean  (SD)  cells  in 
chronic  wounds 
Stastistical 
significance 
CD68  4  4  No 
27e10  20.8  (8.6)  10.4  (6.7)  Yes 
MR  55.4  (15.2)  54.3  (19.2)  No 
SR  10.9  (4.4)  34  (10.5)  Yes 110 
4.2  DERMAGRAFT  STUDY 
4.2.1  Patient  population 
The  study  involved  6  centres,  3  centres  in  the  UK  and  3  centres  in  Canada  and  was 
live  for  8  months  from  the  time  the  first  patient  entering  the  study  to  the  completion  of 
the  last  patient. 
63  patients  were  assessed  at  the  screening  visit.  After  one  or  two  weeks  of  multi-layer 
compression  therapy  prior  to  week  0,10  patients  were  not  randomised  at  the  week  0 
visit.  The  reasons  for  this  is  summarised  in  Table.  4-8 
Table  4-8  Summary  of  patients  not  randomised 
Centre  Sex  Age  Weeks  of 
Compression 
Reason  for  withdrawal 
Cardiff  M  70  1  Ulcer  almost  healed 
Cardiff  F  79  2  Ulcer  infected 
Cardiff  M  74  1  Ulcer  healed  66% 
Cheltenham  M  85  1  Withdrew  consent 
Cheltenham  M  72  1  Withdrew  consent 
Cheltenham  F  84  1  Withdrew  consent 
Toronto  M  81  2  Ulcer  infected 
Toronto  F  73  2  Ulcer  infected 
Mississauga  F  67  2  Ulcer  infected 
Winnipeg  F  75  1  Ulcer  healed 
. Ad 111 
4.2.2  Ethics 
Original  and  amended  protocols  were  assessed  and  approved  by  the  two  ethical  bodies 
with  minimal  disruption  to  the  study,  the  Independent  Ethics  Committee  (IEC)  in 
Canada,  and  Local  Research  Ethics  Committees  (LRECs)  in  the  UK. 
4.2.3  Screening  and  treatment  protocol 
Out  of  the  63  patients  screened,  53  patients  entered  the  randomisation  phase  of  the 
study.  There  were  22  men  and  31  women,  with  an  overall  mean  age  of  68.7  years 
(range  22  -  90  years).  The  overall  mean  age  for  the  22  men  was  68.7  (range  22  -  83 
years)  and  for  the  women  was  69.7  (range  37  -  90  years).  The  overall  mean  body 
weight  of  these  53  patients  was  87.3  Kg  (range  50  -  155  Kg),  men  94.1  Kg  (range  50 
-  155  Kg)  and  women  79.3  Kg  (range  50.9  -  143  Kg)  and  the  body  mass  index  was 
30.4  (range  19  -  61.9)  men  30.6  (range  19  -  47  8)  and  women  30.4  (range  19.3  - 
61.9).  The  mean  ankle-brachial  pressure  index  was  calculated  to  be  1.1  (range  0.7  - 
1.6),  men  1.07  (range  0.7  -  1.6)  and  women  1.1  (range  0.7  -  1.5). 
Out  of  the  53  patients  who  eventually  enrolled  into  the  study,  superficial  venous 
reflux  was  demonstrated  in  45  out  of  49  patients  and  deep  vein  reflux  was  confirmed 
in  44  out  of  49  patients.  Reflux  could  not  be  assessed  in  4  patients  due  to  non- 
availability  of  hospital  ultrasound  equipment.  These  patients  however  were  clearly 
found  to  have  clinical  evidence  of  venous  ulceration. 
The  demographics  were  evenly  distributed  across  the  four  randomisation  groups. 
(Table  4-9) 112 
Table  4-9  Demographics  of  patients  across  the  four  treatment  groups 
Group  Number  Mean  Body 
Weight  (Kg) 
Mean  Body 
Mass  Index 
Mean  Ankle 
Brachial 
Pressure  Index 
Men  Women  Men  Women  Men  Women  Men  Women 
Gpl  5  8  115.8  79.4  38.0  31.4  1.1  1.1 
Gp2  4  9  83.3  92.7  28.4  33.9  1.3  1.1 
Gp3  7  7  85  79.2  26.2  27.8  1.0  1.1 
Gp4  6  7  93.8  75.7  30.9  31.5  1.1  1.1 
4.2.4  Study  Treatment  Randomisation 
After  the  initial  randomisation,  blinding  was  not  possible  to  those  applying  the 
investigational  product,  because  the  characteristics  of  the  study  product  DG,  could  be 
easily  distinguished  from  the  polyglactin  mesh  alone.  The  mesh  alone  may  also 
interact  with  the  wound  to  such  an  extent  that  it  could  make  interpretation  of  the 
results  difficult.  Consequently,  patients  with  DG  plus  multi-layer  compression 
bandage  therapy  versus  a  control  group  of  patients  who  received  multi-layer 
compression  bandage  therapy  only  were  compared. 
Compliance  was  assured  both  in  the  application  of  DG  and  with  the  multi-layer 
compression  therapy,  as  these  occurred  in  the  controlled  setting  of  a  clinic  in  each 
centre. 
53  patients  entered  the  randomised,  controlled  phase  of  the  study.  The  distribution  of 
these  patients  into  the  four  groups,  centre  by  centre  is  seen  in  Table  4-10. 113 
Table  4-10  Distribution  of  patients  in  the  four  treatment  groups 
Centre  1  2  3  4  Total 
Cardiff  6  7  7  6  26 
Cheltenham  2  2  2  2  8 
Stockton- 
on-Tees 
1  1  1  1  4 
Toronto/ 
Mississauga 
2  2  2  2  8 
Montreal  2  1  2  2  7 
Winnipeg  0  0  0  0  0 
Total  13  13  14  13  53 
The  mean  size  of  the  target  ulcer  was  similar  between  the  four  groups,  but  the 
duration  of  the  ulcer  varied  between  the  four  groups.  This  is  shown  in  Table  4-11 114 
Table  4-11  Duration  of  ulceration  and  size  of  ulcer,  which  is  similar  in  the 
four  treatment  groups 
Groups  Group2  Group3 
Median  ulcer  size  at  8.6  5.6  6.8 
Week  0  (cm2)  [6.1-22]  [3.6-20.2]  [3.7-25] 
[Range] 
Median  duration  of  34.7  52.0  43.3 
target  ulcer  (wks)  [13-260]  [9--260]  [12---2391 
[Range] 
Group4 
[3.7-25] 
73.7 
[9  2601 
After  randomisation,  6  patients  withdrew  from  the  study,  of  these  I  patient  developed 
wound  infection,  1  patient  developed  severe  excoriation  from  the  four-layer  bandage, 
3  patients  stopped  using  the  compression  bandages,  and  I  patient  did  not  receive  DG. 
Thus  47  patients  completed  the  study  as  per  protocol.  Table  4-12. 
Table  4-12  Reason  for  withdrawal  after  randomisation 
Centre  Group  Reason  for  Withdrawal 
Cardiff  2  Wound  infection 
Cardiff  3  Excoriation  to  bandages 
---  --  Cardiff  3  --  ----------  Patient  withdrew  consent 
Cheltenham  3  Non-compliance  with  compression 
Cheltenham  3  Non-compliance  with  compression 
Montreal  3  Did  not  receive  DG 115 
4.2.5  Biopsy  procedure 
Three  patients  refused  the  second  biopsy  but  were  followed  up  until  completion  of  the 
study  to  clinically  assess  the  progress  of  the  target  ulcer  towards  healing,  and  four 
week  6  biopsies  were  of  inadequate  depth  to  perform  valuable  histological 
evaluations. 
4.2.6  Assessment  of  Healing 
4.2.6.1  Clinical  Assessment 
Photographs  of  the  wound  and  clinical  assessment  of  the  ulcer  and  patient  were  useful 
in  identifying  early  adverse  events  during  the  study  period. 
Figure  4-8  shows  the  disposition  of  all  patients  and  the  progress  through  the  phases  of 
the  trial rr  i 
116 
Figure  4-8  Algorithim  of  Sample  Size  and  Disposition  of  all  Patients  in  the 
Main  Study 
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4.2.6.2  Histological  Assesment 
4.2.6.2.1  Wax  sections  from  patient  biopsy 
The  ethanol  preserved  part  of  the  biopsies  were  mounted  in  wax,  sectioned,  and 
stained  in  the  laboratories  at  the  Smith  and  Nephew,  Group  Research  Centre,  York, 
UK.  The  stained  slides  were  analysed  by  a  researcher  at  Smith  and  Nephew,  York  and 
by  an  experienced  Histopathologist  with  the  investigator.  Out  of  the  47  patients  who 
completed  the  study,  35  paired  biopsies  were  analysed  at  York  and  33  at  Cardiff.  The 
main  cause  of  non-evaluable  biopsies  was  insufficient  biopsy  depth  in  some  as  they 
only  contained  wound  eschar.  The  shallow  biopsies  were  subsequently  traced  to 
specimens  obtained  from  peripheral  centres  and  not  by  the  investigator  at  the  Cardiff 
centre.  The  second  cause  of  non-evaluable  biopsies  was  tissue  destruction  during 
processing  of  the  sections.  This  was  done  by  Smith  and  Nephew,  UK  (York),  using  an 
automated  method  which  resulted  in  heat  damage  to  one  set  of  slides. 
4.2.6.2.2  Frozen  sections  from  patient  biopsy 
Out  of  the  47  patients  who  completed  the  study,  40  pairs  of  biopsies  were  analysed.  A 
second  sample  was  not  obtained  from  3  patients,  and  in  the  remaining  four  sets  the 
biopsies  were  too  shallow  to  allow  any  meaningful  analysis. 118 
4.2.7  Outcome  Analysis 
4.2.7.1  Clinical 
Of  the  47  patients  who  completed  the  study,  13  patients  (27.7%)  healed  during  the 
course  of  the  study,  and  34  patients  (72.3%)  had  an  ulcer  remaining  at  the  end  of  the 
study  period.  (Table  4-13) 
Table  4-13  Randomised  patients  and  their  disposition  over  the  course  of  the 
study 
Randomisation  Group 
Centre 
No 
1  2  3  4  Total  Overall 
H  U  H  U  H  U  H  U  H  U  Totals 
1  1  5  2  4  0  5  1  5  4  19  23 
2  1  1  40  2  0  1  1  0  2  4  6 
3  0  1  1  0  1  0  0  1  2  2  4 
4  1  1  2  0  0  2  0  2  3  5  8 
5  2  0  0  1  0  1  0  2  2  4  6 
Totals  5  8  5  7  1  9  2  10  13  34  47 
(H  =  healed:  U=  unhealed) 119 
4.2.7.2  Efficacy 
4.2.7.2.1  Number  of  patients  healed  in  the  12  week  study  period 
The  difference  between  the  treatment  groups  (1,2  and  3)  was  not  significant  (Fisher's 
exact  test).  When  groups  I  and  3,  and,  groups  2  and  3  respectively  were  compared, 
they  approached  significance  with  ap=0.06.  The  small  number  of  patients  in  the 
study  groups  may  have  a  contributory  factor  in  the  statistical  outcome. 
However,  when  compared  to  Control  (group  4),  a  higher  proportion  of  patients  healed 
in  groups  I  and  2,  than  group3.  (Table  4-14) 
Table  4-14  Distribution  of  healing  in  the  treatment  groups 
STUDY  POPULATION 
Group  I  Group  2  Group  3 
(n=13)  (n=13)  (n=14) 
Median  Ulcer  Size  at  Week  0 
(cm2)  8.6  5.6  6.8 
Median  Duration  of  Ulceration 
(weeks)  34.7  52.0  43.3 
No.  of  Ulcers  Healed  at  Week  12  5/13  5/13  1/14 
(38%)  (38%)  (7%) 
Croup  4 
(n  =  13) 
9.2 
73.7 
2/13 
15qä 120 
4.2.7.2.2  Time  to  wound  closure 
Ulcer  Area 
At  the  end  of  the  study  period  i.  e.  at  12  weeks,  the  median  reduction  in  ulcer  area  was 
81.4%  for  group  1,88.6%  for  group  2,59.4%  for  group  3,  and  78.1  %  for  group  4. 
(Table.  4-15) 
Table  4-15  Percentage  Reduction  in  Wound  Area  at  week  12  of  Study 
%  Reduction 
in  Area 
Group  I  Group  2  Group  3  Group  4 
Mean  68.1  58.2  41.1  32.1 
Median  81.4  88.6  59.4  78.1 
Std  39.2  63.7  60.5  39.2 
Minimum  -11.3  -119.1  -117.7  -21.7 
Maximum  i  100  100  100  100 
Number  13  13  14  13 
The  healing  rates  for  each  treatment  group  when  compared  to  the  baseline  ulcer  area 
and  duration  demonstrated  that  ulcers  up  to  l  Ocm2  that  had  been  present  for  up  to  I 
year  prior  to  the  study  was  60°'o  (3  out  of  5)  for  group  1,57%  (4  out  of  7)  for  group  2, 
0%  (0  out  of  4)  for  group  3,  and  33%  (1  out  of  3)  for  group  4.  (Table.  4-16) 121 
Table  4-16  Number  of  patients  healed  by  week  12  with  small  ulcers  present 
for  <1  year 
Area  CM2  Gp  l  Gp  2  Gp  3  Gp  4 
3-5.0  H=0 
U=0 
H=2 
U=  1 
H=O 
U=3 
H=0 
U=2 
5.01-7.5  H=  1 
U=2 
H=  1 
U=2 
H=O 
U=  1 
H=  I 
U=0 
7.51-10.0  H=  1 
U=0 
H=  1 
U=0 
H=O 
U=  1 
H=O 
U=0 
Total  (healed)  3/5  4/7  0/4  1/3 
Percentage  60  57  0  33 
(H  =  Healed,  U=  Unhealed) 
Even  when  all  ulcer  sizes  were  grouped  together  (maximum  of  25cm2)  present  for  up 
to  a  year,  the  healing  rates  are  shown  to  be  62.5%  (5  out  of  8)  for  group  1,44%  (4  out 
of  9)  for  group  2,12.5%  (1  out  of  8)  for  group  3,  and  20%  (1  out  of  5)  for  group  4. 
(Table.  4-17) 122 
Table  4-17  Number  of  patients  healed  by  week  12  for  all  ulcer  areas  present 
for  <1  year 
Area  cm  Gp  l  Gp  2  Gp  3  Gp  4 
3-5  H=  1 
U=0 
H=2 
U=  1 
H=O 
U=3 
H=0 
U=2 
5.01-7.5  H=  I 
U=2 
H=  1 
U=2 
H=O 
U=  1 
H=  1 
U=0 
7.51-10.0  H=  1 
U=0 
H=  1 
U=0 
H=O 
U=  1 
H=O 
U=0 
10.1-15.0  H=1 
U=  1 
H=O 
U=0 
H=O 
U=  1 
H=O 
U=  1 
15.01-26.0  H=  I 
U=0 
H=O 
U=2 
H=  1 
U=2 
H=O 
U=2 
Total  5  /8  4/9  1/  8  1/5 
Percentage  62.5  44  12.5  20 
(H  =  Healed,  U=  Unhealed) 
This  demonstrates  that  even  in  patients  with  large  ulcers,  wound  closure  is  achievable 
if  it  has  been  present  for  less  than  1  year. 
If  the  ulcer  has  been  present  for  more  than  a  year,  the  healing  potential  of  the  wound 
seems  to  be  greatly  reduced,  however  some  healing  is  seen  in  smaller  wounds  i.  e 
those  less  than  10cm2.  (Table  4-18) 123 
Table  4-18  Number  of  patients  healed  by  week  12  for  all  ulcer  areas  present 
for  >1  year 
Area  cm  Gp  l  Gp  2  Gp  3  Gp  4 
3-5  H 
U 
=O 
=0 
H 
U 
=1 
=1 
H 
U 
=O 
=2 
H 
U 
=0 
=1 
5.01-7.5  H 
U 
=O 
=2 
H 
U 
=O 
=1 
H 
U 
=O 
=2 
H 
U 
=O 
=2 
7.51-10.0  H 
U 
=O 
=0 
H 
U 
=O 
=1 
H 
U 
=O 
=0 
H 
U 
=1 
=0 
10.1-15.0  H 
U 
=O 
=1 
H 
U 
=O 
=0 
H 
U 
=O 
=0 
H 
U 
=O 
=2 
15.01-26.0  H 
U 
=O 
=2 
H 
U 
=O 
=0 
H 
U 
=O 
=1 
H 
U 
=O 
=1 
Total  0/5  1/4  0/5  1/6 
Percentage  0  25  0  16.7 
(H  =  Healed,  U=  Unhealed) 
4.2.7.2.3  Adverse  Patient  Events 
The  adverse  events  were  reported  according  to  medical  device  guidelines  in  Canada, 
and  according  to  pharmaceutical  guidelines  in  the  UK.  80  episodes  of  adverse  events 
were  recorded  for  the  63  patients  who  were  initially  screened  for  the  study.  Of  the  53 
patients  who  were  eventually  randomised  into  the  study  groups  a  total  of  65  adverse 
events  were  reported  in  33  patients,  and  20  patients  being  unaffected.  The  adverse 
events  ranged  from  allergic  reactions  to  DG  or  the  secondary  dressings,  to  more 
serious  conditions  such  as  Pemphigoid  and  Cerebro-vascular  accident  (CVA). 124 
The  most  commonly  reported  adverse  event  was  infection,  accounting  for  49%  of  the 
total  events;  this  was  seen  in  43%  (23  out  of  the  53  randomised  patients).  (Table  4-19) 
However  when  the  adverse  events  were  broken  down  into  the  four  treatment  groups  , 
it  was  observed  that  there  were  no  differences  in  the  incidence  of  infection  in  the  four 
treatment  groups.  (Table  4-20).  No  deaths  were  reported  during  the  duration  of  the 
study. 125 
Table  4-19  Distribution  of  adverse  effects  encountered  during  the  course  of 
the  study. 
Adverse  Event  No.  Reported  (%) 
(n  =  65) 
No.  Patients  (%) 
(n  =  53) 
Allergy  1  (2%)  1  (2°o) 
Contact  Dermatitis  6(9%)  6(11%) 
Cellulitis  5  (8%)  5(  %) 
Cerebro-vascular  accident  1  (2%)  1  (2%) 
Eczema  13  (20%)  11  (21%) 
Erythema  2  (3%)  2  (4°/o) 
--------------  - 
Infection  32  (49%)  23  (43%) 
Fungal  infection  1  (2%o)  1(2%) 
Injury  2(3%)  2(4%) 
Hypoglycaemic  reaction  1(2%)  1  (2%) 
Pain  2  (3%)  2  (4%) 
Pemphigoid  1(2%)  1(2%) 
Pruritis  1  (2%)  1  (2%) 
Skin  injury  4  (6%)  4(8%) 
Skin  maceration  2  (3%)  2  (4%) 
Surgical  complication  4  (6%)  4  (8%) 
Syncope  1  (2%)  1  (2%) 
Wound  deterioration  1  (2%)  1  (2%) 126 
Table  4-20  Reported  adverse  events  in  the  four  treatment  groups 
Adverse  event  Group  1  (%) 
(n=13) 
Group  2  (%) 
(n=13) 
Group  3  (%) 
(n=  13) 
Group  4(%) 
(n=  13) 
Allergy  1  (8%)  0  0  0 
Cellulitis  1(8%)  2(15%)  0  1  (8°.  /o) 
Dermatitis  2(15%)  ](8%)  ](8%)  4(31%) 
Erythema  1  (8%)  0  0  1  (8%) 
Infection  4(31%)  3(23%)  4(31%)  6(46%) 
Pemphigoid  1  (8%)  0  0  0 
Pruitis  1  (8%)  0  0  0 
Skin  excoriation  2(15%)  1(8%)  3  (23%)  1(8%) 
Skin  injury  1(8%)  1  (8%)  2  (15%)  1  (8%0) 
Skin  maceration  1  (8%)  1  (8%)  0  0 
Wound  deterioration  0  1  (8%)  0  0 
Surgery  complication  0  0  2  (15%)  0 
Syncope  0  0  1  (8%)  0 
Hypoglycaemia  0  0  0  1  (8°rö) 
Pain  0  2(15%)  0  0 
TOTAL  18  15  15  17 127 
Histological  Analysis 
4.2.8  Wax  sections 
All  microscopic  sections  were  full  or  partial  thickness  skin  biopsies,  most  with  a  fully 
ulcerated  surface,  and  a  few  possessing  epithelium  at  the  edge  or  in  the  centre.  These 
epithelised  areas  appeared  to  be  neoepithelium  rather  than  pre-existing  epidermis. 
Most  biopsies  had  a  surface  exudate  of  fibrin  and  other  eosinophillic  material  with  a 
neutrophil  infiltrate.  Beneath  this  was  a  zone  of  granulation  tissue  supporting  the 
blood  vessels. 
The  %  reduction  in  the  wound  area  at  weeks  6  and  12,  and  the  total  number  of 
wounds  healed  were  compared  against  the  three  histological  parameters  at  weeks  0 
and  6. 
4.2.8.1  Extracellular  matrix  (ECM)  and  collagen  distribution 
There  were  no  statistically  significant  (Fisher's  exact  test)  association  between  the 
ECM  levels  and  healing,  but  there  were  some  weak  associations.  A  low  matrix  score 
(i.  e  one  which  had  the  least  amount  of  macromolecules  in  the  ECM)  at  week  6  was 
related  to  increased  numbers  of  healed  wounds  at  week  12  (p  =  0.06)  and  in  the 
percentage  reduction  of  the  wound  area  at  week  12  (p  =  0.08).  A  decrease  in  the 
matrix  score  between  weeks  0  and  6  was  related  to  healing,  and  an  increase  in  the 
matrix  score  in  the  same  two  time  periods  related  to  the  non-healing  nature  of  the 
ulcers  (p  =  0.09). 128 
A  patchy  initial  distribution  of  the  ECM  at  week  0  (i.  e.  a  low  matrix  score)  was 
associated  with  the  percentage  reduction  in  the  ulcer  area  at  week  12  (p  =  0.08)  and 
patchy  distribution  of  the  ECM  at  weeks  0  and  6  was  linked  with  increased  numbers 
of  healed  wounds  at  week  12  (p  =  0.096,  and  p=0.03  1,  respectively).  Comparing  the 
treatments  groups  with  the  control  group,  only  patients  in  group  2  (i.  e.  those  who 
received  4  pieces  of  Dermagraft),  demonstrated  a  reduction  in  the  ECM  score 
between  weeks  0  and  6  when  compared  to  the  control  group  (p  =  0.048). 
There  was  no  significant  relationship  between  the  depth  of  granulation  tissue  at  weeks 
0,6,  and  changes  in  the  granulation  tissue  depth  between  weeks  0  and  6  to  the  healing 
of  the  ulcer.  The  only  interesting  finding  was  the  mean  depth  of  granulation  tissue  in 
group  1  (i.  e.  those  who  received  12  pieces  of  Dermagraft)  at  week  0  was  significantly 
less  than  the  mean  depth  in  the  control  group  (p  =  0.01),  however  this  discrepancy  had 
resolved  in  the  week  6  sections. 
With  regards  to  collagen  pattern  seen  within  the  wound  bed  1  mm  from  the  surface, 
no  link  was  seen  between  the  original  or  changes  in  pattern  of  collagen  between  the 
treatment  groups  and  control  group  at  weeks  0,  week  6,  or  its  change  from  week  0  to 
week  6,  with  healing  or  percentage  reduction  of  the  wound. 
Only  23  pairs  of  biopsies  were  suitable  for  the  assessment  collagen  depth  at  the  base 
of  the  biopsies.  24  pairs  of  biopsies  were  too  shallow  and  did  not  incorporate  the  base 
of  the  wound.  All  23  pairs  showed  the  fibres  running  parallel  to  the  surface  of  the 
wound  rather  than  the  basket  weave  pattern  that  is  normally  seen  in  uninjured  skin. 
High  levels  of  collagen  deposit  defined  as  a  `Dense  Scar'  in  the  week  0  sections 
correlated  with  a  significant  reduction  in  the  area  of  the  ulcer  at  the  week  6  time  point 
(p  =  0.03)  and  in  the  complete  closure  of  the  wound  at  week  12  (p  =  0.02),  but  there 
were  no  significant  differences  between  the  4  groups  of  the  study. 129 
4.2.8.2  Blood  vessels 
The  number  of  vascular  units/mm2  was  counted  in  the  whole  section.  These  units 
were  usually  arranged  in  clusters  of  proliferating  capillaries  like  an  angioma,  fed  from 
a  vessel  in  the  deep  dermis.  It  was  noted  that  some  of  these  units  were  hyperplastic 
with  large  numerous  capillaries  whilst  others  hypoplastic. 
Large  numbers  of  blood  vessels  in  the  week  0  or  week  6  correlated  well  in  the  number 
of  healed  wounds  at  week  12  (p  =  0.06,  p=0.04).  Large  numbers  of  blood  vessels  in 
the  week  6  biopsies  correlated  well  in  the  percentage  reduction  of  the  wound  area  at 
week  12  (p  =  0.05).  (Figure  4-9) 130 
Figure  4-9  Distribution  of  Blood  Vessels  Within  the  Wound  Bed  at  Weeks  0 
and  6 
Patient  l  at  Week  0  (A)  and  Week  6  (B)  -  increased  number  of  blood  vessels  is 
observed  which  correlated  to  healing 
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Patient  2  at  Week  0  (C)  and  Week  6  (D)  -decreased  number  of  blood  vessels  is 
observed  which  correlated  to  no  healing. 131 
When  comparing  the  treatment  groups,  group  2  (i.  e  4  pieces  of  DG)  demonstrated  a 
significantly  greater  numbers  of  blood  vessels  at  week  6  than  the  control  group 
(p<0.05).  This  level  of  difference  was  not  seen  with  patients  given  l  or  12  pieces  of 
DG.  Figure  4-8  illustrates  a  paired  biopsy  from  a  patient  in  the  control  group  and  a 
patient  from  group  2  (DGx4).  The  top  paired  photomicrograph  (the  control  group) 
demonstrated  no  observable  increase  in  the  number  of  blood  vessels  at  week  6  when 
compared  to  week  0,  and  the  bottom  paired  photomicrograph  (DGx4).  demonstrated 
an  increase  in  the  number  of  blood  vessels  at  week  6  when  compared  to  week  0 
(Figure  4-10) 132 
Figure  4-10  Increase  in  the  Number  of  Blood  Vessels  Stimulated  by 
Dermagraft  (4  Pieces) 
Control  patient  at  Week  0  and  Week  6-  negligible  change  in  the  number  of  blood 
vessels  is  observed 
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DG  x4  patient  at  Week  0  (A)  and  Week  6  (B)  -  increase  in  the  number  of  blood 
vessels  is  observed 133 
Vessel  orientation  appears  to  play  a  role  in  the  healing  of  the  ulcers.  The  vessels  were 
classified  as  either  perpendicular  or  randomly  distributed  throughout  the  tissue.  A 
random  distribution  of  vessels  at  week  6  seems  to  be  related  with  an  increased 
reduction  in  the  ulcer  size  at  week  12  (p  =  0.06),  and  a  change  in  the  vessel 
orientation  from  random  at  week  0  to  a  perpendicular  configuration  at  week  6  seems 
to  be  related  to  poor  healing  at  week  6  (p  =  0.09)  and  a  decrease  in  the  number  of 
healed  wound  at  week  12  (p  =  0.03).  There  were  no  significant  differences  in  the 
orientation  of  the  blood  vessels  between  the  treatment  groups  1,2,3  and  the  control 
group  4,  at  weeks  0  and  6. 
The  degree  of  perivascular  fibrin  cuffing  was  assessed  as  a  percentage  of  all  the 
vessels  present.  It  was  noted  that  a  low  percentage  of  fibrin  cuffing  at  week  0  was 
linked  with  increased  percentage  reduction  of  ulcer  size  at  weeks  6  (p  <  0.05)  and  12 
(p  <  0.05).  Similarly,  a  low  percentage  of  fibrin  cuffing  at  week  6  was  linked  with  an 
increased  reduction  in  the  ulcer  size  at  weeks  6,  (p  =  0.05),  12  (p  =  0.05),  and  in  the 
number  of  healed  ulcers  (p  =  0.05). 
4.2.8.3  Cellular  Pattern  and  Distribution 
Neutrophil  polymorphs  and  lymphocytes  were  the  most  common  types  of  cells  seen  in 
the  granulation  tissue  between  the  vessels  and  sometimes  clustered  around  blood 
vessels  cuffed  with  fibrin. 
Out  of  the  47  patients  who  entered  the  study,  week  0  and  week  6  sections  stained  with 
the  neutrophil  antibody  were  available  from  only  33  patients. 
At  week  0  the  mean  number  of  neutrophils  in  the  four  groups  is  shown  in  Table  4-21. 134 
Table  4-21  The  mean  count  of  neutrophils  at  T=0  within  the  four  groups 
Groups  Week  0  Mean  (SD) 
Gpl  (DGxI2)(n  =  8)  99.8  (48.7) 
Gp2  (DGx4)(n  =  9)  139  (62.5) 
Gp3  (DGxl)(n  =  6)  125.5  (49.0) 
Gp4  (Control)(n  =  10)  140.1  (40.5) 
Biopsies  obtained  from  patients  randomised  to  the  Control  group  (Group  4) 
demonstrated  a  higher  proportion  of  neutrophils  than  Group  I  (p  =  0.01),  Group  2  (p 
=  0.03),  or  Group  3  (p  =  0.02)  at  week  0.  However  this  difference  was  not  repeated  in 
the  week  6  sections. 
In  all  groups,  the  mean  count  of  neutrophils  at  week  6  tended  to  be  less  than  the  mean 
count  at  week  0,  but  this  reduction  in  the  counts  were  not  statistically  significant, 
except  in  the  control  group  (p<0.05  ).  (Table  4-22  and  Figures  4-11,4-12) 
The  large  SD  in  all  groups  may  suggest  patient  variability  within  the  groups. 135 
Table  4-22  The  mean  count  of  Neutrophils  within  chronic  wounds  at  T=0 
and 
T=6  weeks 
Groups  Week  0 
Mean  (SD) 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  U 
P  values 
Gpl  (DGx12)  99.8  (48.7)  91.4  (24.2)  0.5 
Gp2  (DGx4)  139  (62.5)  104.2  (67.0)  0.16 
Gp3  (DGx1)  125.5  (49.0)  117.3  (54.0)  0.81 
Gp4  (Control)  140.1  (40.5)  83.8  (51.9)  0.02 
Figure  4-11  Mean  Neutrophil  Counts  in  Chronic  Wounds  at  T=()  and  T=6 
weeks  for  the  Four  Groups. 
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In  all  groups,  the  mean  count  of  neutrophils  at  week  6  tended  to  be  less  than  the  mean 
count  at  week  0,  but  this  reduction  in  the  counts  were  not  statistically  significant, 136 
Figure  4-12  Photomicrographs  of  Neutrophil  Distribution  at  Weeks  0  and  6  in 
the  Four  Treatment  Groups 
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4.2.9  Fro.  -en  sections 140 
4.2.9.1  Inflammatory  Cells 
4.2.9.1.1  Lymphocytes 
Cells  of  the  lymphocytic  morphology,  B-  and  T-  lymphocytes  are  small  round  cells 
with  little  cytoplasm  and  a  round  nucleus,  were  preferentially  found  in  the  peri- 
vascular  areas. 
B-Lymphocytes 
The  CD19  antigen  is  the  most  broadly  expressed  surface  marker  for  B-lymphocytes 
(Dorken  B  et  al.,  1992a). 
The  mean  count  of  B-lymphocytes  between  the  four  groups  at  Week  0  seems  to  be  of 
similar  magnitude.  This  suggests  that  there  is  a  similar  distribution  of  B-lymphocytes 
at  Week  0  within  the  four  treatment  groups.  (Table  4-23) 141 
Table  4-23  The  mean  count  of  B  lymphocytes  at  Week  0  within  the  four 
groups 
Groups  Week  0  Mean 
Gpl(DGx12)  4.4  (4.3) 
Gp2(DGx4)  12.8  (7.7) 
Gp3(DGxl)  4.7  (3.6) 
Gp4(Control)  7.1  (5.0) 
There  seems  to  be  very  little  change  in  the  mean  count  of  B-Lymphocytes  at  Week  6 
when  compared  to  the  mean  count  at  Week  0  across  all  four  groups.  (Table.  4-24, 
Figure  4-13) 
Table  4-24  The  mean  count  of  CD19+"  B  lymphocytes  within  chronic  wounds 
at  Week  0  and  Week  6 
Groups  Week  0 
Mean  SD 
Week  6 
Mean  (SD) 
Mann  Whitney-ti 
P  values 
Gpl(DGx12)  4.4  (4.3)  5.6  (4.4)  0.35 
Gp2(DGx4)  12.8  (7.7)  15.2  (6.2)  0.85 
Gp3(DGxl)  4.7  (3.6)  7.1  (6.5)  0.10 
Gp4(Control)  7.1  (5.0)  8.2  (4.90  0.95 142 
Figure  4-13  Mean  CD19+ie  B-Lymphocyte  Counts  in  Chronic  Wounds  at  Week 
0  and  Week  6  for  the  Four  Groups. 
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There  seems  to  be  very  little  change  in  the  mean  count  of  B-Lymphocytes  at  Week  6 
when  compared  to  the  mean  count  at  Week  0  across  all  four  groups 
T-Lvmphocytes 
Like  B-lymphocytes,  T-lymphocytes  were  identified  in  their  greatest  numbers  in  the 
peri-vascular  areas.  T-Lymphocytes  were  identified  by  the  pan  lymphocytes  marker  - 
CD3,  T  helper/inducer  lymphocytes  -  CD4,  and  T  suppressor/cytotoxic  lymphocytes  - 
CD8. 143 
There  is  no  difference  in  the  mean  count  of  T-lymphocytes  as  identified  by  staining 
positive  with  anti-CD3  monoclonal  antibody  between  the  four  groups  at  the  start  of 
the  study  (Week  0).  (Table.  4-25) 
Table  4-25  The  mean  count  of  CD3+ie  T-lymphocytes  at  Week  0  within  the 
four  groups 
Groups  Week  0  Mean 
(SD) 
Gpl(DGx12)  42.5  (17.9) 
Gp2(DGx4)  41.0  (14.4) 
Gp3(DGxl)  33.4  (15.8) 
Gp4(Control)  31.7  (10.3) 
There  is  little  change  in  the  mean  CD3+``  counts  between  the  two  time  periods  (Week 
0  and  Week  6)  in  groups  1  and  3,  but  there  is  a  small  non-significant  increase  in  the 
mean  CD3+%'"  counts  between  weeks  0  and  6  in  groups  2  and  4  in  response  to 
treatment.  (Table  4-26,  Figure  4-14) 144 
Table  4-26  The  mean  count  of  CD3+"  T-Lymphocytes  within  chronic  wounds 
at  Week  0  and  Week  6 
Groups  Week  0 
Mean  (SD) 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  11 
P  values 
Gpl(DGx12)  42.5  (17.9)  43.1  (14.8)  0.68 
Gp2(DGx4)  41.0  (14.4)  47.8  (23.1)  0.60 
Gp3(DGxl)  33.4  (15.8)  30.0  (9.7)  0.72 
Gp4(Control)  31.7  (10.3)  39.1  (9.9)  0.60 
Figure  4-14  Mean  CD3+`'  T-Lymphocyte  Count  in  Chronic  Wounds  at  Week  0 
and  Week  6 
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There  is  a  small  non-significant  increase  in  the  mean  CD3+"  counts  between  weeks  0 
and  6  in  groups  2  and  4  in  response  to  treatment. 145 
Similarly,  the  mean  count  of  helper/inducer  T-lymphocytes  (a  sub-population  of  T- 
lymphocytes),  as  identified  by  staining  positive  with  anti-CD4  monoclonal  antibody, 
exhibits  no  gross  variation  between  the  four  groups  at  the  start  of  the  study  at  Week  0. 
(Table  4-27) 
Table  4-27  The  mean  count  of  CD4+"  T-lymphocytes  at  Week  0  within  the 
four  groups 
Groups  Week  0  Mean  SD 
Gpl(DGxI2)  42.9  (13.6) 
Gp2(DGx4)  39.6  (10.9) 
Gp3(DGxl)  33.3  (12.0) 
Gp4(Control)  34.2  (11.9) 
There  is  a  slight  decrease  in  the  mean  CD4+'`  population  within  the  wound  bed  of 
groups  l  and  3  in  response  to  treatment  with  DG,  and  a  slight  increase  in  the  mean 
CD4+\e  population  in  groups  2  and  4,  but  this  is  not  statistically  significant.  (Table  4- 
29).  This  is  also  seen  graphically  in  Figure  4-15. 146 
Table  4-28  The  mean  count  of  CD4+`e  helper/inducer  T-Lymphocytes  within 
chronic  wounds  at  Week  0  and  Week  6 
Groups  Week  0 
Mean  (SD) 
- 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  U 
P  values 
Gpl(DGx12)  -  -  42.9(l).  6)  ------  ------  39.9  (12.40  --- 0.5 
Gp2(DGx4)  39.6  (10.9)  41.5(14.3)  0.9 
Gp3(DGxl)  33.3  (12.0)  30.0  (9.70  0.72 
Gp4(Control)  34.2  (11.9)  39.1  (9.8)  0.2 
Figure  4-15  Mean  CD4+ve  helper/inducer  T-Lymphocytes  Counts  in  Chronic 
Wounds  at  Week  0  and  Week  6  for  the  Four  Groups 
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There  is  little  change  in  the  mean  count  of  CD4+"  cells  at  week  6  when  compared  to 
week  0 
The  T  suppressor/cytotoxic  lymphocytes  are  identified  by  the  positive  staining  of  cells 
within  the  wound  bed  tissue  with  the  anti-CD8  monoclonal  antibody.  Staining  with 
this  antibody  demonstrates  that  there  was  little  difference  in  the  counts  between  the 
four  groups  atWeek  0.  (Table  4-29) 
'T'able  4-29  The  mean  count  of  CD8+`  suppressor/cytotoxic  T-lymphocytes  at 
Week  0  within  the  four  groups 
Groups  Week  0  Mean  (SD) 
Gpl(D(.  x12)  18.4  (10.4) 
Gp2(DGx4)  19.2  (10.0) 
Gp3(DGxl)  11.2(10.8) 
Gp4(Control)  11.5(6.1) 
There  is  a  slight  decrease  in  the  mean  CD8+``  count  within  the  wound  bed  of  group  3 
in  response  to  treatment  with  DG,  and  a  slight  increase  in  the  mean  CD8+"°  count  in 
groups  1,2,  and  4,  but  this  is  not  statistically  significant.  However  one  can  observe 
from  the  graph  that  the  mean  values  of  CD8+'`  within  the  control  group  (Group  4) 
seems  to  be  tightly  orientated  around  the  mean  at  Week  0  and  Week  6,  and  hence  can 
postulate  that  compression  alone  in  these  groups  of  patients  causes  an  increase  in  the 148 
mean  counts  at  week  6,  an  observation  not  apparent  in  the  treatment  groups.  ('Table  4- 
30  and  Figure  4-16) 
Table  4-30  The  mean  count  of  CD8+"  T-Lymphocytes  within  chronic  wounds 
at  Week  0  and  Week  6 
Groups  I  Week  0 
Mean  (SD) 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  U 
P  values 
Gpl(DGxl2)  18.4(10.4)  18.2(12.8)  0.3 
Gp2(DGx4)  19.2  (10.0)  20.4  (12.1)  0.65 
Gp3(DGx1)  11.2  (10.8)  11.5  (5.4)  0.79 
Gp4(Control)  11.5  (6.1)  16.1  (9.9)  0.32 149 
Figure  4-16  Mean  CD8+`e  Counts  in  Chronic  Wounds  at  Week  0  and  Week  6 
for  the  Four  Groups. 
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There  is  a  slight  increase  in  the  mean  CD8+"  count  in  groups  1,2,  and  4,  but  this  is 
not  statistically  significant 150 
4.2.9.1.2  Macrophages 
Cells  exhibiting  macrophage  morphology  and  staining  with  the  pan-macrophage 
marker  anti-CD68  monoclonal  antibody  were  found  throughout  the  wound  bed 
sections  in  all  four  groups  at  both  weeks  0  and  6,  with  dense  aggregations  in  the 
perivasular  areas.  This  made  identifying  and  counting  individual  cells  very  difficult. 
For  this  reason,  the  pan-macrophage  expression  was  graded  on  aI  to  4  basis. 
From  the  table  below,  it  can  be  seen  that  there  is  very  little  change  in  the  distribution 
of  CD68+4''  cells  between  the  four  groups  at  Week  0  and  Week  6.  (Table  4-31) 
Table  4-31  The  Mean  Score  of  CD68+"  cells  in  Chronic  Wounds  at  Week  0 
and  Week  6 
Groups  Week  0  Mean  Score  Week  6  Mean  Score 
Gpl(DGx12)  4  --  -4 
Gp2(DGx4)  4  4 
Gp3(DGx1)  3.5  3.5 
Gp4(Control)  4  4 
When  the  trend  of  change  at  week  6  was  compared  to  week  0  for  each  patient  in  each 
group,  it  can  be  seen  that  there  is  very  little  change  in  the  mean  score  of  CD68+'`*  cells 
in  the  two  time  frames.  (Table  4-32) 151 
Table  4-32  Comparison  of  CD68  in  Chronic  Wounds  staining  intensity  at 
Week  6  to  Week  0. 
Groups  Change  in  the  Intensity  of  Staining  at 
Week  6  when  Compared  to  Week  0 
Gpl(DGx12) 
Increase  Decrease 
32 
Unchanged 
5 
Gp2(DGx4)  1  3  7 
Gp3(DGxI)  [  1  1  6 
Gp4(Control)  2  4  4 
Subpopulations  of  Macrophages 
27e10 
The  27e  10  antigen  is  usually  found  as  a  surface  marker  on  early  macrophages.  These 
macrophages  are  often  found  in  abundance  in  acutely  inflamed  tissue  but  occur  in 
small  numbers  in  chronic  wounds. 
There  is  little  difference  between  groups  2,3,  and  4  for  the  27e10+"  macrophage 
markers  at  week  0.  (Table  4-33)  However,  there  seems  to  be  a  statisticaliv  significant 
number  of  27e10+`'  macrophages  in  group  I  when  compared  to  the  control  group 
(p=0.03).  This  may  not  be  a  true  significance  but  may  be  due  to  chance  as  the  number 
of  patients  in  each  group  is  small  and  not  a  true  reflection  of  an  unexplained  increase 
of  early  macrophages  within  this  group  of  patients. 152 
Table  4-33  The  mean  count  of  27e10+"  macrophages  at  Week  0  within  the 
four  groups 
Grou  s  Week  0  Mean  (SD) 
Gpl(DGx12)  18.4  (5.6) 
Gp2(DGx4)  14.0  (4.2) 
Gp3(DGxl)  12.0  (6.6) 
Gp4(Control)  13.3  (3.5) 
There  seems  to  be  an  increase  in  the  mean  count  of  early  macrophages  at  week  6 
when  compared  to  week  0  in  all  groups,  and  this  increase  is  statistically  significant  in 
group  2  (p<0.05).  (Table.  4-34,  Figures.  4-17,4-18) 
Table  4-34  The  mean  count  of  27e10+`e  macrophages  within  chronic  wounds 
at  Week  0  and  Week  6 
Groups  Week  0 
Mean  (SD) 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  U 
P  values 
Gpl(DGx12)  18.4  (5.6)  20.2  (7.4)  0.63 
Gp2(DGx4)  14.0  (4.2)  21.0  (7.7)  0.02 
Gp3(DGxl)  12.0  (6.6)  17.1  (7.0)  0.16 
Gp4(Control)  13.3  (3.5)  20.0  (12.4)  0.3 153 
Figure  4-17  Mean  27e10+`f  Counts  in  Chronic  Wounds  at  Week  0  and  Week  6 
for  the  Four  Groups. 
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There  seems  to  be  an  increase  in  the  mean  count  of  early  macrophages  at  week  6 
when  compared  to  week  0  in  all  groups,  and  this  increase  is  statistically  significant  in 
group  2 154 
Figure  4-18  Photomicrograph  of  27e10+`  cells  at  Week  0  and  Week  6in  the 
Four  Treatment  Groups 
Group  I  (DGx12)  -  There  is  an  increase  in  the  number  of  early  macrophages  at  week 
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Group  2  (DGx4)  -  There  is  an  increase  in  the  number  of  early  macrophages  at  week  6 
compared  to  week  0  which  is  statistically  significant 
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Group  3  (DGxl)  -  There  is  an  increase  in  the  number  of  early  macrophages  at  week  6 
compared  to  week  0 
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Group  4  (Control)  -  There  is  relatively  little  change  in  the  number  of  early 
macrophages  at  week  6  compared  to  week  0 
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Mannose  Receptors  (MR) 
The  mannose  receptor  is  expressed  on  the  surface  of  primed  macrophages,  which 
subsequently  disappears  when  these  macrophages  become  activated. 
There  is  little  difference  between  the  four  treatment  groups  for  the  mean  count  of 
MR-'-"'  cells  at  week  0.  (Table  4-35). 
Table  4-35  The  mean  count  of  MR+"  macrophages  at  Week  0  within  the  four 
groups 
[Groups  Week  0  Mean  SD 
Gpl(DGx12)  57.9  (19.6) 
Gp2(DGx4)  57.9  (12.7) 
Gp3(DGxl)  50.5  (15.1) 
Gp4(Control)  60.2  (20.0) 
There  is  no  significant  change  in  the  mean  count  of  MR+`  macrophages  at  week  6 
when  compared  to  week  0.  There  seems  to  be  a  slight  increase  in  the  mean  MR"` 
count  at  week  6  when  compared  to  week  0  in  group  1,  but  this  may  simply  be  a 
variation  rather  than  a  true  reflection  due  to  the  small  number  of  patients  within  the 
group.  (Table  4-36,  Figure  4-19) 159 
Table  4-36  The  mean  count  of  MR+`  macrophages  within  chronic  wounds  at 
Week  0  and  Week  6 
Groups  Week  0 
Mean  (SD) 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  U 
P  values 
Gpl(DGxl2)  57.9  (19.6)  64.6  (17.8)  0.35 
Gp2(DGx4)  57.9  (12.7)  55.4  (18.9)  0.75 
Gp3(DGxl)  50.5  (15.1)  48.3  (8.8)  0.9 
Gp4(Control)  60.2  (20.0)  59.5  (19.0)  0.9 
Figure  4-19  Mean  MR+"  Counts  in  Chronic  Wounds  at  Week  0  and  Week  6 
for  the  Four  Groups 
120 
100  "  " 
"  " 
$ 
" 
80  ' 
"  "  _"  0  "  " 
60  "  : 
"" 
"Z 
40  $"  "  " 
c  20  e  a 
X. 
0 
Gpl  Gp2  Gp3  GP4 
Groups 
The  distribution  of  MR+"  cells  seems  to  be  similar  in  all  tour  treatment  groups 160 
Sialoadhesin  Receptors  (SR) 
Sialoadhesin  receptors  are  surface  antigens  expressed  by  tissue  macrophages.  They 
are  believed  to  be  the  result  of  those  primed  macrophages  that  remain  unactivated 
within  the  wound  bed. 
There  is  little  difference  between  the  four  treatment  groups  for  the  SR+``  macrophage 
markers  at  week  0  (Table  4-37). 
Table  4-37  The  mean  count  of  SR+``  macrophages  at  Week  0  within  the  four 
groups 
Groups  Week  0  Mean 
Gpl(DGxl2)  36.9  (10.4) 
Gp2(DGx4)  31.0  (9.2) 
Gp3(DGxl)  28.8  (3.8) 
Gp4(Control)  36.8  (18.2) 
There  is  a  trend  for  the  mean  count  of  SR+"`  macrophages  to  reduce  at  week  6  when 
compared  to  the  mean  count  at  week  0  in  all  four  groups.  In  those  patients  treated 
with  four  pieces  of  DG  (group  2),  this  is  statistically  significant  (p<0.05).  (Table  4-38, 
Figures  4-20,4-21) 161 
Table  4-38  The  mean  count  of  SR+`e  macrophages  within  chronic  wounds  at 
Week  0  and  Week  6 
Groups  Week  0 
Mean  (SD) 
Week  6 
Mean  (SD) 
Mann  - 
Whitney  U 
P  values 
Gpl(DGx12)  36.9  (10.4)  26.8  (12.7)  0.11 
Gp2(DGx4)  31.0  (9.2)  22.8  (7.0)  0.03 
Gp3(DGxl)  28.8  (3.8)  23.5  (7.50  0.10 
Gp4(Control)  36.8  (18.2)  26.5  (10.1)  0.20 
Figure  4-20  Mean  SR+"  Counts  in  Chronic  Wounds  at  Week  0  and  Week  6  for 
the  Four  Groups 
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The  mean  count  of  SR"'  macrophages  to  reduce  at  week  6  when  compared  to  the 
mean  count  at  week  0  in  all  four  groups,  and  is  statistically  significant  in  group  2 
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Figure  4-21  Photomicrographs  of  SR+"  Cells  at  Week  0  and  Week  6  in  the 
Four  Treatment  Groups 
Group  1  (DGx12)  -There  is  a  reduction  in  the  number  of  tissue  macrophages  at  week 
6  when  compared  to  week  0 
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Group  2  (DGx4)  -  There  is  a  reduction  of  tissue  macrophages  at  week  6  when 
compared  to  week  0 
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Group  3  (DGxI)  -  There  is  little  difference  in  the  number  of'tissue  macrophages  at 
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Group  4  (Control)  -  There  is  little  difference  in  the  number  of  tissue  macrophages  at 
week  6  when  compared  to  week  0 
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4.2.10  ('ytokines 
Cytokines,  produced  within  cells  leech  out  and  were  identified  by  antibodies  for  the 
specific  cytokine  within  the  wound  bed  tissue.  Hence  the  intensity  of  staining  of  the 
sections  with  a  specific  antibody  at  week  6  was  compared  to  the  intensity  at  week  0 
sections  as  previously  described  in  chapter  3.2.11.2.2.  A  descriptive  comparison  was 
made  between  the  two  time  frames  for  each  patient. 
4.2.10.1  Tumour  Necrosis  factor  a  (TNFa) 
Staining  was  confined  to  cells  in  the  vascular  area  of  the  sections,  but  was  not  always 
associated  with  the  perivascualar  regions  of  the  sections.  There  is  very  little  change  in 
the  mean  score  for  the  intensity  of  staining  for  TNFa  at  week  6  when  compared  to 
week  0  in  the  four  treatment  groups.  (Table.  4-39)  Comparing  the  groups  for  an 
increase  or  decrease  in  intensity  of  staining  at  the  two  time  frames,  exhibited  a  small 
increase  in  TNFa  expression  at  week  6  when  compared  to  week  0  in  patients  in 
Groups  2  and  3,  and  a  small  decrease  in  Group  4.  (Table  4-40) 167 
Table  4-39  The  Mean  Score  for  the  Intensity  of  TNFa  staining  at  Week  0  and 
Week  6 
Groups  Mean  Week  0  Score  Mean  Week  6  Score 
GpI  (DGx12)  1  1 
Gp2  (DGx4)  1  1 
-----  Gp3  (DGxI)  1  1.5 
LGP4 
(Control)  1  1 
Table  4-40  Comparison  of  TNFa  in  staining  intensity  in  patients  at  Week  6  to 
Week  0 
Groups  Change  in  the  Intensity  of  Staining  at  Week  6 
when  Compared  to  Week  0 
Increase  Decrease  Unchanged 
Gpl  (DGx12)  334 
Gp2  (DGx4)  326 
Gp3  (DGxI)  413 
Gp4  (Control)  128 168 
4.2.10.2  Interleukin  1ß  (IL1-ß) 
Staining  seems  to  be  concentrated  in  the  cells  in  the  perivascular  area,  and  sparse 
staining  was  seen  in  areas  where  there  was  little  vasculature. 
There  seems  to  be  a  small  reduction  in  the  IL1-ß  expression  in  patients  in  Group  2  at 
week  6  when  compared  to  week  0,  and  small  increase  in  Groups  I  and  4,  but  these 
changes  are  too  small  to  be  correlated  to  healing.  (Tables  4-41  and  4-42) 
Table  4-41  Mean  Score  for  the  Intensity  of  IL1-0  Staining  at  Week  0  and 
Week  6 
Groups  Mean  Week  0  Score  Mean  Week  6  Score 
GpI  (DGx12)  2  1) 
Gp2  (DGx4)  3  2 
-  Gp3  (DGxl)  2  1 
Gp4  (Control)  3  3 169 
Table  4-42  Comparison  of  ILI-ß  in  staining  intensity  in  patients  at  Week  6  to 
Week  0 
Groups  Change  in  the  Intensity  of  Staining  at  Week  6 
when  Compared  to  Week  0 
Increase  Decrease  Unchanged 
Gpl  (DGx12)  4  2  4 
Gp2  (DGx4)  2  5  4 
Gp3  (DGxI)  2  2  4 
Gp4  (Control)  4  3  4 
4.2.10.3  Vascular  Endothelial  Growth  Factor  (VEGF) 
Staining  for  VEGF  is  distributed  in  the  peri-vascular  tissue  with  negative  staining  of 
the  vascular  endothelial  lining. 
There  is  very  little  change  in  the  mean  intensity  of  VEGF  staining  between  the  two 
sections  at  week  6  and  week  0.  Patients  in  groups  2  and  3  however,  demonstrated  a 
reduction  in  the  VEGF  staining  at  week  6  when  compared  to  week  0.  ('f'ables  4-43 
and  4-44) 170 
Table  4-43  Mean  Score  for  the  Intensity  of  VEGF  Staining  at  Week  0  and 
Week  6 
r  Groups  ] 
_Mean 
Week  0  Score  Mean  Week  6  Score 
Gpl  (DGx12)  1 
Gp2  (DGx4)  1  0 
Gp3  (DGxI)  1  0.5 
Gp4  (Control)  1  1 
Table  4-44  Comparison  of  VEGF  in  staining  intensity  in  patients  at  Week  6  to 
Week  0 
Groups 
Gpl  (DGx12) 
Gp2  (DGx4) 
Gp3  (DGx1) 
Gp4  (Control) 
Change  in  the  Intensity  of  Staining  at  Week  6 
when  Compared  to  Week  0 
Increase  Decrease  Unchanged 
334 
056 
12  ---_  5 
335 
4.2.10.4  Basic  Fibroblast  Growth  Factor  (bFGF) 
bFGF  usually  stains  an  area  adjacent  to  the  blood  vessels,  and  sometimes  it  can  be 
seen  to  highlight  the  endothelial  lining.  There  is  very  little  change  in  the  density  of 
bFGF  staining  between  the  two  sections  at  week  6  and  week  0.  There  is  a  decrease  in 
bFGF  density  at  week  6  when  compared  to  week  0  in  patients  in  Group  2  and  an 171 
increase  at  week  6  when  compared  to  week  0  in  patients  Groups  3  and  4.  (Tables  4-45 
and  4-46) 
Table  4-45  Mean  Score  for  the  Intensity  of  bFGF  Staining  at  Week  0  and 
Week  6 
Groups  Mean  Week  0  Score  Mean  Week  6  Score 
Gpl  (DGx12)  3  3 
Gp2  (DGx4)  2  2 
Gp3  (DGxi)  2  3 
Gp4  (Control)  2  2 
Table  4-46  Comparison  of  bFGF  in  staining  intensity  in  patients  at  Week  6  to 
Week  0 172 
4.2.10.5  Transforming  Growth  Factor  0  (TGF-ß) 
Staining  to  TGFß  is  usually  found  within  the  ground  substance  that  makes  up  the 
granulation  tissue,  and  blood  vessels  are  specifically  negatively  stained. 
There  was  very  little  change  in  the  mean  intensity  density  of  TGFß  staining  at  Week  0 
and  Week  6.  However,  in  all  four  groups,  there  was  an  increase  in  the  intensity  of 
staining  at  week  6  when  compared  to  week  0.  (Tables  4-47  and  4-47) 
Table  4-47  Mean  Score  for  the  Intensity  of  TGFO  Staining  at  Week  0  and 
Week  6 
Groups  Mean  Week  0  Score 
Gpl  (DGx12)  1 
Gp2  (DGx4)  1 
Gp3  (DGxl)  I 
Gp4  (Control)  11 
Mean  Week  6  Score 
1.5 173 
Table  4-48  Comparison  of  TGFO  in  staining  intensity  in  patients  at  Week6  to 
Week  0 
Groups  Change  in  the  Intensity  of  Staining  at  Week  6 
when  Compared  to  Week  0 
Increase  Decrease  Unchanged 
Gpl  (DGx12)  3  0  7 
Gp2  (DGx4)  3  1  6 
Gp3  (DGxI)  2  0  6 
Gp4  (Control)  4  3  4 174 
5  CHAPTER  FIVE:  DISCUSSION 175 
Professionals  and  health  care  workers  have  recognised  the  difficulties  that  can  be 
associated  with  achieving  wound  closure,  with  the  projected  demographic  changes 
within  the  UK,  resulting  in  an  increase  in  the  elderly  population  in  the  coming  years. 
Additional  resources  for  wound  care  will  be  required  to  meet  the  increase  in  problems 
within  this  group,  and  hence  a  considerable  amount  of  attention  has  been  placed  on 
wound  healing  in  the  last  ten  years 
It  has  been  estimated  that  chronic  wounds  such  as  pressure  sores,  diabetic  ulcers, 
venous  and  arterial  ulcers,  contribute  to  morbidity  and  occasionally  mortality,  in 
patients.  This  incurs  a  considerable  cost  to  the  National  Health  Service.  It  has  been 
estimated  that  the  financial  burden  of  venous  disease  in  Britain  is  between  £294  -  650 
million  per  year,  depending  on  the  variation  in  practice,  and  the  location  of  care 
provision,  (eg.  Community  or  out-patient  clinic)  (Price  P  et  al.,  2000). 
Venous  leg  ulcers  affect  about  1%  of  the  adult  population  at  some  time  during  their 
life-time.  In  the  over  65s  this  can  increase  to  around  3%  of  the  population  group,  from 
3/1000  at  age  61  -  70  years,  to  20/1000  in  individuals  aged  80  years  and  over. 
(Callam  MJ  et  al.,  1985,  Baker  SR  et  al.,  1991,  Callam  MJ,  1992). 
In  the  United  States,  treatment  costs  are  $3  billion  dollars  with  a  loss  of  2  million 
work  days  per  year  (McGuckin  M  et  al.,  2002).  Some  ulcers  can  be  difficult  to  heal.  A 
5  year,  prospective,  cohort  study  of  382  patients  reported  that  in  patients  surviving  5 
years,  38%  still  had  open  ulcers  and  4%  required  amputation  (Nelzen  0  et  al.,  1997). 
The  most  common  types  of  leg  ulcers  seen  in  UK  clinics  are  venous  (70-80%) 
(Callam  MJ  et  al.,  1987)  or  arterial  in  origin  (20-30%)  (Callam  MJ  et  al.,  1987) 
Disruption  of  the  ordered  progression  towards  healing,  in  patients  can  result  in  a 
chronic  wound  as  seen  in  venous  leg  ulcers.  Although  venous  leg  ulcers  do  not 176 
usually  cause  the  loss  of  a  limb,  they  can  cause  major  morbidity  and  sometimes  life 
threatening  cellulitis. 
Barwell  et  al  in  2000,  has  shown  that  following  surgical  correction  of  isolated 
superficial  venous  reflux  in  ulcerated  legs,  12  -  and  24  -  week  healing  rates  for  the 
operated  leg  were  50%  and  72%,  when  compared  to  62%  and  74%  for  the  non- 
operated  legs.  However,  in  this  study  ulcer  recurrences  were  14%,  20%,  and  26%  at  1, 
2,  and  3  years  for  the  operated  legs  and  28%,  30%  and  44%  for  non-operated  legs, 
suggesting  a  long  term  effect  on  ulcer  prevention  if  these  groups  of  patients  undergo 
surgery  (Barwell  JR  et  al.,  2000).  However,  there  exists  a  large  population  of  patients, 
in  whom  surgery  may  not  be  possible  due  the  pre-existence  of  other  co-morbid 
medical  conditions  or  damage  to  the  deep  venous  system  of  the  leg. 
At  present  the  choice  of  treatment  of  impaired  healing  or  chronic  wounds  in  clinical 
practice  is  largely  dependent  on  the  skill  and  experience  of  the  medical/nursing 
practitioners.  Traditionally,  treatment  has  consisted  of  elevation,  wound  care, 
compression  and  patient  education  based  on  prevention.  Compression  therapy  has 
been  shown  to  be  the  most  effective  intervention  for  venous  leg  ulcers  to  overcome 
the  effects  of  venous  hypertension  (Krishnamoorthy  L  and  Melhuish  JM,  2000).  Even 
with  optimal  care  (elevation  of  limb,  compression  and  debridement)  and  follow  up, 
venous  leg  ulcers  recur  in  29  -  59%  of  patients  and  are  associated  with  significant 
disability  and  costs  (Kowallek  DL  and  De  Palma  RG,  1997,  Morrell  CJ  et  al.,  1998). 
Several  risk  factors  including  a  large  surface  area,  longer  ulcer  duration,  the  presence 
of  fibrin  over  the  wound  surface  (>50%)  have  been  shown  to  play  a  role  in  the  non- 
healing  nature  of  venous  leg  ulcers  despite  compression  therapy  (Margolis  DJ  et  al., 
1999,  Phillips  TJ  et  al.,  2000,  Margolis  DJ  et  al.,  2000). 177 
The  future  diagnosis  and  treatment  of  wounds,  as  well  as  the  development  of 
bioactive  dressings,  will  bring  a  requirement  for  wound  assessment  to  determine  the 
most  appropriate  treatment.  However,  the  mechanisms  for  the  evolution  of  a  normally 
healing  acute  wound  into  a  non-healing  chronic  wound  need  to  be  defined. 
Normal  wound  healing  is  a  complex  sequence  of  overlapping  cellular  and  molecular 
processes,  including  inflammation,  cell  migration,  angiogenesis,  provisional  matrix 
deposition,  collagen  deposition  and  re-epithelisation  (Clark  RAF,  1996). 
The  inflammatory  phase  of  wound  healing  is  the  first  and  essential  stage  in  the 
healing  process,  and  it  is  assumed  that  this  response  has  major  influences  on 
subsequent  healing.  After  the  first  twenty  four  hours  of  injury,  these  cells  are  mainly 
comprised  of  macrophages  and  lymphocytes.  The  role  of  lymphocytes  and  their 
relative  changes  as  healing  proceeds  has  been  described  by  several  authors  in  the  past 
(Martin  CW  and  Muir  IF,  1990,  Fishel  RS  et  al.,  1987,  Peterson  JM  et  al.,  1987). 
This  work  describes  in  detail  the  various  aspects  of  the  role  of  macrophages  and  their 
various  stages  of  differentiation  and  activation  stages  in  acute  and  chronic  human 
wounds. 178 
5.1  PILOT  STUDY 
Macrophages  are  known  to  direct  new  tissue  formation,  by  producing  an  array  of 
bioactive  substances,  including  growth  and  regulatory  factors.  (Hunt  TK  et  al.,  1984) 
It  was  hypothesized  that  there  would  be  major  differences  in  the  level  of  activation  of 
wound  macrophages  between  acute  and  chronic  wounds.  Ten  acute  and  ten  chronic 
wounds  were  assessed  to  ascertain  the  possible  observable  differences  in  the 
macrophage  subpopulation  in  the  two  wound  types. 
5.1.1  Biopsies 
To  standardise  collection  the  biopsies  were  obtained  from  the  centre  of  the  wound 
bed.  The  data  was  standardised  by  analysing  the  positively  stained  cells  in  the 
vascularised  areas  of  the  sections. 
5.1.2  Specimen  preparation 
For  the  majority  of  histochemical  methods  the  technique  of  cutting  sections  on  a 
cryostat  and  allowing  them  to  thaw  to  room  temperature,  maintains  good 
morphological  relationships,  and  produces  minimal  changes  to  biological  structures. 
This  method  was  first  described  by  Simpson  in  1941,  (Simpson  WL,  1941),  and  was 
based  on  the  quenching  of  the  tissue  in  Isopentane  in  liquid  nitrogen  to  inhibit 
autolysis,  prevent  putrefaction,  diffusion,  dissolution  of  substances  within  the  tissues, 
and  the  formation  of  large  ice  crystals. 179 
5.1.3  Immunohistochemical  processing  of  the  slides 
The  purpose  of  fixation  is  to  preserve  all  the  components  of  the  tissue  in  their  true 
situation  without  diffusion  and  also  minimize  tissue  damage  from  osmosis.  For 
immunohistochemistry,  the  antigen  to  be  localized  must  be  made  insoluble  but 
available  for  reaction  with  the  applied  antibody. 
Acetone  is  a  protein  precipitant  fixative.  It  precipitates  proteins  by  destroying  the 
hydrophobic  bonds  that  hold  the  tertiary  (three  dimensional)  structure  of  the  protein 
molecules.  The  primary  and  secondary  structures  of  the  protein  are  left  intact,  so  the 
amino  acid  sequences  acting  as  antigens  remain  available  for  antigen-antibody 
reaction  to  occur.  Hence  it  is  suitable  when  the  antigen  is  a  large  protein.  Acetone 
fixation  also  allows  a  wide  range  of  of  primary  antibodies  to  be  used  without 
destroying  the  epitopes  they  are  trying  to  identify.  (Bankcroft  JD  and  Cook  HC.  1994) 
Formaldehyde  fixatives  are  cross  linkers,  i.  e  they  form  links  between  reactive  end- 
groups  of  adjacent  protein  chains.  Such  proteins  can  only  retain  their  antigenicity  if 
the  cross-linking  does  not  affect  the  amino  acid  sequences  that  bind  to  the  antibody. 
Cross  linking  fixatives  are  often  essential  for  fixing  small  proteins  which  are  so 
soluble  that  they  tend  to  diffuse  and  disperse  and  hence  not  long  enough  to  be  made 
insoluble  by  precipitant  fixatives.  (Pearse  AGE  1980,  Hopwood  D.  1985,  Puchtler  H 
and  Meloan  SN.  1985,  Fox  CH  et  al.  1985) 
Both  fixatives  have  been  tested  for  this  study  and  it  was  found  that  acetone  fixation 
yielded  the  best  results,  and  hence  the  formaldyhyde  results  were  not  discussed  in  this 
thesis. 
The  techniques  of  immunohistochemistry  currently  used  today  owe  much  to  the 
extensive  work  done  by  key  researchers  over  the  last  sixty  years.  One  of  the  most 180 
significant  influence  in  its  development  was  a  paper  by  Coons  et  al,  in  1941 
describing  the  fluorescent-labeled  antibody  technique.  (Coons  AH  et  al.  1941).  Whilst 
useful  in  some  diagnostic  areas,  such  as  determining  the  nature  of  protein  deposits  in 
renal  and  skin  diseases,  it  had  its  limitations.  One  of  its  main  drawback  was  its 
difficulty  to  demonstrate  morphological  details  of  cells. 
Enzyme  labeling  of  antibodies  followed  by  the  appropriate  substrate/chromogen 
mixture  such  as  DAB  reported  by  Nakane  and  Pierce  in  1966,  overcame  this 
disadvantage  as  the  labeled  cells  could  be  counterstained  with  traditional  nuclear 
stains  such  haemotoxylin.  (Nakane  PK  and  Pierce  GB  1966) 
The  Streptavidin/biotin  technique  used  in  this  study  is  currently  the  most  popular 
system.  This  consists  of  a  tetravalent  glycoprotein  from  egg  white  which  has  a  high 
affinity  for  biotin.  The  biotin  can  then  be  linked  to  specific  antibodies  without  causing 
any  loss  in  their  specific  binding  activity.  This  amplifies  the  presence  of  the  antigen 
without  increasing  the  background  staining  (Hsu  SM,  1990  Hsu  SM  et  al.,  1981) 
5.1.4  Analysis 
Previously  work  from  this  unit  has  demonstrated  that  there  are  low  numbers  of 
macrophages  in  undamaged  normal  skin  specimens  when  compared  to  acute  wounds 
(with  a  mean  count  of  10.8  positive  cells  per  x  40  hpf,  when  compared  to  a  mean 
count  of  44.6  positive  cells  per  x  40  hpf  in  acute  wounds)  (Boyce  DE,  2000). 
This  study,  demonstrates  that  macrophages  are  present  in  large  numbers  in  both  acute 
and  chronic  wounds,  as  demonstrated  by  the  large  number  of  cells  stained  by  the  pan- 
macrophage  marker  CD68,  but  the  subpopulation  of  macrophages  can  vary.  There  are 
significantly  (Mann  Whitney  U  test)  large  numbers  of  early  stage  macrophages 181 
(27e  10+'  cells)  within  the  acute  wounds  when  compared  to  chronic  wounds  (ps  0.01) 
and  significantly  larger  numbers  of  tissue  macrophages  (SW'  cells)  within  the 
chronic  wounds  when  compared  to  the  acute  wounds  (ps  0.01).  The  number  of 
primed  macrophages  (MR+ve  cells)  is  present  in  large  numbers  in  both  wound  types. 
This  suggests  that  both  wound  types  demonstrate  an  array  of  macrophage 
subpopulations.  In  the  acute  wounds,  one  might  postulate  that  there  seems  to  be  a 
continuous  influx  of  monocytes.  These  differentiate  into  early  stage  macrophages 
expressing  the  27e10  antigen,  which  become  primed  expressing  the  MR  antigen. 
These  primed  cells  then  become  activated  secreting  growth  factors  or  becoming 
directly  involved  in  the  healing  process,  and  removed  from  the  wound  environment, 
allowing  more  room  for  further  monocyte  infiltration  from  the  blood  stream.  This 
could  explain  the  presence  of  a  small  number  of  tissue  macrophages  observed  within 
acute  wounds. 
In  the  chronic  wounds  however,  the  primed  macrophages  fail  to  undergo  activation 
and  hence  mature  into  SR+'  tissue  macrophages.  Cassidy  et  al  in  1989  and  Perry  et  al 
in  1992  have  already  suggested  possible  roles  for  this  subset  of  macrophages.  They 
function  by  adhering  to  other  cells  in  the  wounded  tissue  and  help  to  minimise  the 
tissue  damage  by  activated  granulocytes.  They  aid  in  the  clearance  of  senescent 
neutrophils  within  chronic  wounds,  and  through  their  direct  receptor-cell  interaction, 
influence  cells  such  as  lymphocytes  and  thymocytes,  influencing  the  behaviour  of 
these  cells  in  chronic  inflammation.  These  cells  may  also  act  in  an  unknown  manner 
that  is  still  unclear  at  present  by  preventing  or  reducing  further  influx  of  monocytes 
into  the  wound  area.  This  is  reflected  in  this  study  by  the  presence  of  small  numbers 
of  early  stage  macrophages  in  chronic  wounds.  (Cassidy  LF  et  al  in  1989,  Perry  VH  et 
al.,  1992). 182 
5.2  DERMAGRAFT  STUDY 
The  Unna  boot  produced  in  the  19`h  century  was  the  first  recorded  bandage 
specifically  designed  to  apply  compression  to  the  lower  leg.  The  bandage  is 
impregnated  with  zinc  oxide  which  reduces  the  bacterial  load  within  the  leg  ulcers 
and  increases  the  inflammatory  response  in  granulation  tissue,  and  applied  in  a  spiral 
pattern  with  a  50%  overlap  (Agren  MS  et  al.,  1993).  Compression  therapy  in  one  form 
or  the  other  has  been  the  main  stay  of  patient  treatment  for  venous  leg  ulcers  and  has 
proved  to  be  the  most  effective  non-invasive  treatment  to-date.  (Falanga  V,  1993, 
Partch  H,  1995,  Blair  SD  et  al.,  1998) 
When  conservative  therapy  with  compression  fails,  attempts  at  wound  closure  have 
included  the  correction  of  the  underlying  venous  insufficiencies  and  autologous  split- 
thickness  skin  grafting,  but  these  involve  increased  costs  and  hospitalisation  (Lofgren 
KA  et  at.,  1965,  Cikrit  DF  et  al.,  1988).  As  these  patients  tend  to  be  more  elderly  they 
may  suffer  from  other  co-morbid  conditions  which  may  play  a  role  in  the  chronicity 
of  the  ulcers  and  limit  the  type  of  invasive  surgery  that  can  be  performed. 
Major  technical  advances  in  tissue  engineering  over  recent  years  have  made  it 
possible  to  culture  human  keratinocytes  in  laboratory  conditions.  Such  autologous 
sheets  of  keratinocytes  have  been  used  in  the  treatment  of  venous  leg  ulcers  with 
encouraging  results  (Leigh  IM  et  al.,  1987,  Phillips  TJ  et  al.,  1992). 
There  are  several  limitations  to  the  use  of  cultured  keratinocytes,  (or  cultured 
epidermal  autografts  -  CEA). 
1.  It  can  take  up  to  three  weeks  to  obtain  sufficient  amounts  of  CEA  sheets  for 
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2.  The  average  `take'  of  these  grafts  is  less  than  split  skin  grafts  (Phillips  TJ  and 
Gilchrist  BA.  1992) 
3.  The  graft  `take'  is  worst  in  areas  of  high  pressure  or  shear  forces  *  which  is 
believed  to  be  due  to  the  inadequate  formation  of  epidermal  keratinocyte 
anchoring  fibrils  and  the  absence  of  rete  ridges 
4.  Marked  wound  contracture,  and 
5.  The  high  cost  of  graft  production. 
There  have  been  more  promising  results  with  the  incorporation  of  dermal  components 
to  CEA  cultures.  This  seems  to  improve  the  take  and  reduce  contraction  of  the  grafts 
(Couno  CB  et  al.,  1987,  Odessey  R,  1992).  There  are  some  commercially  available 
dermal  substitutes,  -  ApligrafFM,  Alloderm 
,  and  Integra,  which  provide  the 
dermal  component  to  increase  adherence  of  CEA  (Falanga  V  et  al.,  1998,  Wainwright 
D  et  al.,  1996,  Heimbach  D  et  al.,  1988,  Freedlander  E,  1998,  Pomahac  B  et  al.,  1998, 
Hansborough  JF  and  Franco  ES,  1998). 
DermagraftTM(DG),  "a  tissue  engineered  human  replacement  has  previously  been 
shown  to  improve  healing  in  diabetic  patients  with  plantar  foot  ulcers.  It  is  believed 
that  DG  stimulates  healing  in  this  group  of  patients  by  providing  metabolically  active 
products  such  as  matrix  proteins  and  growth  factors  directly  to  the  wound  bed 
(Gentzkow  GD  et  al.,  1996.  ). 
It  has  been  postulated  in  chapter  2  of  this  thesis  that  DG  might  exhibit  the  same 
stimulatory  effect  in  achieving  healing  in  other  recalcitrant  wounds  such  as  venous  leg 
ulcers. 
There  was  a  need  for  a  controlled  trial  to  assess  the  efficiency  of  DG  on  venous  leg 
ulcer  patients  and  to  monitor  the  selected  biological  markers  in  this  thesis.  This  was 184 
assessed  by  applying  the  DG  pieces  to  the  wound  bed  and  the  conventional  therapy  of 
compression  in  the  form  of  a  four-layer  compression  bandage  in  the  promotion  of 
healing  venous  leg  ulcers.  This  was  compared  with  four-layer  compression  alone.  It 
was  also  important  to  try  and  determine  the  optimal  treatment  dose  of  DG  in 
achieving  wound  closure.  Studies  in  patients  with  diabetic  foot  ulcers  have 
demonstrated  that  weekly  application  of  DG  for  at  least  eight  weeks  is  needed  to 
achieve  healing  (Naughton  G  et  al.,  1997,  Pollack  RA  et  al.,  1997), 
5.2.1  Patient  population 
The  sample  size  in  each  treatment  arm  of  the  study  was  small;  this  being  further 
reduced  by  patient  withdrawal,  insufficient  biopsy  size,  and  the  availability  of  paired 
biopsy  samples. 
Although  in  total,  5  out  of  the  6  centres  contributed  27  patients  for  this  study,  Cardiff 
contributed  26  patients  (almost  50%)  of  the  study  population.  This  may  be  because 
Cardiff  is  one  of  the  few  tertiary  multidisplinary  specialist  referral  centres  in  the  UK 
and  have  a  greater  patient  catchment  when  compared  to  the  other  centres  recruiting 
patients  in  a  hospital  setting. 
However,  it  was  noted  that  the  median  ulcer  size  and  median  duration  of  the  study 
ulcer  were  of  similar  magnitude  for  all  study  groups  indicating  a  patient  population  of 
those  with  `harder  to  heal'  venous  ulcers. 
The  results  demonstrate  that  the  largest  number  of  patients  that  achieved  complete 
wound  closure  were  treated  with  12  or  4  pieces  of  DG  (5/13  and  5/13  respectively). 
This  is  compared  to  only  2/13  in  the  control  group  that  was  treated  with  compression 
only.  This  is  similarly  reflected  in  a  greater  reduction  in  the  size  of  the  ulcer  at  week 185 
12  for  the  12  and  4  pieces  of  DG  groups  (81.4  and  88.6%  respectively).  The  control 
group  demonstrated  a  reduction  in  the  ulcer  size  in  only  78.1%. 
Considering  that  DG  is  an  expensive  product,  the  4  pieces  of  DG  regime  (group  2) 
would  be  the  best  suggested  treatment  that  achieves  the  most  economic  response  both 
in  terms  of  healing  and  cost. 
It  is  suggested  that  for  the  future  pivotal  study  for  DG  treatment  of  venous  leg  ulcers, 
4  pieces  of  DG  would  be  the  prescribed  treatment  regime. 
5.2.2  Safety 
The  most  commonly  reported  adverse  event  for  the  patients  was  wound  infection. 
Wound  infection  was  assessed  by  the  criteria  described  by  Cutting  and  Harding  in 
1994  (Cutting  K  and  Harding  KG,  1994).  This  accounted  for  49%  of  all  noted  adverse 
events.  However  there  were  no  significant  differences  in  these  adverse  events  between 
the  treatment  groups  or  the  control  group. 
Diagnosis  of  wound  infection  was  a  clinical  observation  made  by  the  investigators  at 
the  various  centres  and  any  treatment  instigated  was  in  accordance  with  the  local 
practice  of  these  centres.  Wounds  were  not  routinely  swabbed  as  numerous  authors 
have  published  data  suggesting  that  all  wounds  if  swabbed  would  demonstrate  the 
presence  of  bacteria.  Wound  colonisation  is  not  always  the  same  as  invasive  infection, 
thus  raising  the  reliability  of  wound  swabs  in  these  situations  (Chesham  J  and  Platt  D, 
1987,  Trengrove  NJ  et  al.,  1996,  Thomson  PD  and  Smith  DJ  Jr,  1994.  ).  Although 
efforts  have  focused  on  identification  and  quantification  of  organisms  involved,  the 
predictive  value  of  this  variable  is  limited.  It  has  also  been  found  that  large  acute 
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thought  that  the  most  useful  method  for  determining  the  microbial  load  and  the 
presence  of  invasive  pathogens  in  a  wound  is  to  biopsy  the  wound  when  there  is  a 
clinical  suspicion  of  infection.  (Fowler  E.  1998,  Neil  JA  and  Munro  CL.  (1997). 
However  the  validity  and  the  value  of  single  biopsy  specimen  in  chronic  wounds  is 
debatable  (Schnieder  M  et  al.  1983),  traumatic  to  the  patient  and  facilities  for  the 
analysis  of  such  tissue  are  not  widely  available. 
A  more  accurate  predictor  of  colonisation  or  infection  is  the  behaviour  of  the  wound 
and  hence  careful  and  frequent  assessment  of  the  patient  and  the  wound,  as  practised 
in  this  study,  can  forecast  when  the  offending  organisms,  their  toxins  or  both  reach 
sufficient  concentrations  to  overwhelm  the  individual  hosts'  defences.  Thus  it  was 
decided  in  this  study  to  rely  on  the  experiences  of  the  clinical  investigators  rather  than 
a  laboratory  test  to  diagnose  wound  infection. 
Submitting  the  patients  to  more  biopsies  to  possibly  qualify  wound  infection  was  not 
thought  to  be  suitably  ethical. 
DG  being  a  bioengineered  product  may  stimulate  an  inflammatory  response  which 
might  be  incorrectly  interpreted  as  wound  infection.  However  the  application  of  DG 
onto  the  wound  bed  did  not  adversely  affect  the  infection  rate  in  the  treated  groups 
compared  to  the  control  group. 
5.2.3  Histological 
Sampling  times  can  affect  the  results  of  any  study.  Our  histological  sampling  times 
had  been  chosen  at  weeks  0  and  6.  This  allowed  for  a  reliable  histological  base  sample 
and  the  best  time  frame  in  which  to  observe  the  effects  of  DG  as  demonstrated  by 
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5.2.3.1  Wax  sections 
Extracellular  matrix  (ECM)  and  collagen  distribution 
Chronic  wounds  such  as  venous  leg  ulcers  usually  contain  large  amount  of  fibrin 
intercalated  among  the  collagen  bundles,  and  are  particularly  prominent  around  the 
vessels  forming  a  fibrin  cuff.  It  has  been  proposed  that  the  perivascular  fibrin  cuffs 
inhibit  the  diffusion  of  oxygen  form  the  blood  vessels  to  the  tissues,  and  thus  impede 
wound  repair  (Burnand  KG  and  Browse  NL,  1982).  Fibrin  cuffs  have  been  shown  to 
become  highly  cross  linked  to  the  collagen  bundles.  (Mosesson  MW  et  al.,  1989, 
Shainoff  JR  et  al.,  1991,  Siebenlist  KR  and  Mosesson  MW,  1992)  The  matrix  exhibits 
reduced  porosity  preventing  cell  penetration,  reduced  susceptiblity  to  fibrinolysis,  and 
alter  the  interaction  between  the  cells  and  the  cytokines  (Brommer  EJP  and  Van 
Bocke  LJH,  1992).  It  has  also  been  proposed  that  the  fibrin  cuffs  may  trap  growth 
factors  and  hinder  their  distribution  into  the  wound  (Falanga  V  and  Eaglestein  WH, 
1993),  thus  the  wound  environment  essentially  becomes  nutritionally  depleted  without 
function. 
By  introducing  Dermagraft  with  its  fresh  stock  of  fibroblasts  producing  proteolytic 
enzymes  and  growth  factors,  may  first  trigger  proteolysis  of  the  ECM  and  stimulate 
the  wound  to  heal.  Histologically,  this  may  result  in  the  patchy  appearance  of  the 
ECM,  as  seen  in  the  biopsies  of  those  patients  who  eventually  had  a  reduction  in  the 
size  of  their  ulcer  or  complete  closure,  in  this  study. 
A  correlation  was  observed  between  the  depth  of  collagen  deposit  at  the  base  of  the 
ulcer  and  healing.  The  presence  of  a  'dense  scar'  (described  as  orientated  fibres 188 
composed  of  densely  packed  fine  collagen)  correlated  with  a  reduction  in  the  ulcer 
size  and  wound  closure.  In  surgical  wounds,  such  as  pilonidal  excisions  which  were 
allowed  to  heal  by  secondary  intention,  it  has  been  shown  that  as  healing  progresses, 
the  depth  of  the  collagenous  layer  increased  significantly  over  time  and  accounted  in 
part  to  the  reduction  in  the  wound  volume  (Berry  DP,  1997).  Similar  increases  in  the 
collagen  layer  at  the  base  of  venous  ulcers  (described  as  orientated  fibres  composed  of 
densely  packed  fine  collagen),  seen  in  this  study,  may  contribute  to  the  reduction  in 
the  volume  of  the  ulcers. 
Blood  vessels 
In  acute  tissue  injury  destruction  and  disruption  of  the  cells  causes  proteolytic 
enzymes  to  be  released  into  the  connective  tissue.  This  degrades  the  ECM  and  causes 
fragmentation  of  the  basement  membrane  (Kalebic  T  et  al.,  1983).  This  allows 
endothelial  cells  to  migrate  into  the  wound  in  response  to  fibroblast  growth  factor 
(FGF),  fibronectin  fragments,  heparin,  and  other  endothelial  cell  chemoattractants.  As 
the  endothelial  cells  migrate  into  this  environment,  they  form  tubes  and  facilitate 
adhesion  and  migration  of  the  neovascularature.  The  FGF  and  other  mitogens 
stimulate  endothelial  proliferation  (Folkman  J  and  Klagsbrun  M,  1987),  resulting  in  a 
continual  supply  of  endothelial  cells  for  capillary  extension.  Capillary  sprouts 
eventually  branch  at  their  tips  and  join  others  to  form  capillary  loops  and  capillary 
plexuses.  Histologically,  these  plexuses  will  be  randomly  distributed  within  the  tissue. 
It  has  been  demonstrated  in  this  study  that  a  random  distribution  of  blood  vessels  in 
the  biopsy  specimens  was  related  to  a  decrease  in  the  wound  volume.  However  due  to 189 
the  small  number  of  patients  in  each  group,  this  observation  was  not  statistically 
significant  in  any  of  the  four  groups  or  to  the  dosage  regime  of  DG. 
Patients  who  received  4  pieces  of  DG  also  exhibited  a  higher  number  of  blood  vessels 
at  week  6  compared  to  week  0,  than  the  other  three  groups.  This  was  related  to  wound 
closure  or  in  the  reduction  of  the  ulcer  size  (p<0.05) 
As  stated  before,  prominent  fibrin  cuffing  around  the  vessels  impairs  wound  healing. 
In  this  study  although  the  degree  of  fibrin  cuffing  did  not  change  markedly  between 
the  two  time  periods,  a  low  proportion  of  fibrin  cuffing  either  at  week  0  or  week  6 
was  associated  with  a  reduction  in  ulcer  size. 
Bergan  et  al.  in  2001,  demonstrated  that  if  the  amount  of  fibrin  cuff  around  blood 
vessels  could  be  inhibited,  in  their  case  with  the  application  of  Daflon(R),  the  amount 
of  fibrin  cuffing  is  reduced  and  this  is  seen  clinically  by  acclerated  healing  of  venous 
ulcers.  (Bergan  JJ  et  al.,  2001)  This  study  supports  the  findings  observed  in  this  thesis. 
5.23.2  Frozen  Sections 
Cell  Pattern  and  Distribution 
Neutrophils 
An  early  event  in  healing  wounds  is  the  migration  of  neutrophils  into  the  wound 
environment,  closely  followed  by  monocytes,  but  as  there  are  more  neutrophils  in  the 
circulation,  they  appear  in  the  wounded  tissue  in  greater  numbers.  A  variety  of 
chemotactic  agents  attract  both  cell  types  to  the  site  of  injury  (Williams  TJ,  1988). 
Neutrophils  destroy  any  foreign  contamination  or  bacteria  via  phagocytosis  and 190 
subsequent  enzymatic  and  oxygen  free  radical  mechanisms  (Tonnesen  MG  et  al., 
1988,  Elsbach  P  and  Weiss  J,  1992,  Klebanoff  SJ,  1992).  Neutrophil  infiltration 
usually  ceases  within  a  few  days,  and  most  of  the  neutrophils  become  trapped  within 
the  eschar,  which  sloughs  during  tissue  regeneration.  As  healing  progresses  there  is  a 
resolution  of  the  mononuclear  inflammatory  response.  Persistent  wound 
contamination  with  debris,  foreign  bodies  or  bacteria  results  in  a  persistent  neutrophil 
inflammatory  response  and  their  accumulation  in  chronic  wounds.  They  may continue 
to  produce  enzymes  such  as  elastase  that  breakdown  connective  tissue  and  impair 
wound  healing.  As  healing  proceeds,  there  is  a  reduction  in  the  mean  number  of 
neutrophils  in  acute  wounds  (Hofer  HP  et  al.,  1994).  In  this  study,  there  was  a  gradual 
reduction  in  the  mean  number  of  neutrophils  within  the  chronic  wound  between  week 
0  and  week  6  biopsies,  but  it  was  not  related  to  a  reduction  in  the  ulcer  size  or  wound 
closure.  The  maximum  reduction  in  the  mean  number  of  neutrophils  was  seen  in  the 
control  group.  DG  on  the  wound  surface  in  the  treatment  groups  may  continue  to 
stimulate  the  presence  of  neutrophils  in  the  tissue  environment  as  it  is  a  foreign 
material.  Thus  is  reflected  in  the  slower  reduction  of  neutrophil  counts  in  the 
treatment  group. 
5.2.4  Inflammatory  Cells 
5.2.4.1  Lymphocytes 
Lymphocytes  comprise  a  significant  proportion  of  the  mononuclear  cell  infiltrate,  but 
little  is  known  of  the  role  of  these  cells  in  the  healing  process.  They  are  a 
heterogenous  group  with  a  wide  variety  of  functions.  Natural  Killer  (NK)  cells  are  a 191 
small  part  of  the  lymphoid  pool  and  are  concerned  with  viral  and  tumour  immunity.  B 
lymphocytes  are  responsible  for  the  `antibody-mediated'  immunity,  and  T 
lymphocytes  for  `cell-mediated'  immunity. 
B  lymphocytes 
Martin  and  Muir  in  1990,  suggested  that  these  cells  are  not  routinely  present  in  human 
wounds,  but  their  data  was  limited  to  biopsies  obtained  from  wounds  at  day  1  and  day 
3  (Martin  CW  and  Muir  IF,  1990.  ). 
In  this  study,  small  mean  counts  of  CD  19+'  B  lymphocytes  were  present  in  chronic 
wounds  both  before  and  after  treatment,  and  there  was  a  non  significant  increase  in 
the  mean  count  of  CD19+`'e  B  lymphocytes  at  Week  6.  The  significance  of  the 
presence  of  B  lymphocytes  within  wounded  tissue  is  still  unclear. 
It  could  be  postulated  that  their  presence  is  related  to  ongoing  wound  contamination 
of  some  type.  This  could  be  due  to  the  progressive  colonisation  of  bacteria  in 
wounded  tissue.  It  is  known  that  some  bacterial  polysaccharides,  polymeric  proteins 
and  lipopolysaccharides,  called  `thymus  independent  (TI)'  antigens,  may  exhibit  an 
intrinsic  activity  which  can  stimulate  proliferation  and  differentiation  of  B 
lymphocytes  in  the  absence  of  T  lymphocyte  helper  cells.  (Janeway  C  and  Travers  P, 
1996) 
If  infection  and  chronicity  were  the  main  reasons  for  their  presence,  then  one  would 
expect  to  find  a  large  mean  count  of  B  lymphocytes  within  the  chronic  wounds.  The 
small  mean  count  of  CD194'  B  lymphocytes  at  week  0  and  its  increase  at  week  6 
were  more  obvious  in  the  treatment  groups  and  hence  one  could  postulate  that  their 
continued  presence  be  due  to  some  unknown  effect  of  DG  on  the  wound  bed. 192 
In  1998,  Cowin  et  al,  demonstrated  the  presence  of  B  lymphocytes  in  adult  murine 
wound  tissue  but  not  in  foetal  wounds  (Cowin  AJ  et  at.,  1998).  They  postulated  that  B 
lymphocytes  contributed  to  the  fibrotic  healing  seen  in  adults,  but  which  was  absent  in 
foetal  healing.  Thus  the  rise  in  the  numbers  of  B  lymphocytes  at  week  6  when 
compared  to  week  0  in  our  patients  may  reflect  similar  roles  for  these  cells  in  the 
wound  healing  process.  It  is  known  human  adult  cutaneous  wound  healing  results  in 
the  formation  of  scar  tissue,  and  the  B  lymphocytes  may  aid  the  formation  of  the 
fibrotic  scar  tissue  by  a  yet  unrecognised  mode  of  action.  This  view  however,  is  in 
conflict  with  the  `standard'  opinion,  which  assumes  that  B  lymphocytes  have  no  role 
in  wound  healing  (Schaffer  M  and  Barbul  A,  1998,  Martin  CW  and  Muir  IF,  1990) 
T  lymphocytes 
The  potential  role  for  T-lymphocytes  in  wound  healing  have  largely  been  limited  to  in 
vivo  studies  on  murine  models  (Peterson  JM  et  al.,  1987,  Fishel  RS  et  al.,  1987, 
Barbul  A,  1988).  Total  depletion  of  T  lymphocytes  demonstrates  a  reduction  in 
collagen  and  thus  the  mechanical  strength  of  wounds.  The  selective  depletion  of  CD8+ 
lymphocytes  result  in  enhanced  wound  healing.  Depletion  of  CD4+  lymphocytes 
demonstrated  no  significant  delay  in  wound  healing.  The  authors  concluded  that  CD8+ 
lymphocytes  were  responsible  for  a  `down-regulation'  of  the  healing  process.  Other 
authors  have  shown  that  CD4+  lymphocytes  or  their  cytokines  are  responsible  for  the 
`up-regulation'  of  wound  healing  in  rat  epitenon  models  (Wojciak  B  and  Crossan  JF, 
1994). 
It  has  been  demonstrated  in  this  study  that  there  is  an  increase  in  the  mean  count  of 
CD3+  (pan  T  lymphocyte  marker)  at  week  6  when  compared  to  week  0  in  those 193 
groups  treated  with  four  or  more  pieces  of  DG  and  the  control  group.  The  increase  in 
the  treated  groups  may  be  related  to  repeated  dosage  of  DG  when  compared  to  a 
single  dosage  at  week  0,  but  the  increase  in  the  control  group  seems  more  difficult  to 
explain.  The  significance  of  this  finding  remains  unclear. 
The  relatively  unequivocal  changes  in  the  CD4+  and  CD8+  cells  in  response  to 
treatment  may  be  a  reflection  of  the  chronicity  of  the  wound.  This  is  reflected  by  the 
low  CD4:  CD8  ratios  in  this  study.  Boyce  et  al,  demonstrated  that  the  mean  CD4:  CD8 
ratio  in  chronic  wounds  were  low  when  compared  with  acute  healing  wounds  which 
initially  have  a  high  ratio  reducing  to  lower  levels  as  healing  proceeds.  The  mean 
CD4:  CD8  ratio  in  undamaged  skin  seems  to  be  of  similar  magnitude  to  chronic 
wounds.  (Boyce  DE  et  al.,  2000) 
The  similarities  in  the  ratios  between  undamaged  skin  and  chronic  wound  as 
demonstrated  in  this  study,  suggests  that  DG  does  not  regulate  T  lymphocytes  in 
chronic  wounds  but  mediate  wound  closure  by  other  mechanisms,  possibly  by 
providing  the  necessary  cytokines. 194 
5.2.4.2  Macrophages 
Macrophages  are  known  to  be  essential  for  normal  healing.  Their  initial  role  is  in  the 
inflammatory  and  debridement  phase  before  fibroplasia  (Jiang-Ping  C  et  at.,  1991, 
Nielsen  BW  et  at.,  1994).  They  then  become  the  predominant  cell  prior  to  fibroblast 
proliferation  and  it  has  been  demonstrated  that  they  play  a  major  role  in  the 
orchestration  of  wound  repair  (Riches  DWH,  1996). 
Large  numbers  of  macrophages  have  been  shown  to  be  present  in  acute  and  chronic 
wounds  when  compared  to  undamaged  skin.  (Boyce  DE,  2000)  The  pilot  study 
demonstrated  that  there  is  an  accumulation  of  early  stage  macrophages  within  acute 
wounds  when  compared  to  chronic  wounds,  and  a  significant  accumulation  of  tissue 
macrophages  within  the  chronic  wounds  when  compared  to  acute  wounds. 
In  this  study,  the  different  macrophage  sub-populations  within  the  four  groups  prior  to 
initiation  of  treatment  was  of  similar  magnitude. 
At  Week  6,  it  can  be  seen  that  in  general  the  mean  count  of  early  stage  macrophages 
increased  in  all  four  groups  with  the  greatest  increase  observed  amongst  those  patients 
treated  with  four  pieces  of  DG.  When  comparing  the  changes  in  the  mean  count  of 
tissue  macrophages  at  Week  6,  there  seems  to  be  a  general  reduction  in  the  counts 
with  a  maximal  reduction  seen  in  those  patients  treated  with  four  pieces  of  DG. 
The  increase  in  the  early  stage  macrophages  and  a  decrease  in  the  tissue  macrophages 
in  all  four  groups  may  also  be  due  to  the  compression  therapy  all  the  patients 
received.  This  study  however,  demonstrates  an  observable  increase  in  the  early  stage 
macrophages  and  a  decrease  in  the  tissue  macrophages  in  the  treated  group  (maximal 
in  Group  2),  suggesting  that  DG  must  contribute  to  the  `switching'  of  chronic  wounds 
to  acute  status,  encouraging  healing  to  take  place.  It  can  also  be  inferred  from  the 195 
results  that  application  of  DG  at  regular  intervals  provides  the  necessary  local 
favourable  environment  for  healing  to  take  place. 196 
5.2.4.3  Cytokines 
Cytokines  are  regulatory  proteins  with  an  array  of  names  which  has  arisen  because  of 
co-  discovery  by  several  different  investigators  in  different  inflammatory,  and  non- 
inflammatory  cells  at  similar  times.  The  term  cytokine  is  the  most  general  definition 
and  not  restricted  to  the  immunohaemopoietic  system  (Cohen  S  et  al.,  1974). 
Macrophages  play  multiple  roles  in  both  the  degradative  and  reparative  phases  of 
wound  healing.  They  regulate  the  various  phases  of  wound  healing  by  producing  an 
array  of  cytokines  which  have  the  potential  to  improve  wound  healing  by  several 
mechanisms 
(1)  Attraction  of  inflammatory  cells  and  fibroblasts  into  the  wound  via  the  secretion 
of  chemotactic  agents 
(2)  Stimulate  cellular  proliferation  by  acting  as  mitogens 
(3)  Stimulate  angiogenesis  and  regulate  the  in  growth  of  new  blood  vessels 
(4)  Have  an  important  effect  on  the  production  and  degradation  of  extracellular 
matrix,  and 
(5)  Influence  the  synthesis  of  other  or  identical  cytokines  and  growth  factors  by 
neighbouring  cells.  (Greenhalgh  DG,  1996) 
The  more  important  cytokines  involved  in  wound  healing  such  as  those  targeting 
mesenchymal  cells,  regulating  neovascularisation,  remodeling  were  assessed  between 
wound  bed  sections  at  week  0  and  week  6. 197 
Tumour  Necrosis  Factor  (TNFa) 
TNFa,  a  pro-inflammatory  cytokine  is  released  primarily  by  the  macrophage  lineage. 
It  is  crucial  in  initiating  the  immune  cascade  during  the  host  response  to  injury  or 
bacteria.  TNFa  is  involved  in  the  recruitment  and  maturation  of  the  cellular 
component  of  inflammation,  «fiich  includes  the  up-regulation  of  cell-surface  adhesion 
molecules  that  plays  a  vital  role  in  the  immune  cell  to  endothelium  interaction,  thus 
facilitating  neutrophil  chemotaxis  (Omann  GM  and  Hinshaw  DB,  1997,  Moser  R  et 
al.,  1989). 
Its  main  effects  include  haemostasis,  increased  vascular  permeability  and 
proliferation.  It  also  promotes  many  cellular  metabolic  events  that  increase  the  supply 
of  nutrient  substrates  and  acute-phase  protein  synthesis  essential  for  wound  healing 
(Fong  Y  and  Lowry  SF,  1996). 
Feiken  et  al,  in  1995,  observed  that  TNFa  levels  are  usually  detected  in  acute 
experimental  wounds  in  the  mouse  model  after  12  hours  post  wounding,  peaking  at  72 
hours,  and  then  tailing  off  quite  rapidly  (Feiken  E  et  al.,  1995) 
Excessive  production  of  TNFa  has  been  demonstrated  to  lead  to  adverse  clinical 
outcomes  such  as  cahexia  in  cancer  patients  and  some  of  the  severe  effects  seen  in 
gram  negative  sepsis  (Larrick  JW  and  Kunchel  SL,  1988).  It  is  partly  mediated 
through  the  recruitment  and  activation  of  neutrophils,  (Bevilacqua  MF  et  al.,  1986, 
NawtiToth  PP  and  Stern  DM,  1986).  In  this  situation,  the  cells  are  responsible  for 
increased  tissue  damage  through  the  production  of  proteolytic  enzymes  and 
arachidonic  acid  metabolites  (Striter  RM  et  al.,  1990,  Tracey  KJ  et  al.,  1988). 
Rapala  et  al  demonstrated  that  TNFa  reduced  granulation  tissue  ingrowth  after  7  days 
in  acute  experimental  wounds  in  a  dose-dependent  manner,  but  the  effects  were  not 198 
long  lasting.  Similarly,  Buck  et  al.  observed  that  chronically  elevated  levels  of  TNFa 
in  rats  impaired  wound  healing,  but  these  effects  were  partially  reversed  by  the 
addition  of  a  TNFa  anatgonist  in  another  study  (Rapala  K  et  al.,  1991,  Buck  M  et  al., 
1996) 
Wallace  and  Stacey  demonstrated  no  cause  effect  relationship  between  elevated  levels 
of  TNFa  in  non-healing  verses  healing  venous  leg  ulcers  in  humans  (Wallace  HJ  and 
Stacey  MC,  1998). 
In  this  study  low  concentrations  of  TNFa  (as  demonstrated  by  the  weak  staining  of 
the  antibody)  were  seen  within  wound  beds  at  week  0  and  week  6,  in  all  four  groups, 
irrespective  of  any  wound  size  reduction  or  treatment.  Murphy  et  al  has  illustrated  that 
compression  therapy  can  result  in  wound  closure,  and  reduce  the  TNFa  levels  within 
the  wound.  Hence  the  low  TNFa  levels  observed  in  this  study  at  week  0  and  week  6 
may  be  due  to  compression  therapy  which  preceded  DG  application  by  two  weeks  and 
DG  itself  may  have  no  effect  on  the  level  of  TNFa  in  the  wound  environment 
(Murphy  MA  et  al.,  2002) 
Interleukin  1-beta  (ELI  O) 
ILl-ß  is  primarily  produced  by  cells  of  the  macrophage  lineage,  and  by  keratinocytes 
in  active  wounds  (Sauder  DN  et  al.,  1990,  Goretsky  MJ  et  al.,  1996).  It  is  also 
produced  by  endothelial  cells,  fibroblasts  and  smooth  muscle  cells.  It  activates 
neutrophils,  upregulates  adhesion  molecules,  promotes  chemotaxis  and  supports 
endothelial  cells  to  secrete  pro-inflammatory  cytokines  (Fong  Y  and  Lowry  SF,  1996, 
Loppnow  H  et  al.,  1998). 199 
IL1-ß  become  detectable  within  the  first  24  hours  after  injury,  and  peaks  between  the 
first  and  third  day,  declining  rapidly  to  undetectable  levels  within  seven  days 
(Goretsky  MJ  et  al.,  1996,  Fahey  TJ  et  al.,  1990). 
Several  studies  have  demonstrated  that  elevated  levels  of  IL1-ß  contribute  to  wound 
chronicity,  thus  the  early  beneficial  effects  of  IL1-ß  in  wound  healing  becomes 
disturbed  if  high  levels  persists  after  the  first  week  (Trengove  NJ  et  al.,  2000,  Barone 
EJ  et  al.,  1998).  Work  from  the  author's  laboratories,  has  demonstrated  that  high 
levels  of  IL1-ß  correlates  with  the  non-healing  status  of  venous  leg  ulcers  (personal 
communication). 
In  this  study,  IL1-0  staining  was  shown  to  be  more  intense  than  TNFa,  and  is 
concentrated  within  the  cells  in  the  perivascular  area.  In  group  2,  (those  patients 
treated  with  four  pieces  of  DG)  there  is  a  reduction  in  the  intensity  of  staining  for  IL  1- 
0  at  week  6  when  compared  to  week  0.  This  group  has  a  higher  proportion  of  patients 
with  healed  wounds  compared  to  the  control  group.  Patients  in  group  1(those  that 
received  twelve  pieces  of  DG)  who  also  had  a  higher  proportion  of  healed  wounds, 
did  not  demonstrate  a  similar  reduction  in  the  intensity  of  staining  for  IL  I0  at  week  6 
when  compared  to  week  0  however.  As  stated  previously,  fibroblasts  produce  IL  I  P. 
The  positive  staining  for  IL!  ß  in  this  group  of  patients  (Group  1)  may  actually 
originate  from  fibroblasts  that  are  present  in  DG  that  is  applied  onto  the  wound  bed 
weekly  rather  than  endogenous  production  of  ILIß  within  the  stimulated  wound  bed. 
Vascular  Endothelial  Growth  Factor  (VEGF) 
VEGF  is  released  by  macrophages  and  fibroblasts  in  wounded  tissue  (Frank  S  et  al., 
1999).  The  levels  rise  reaching  detectable  levels  in  the  acutely  wounded  tissue  at  24 200 
hours.  The  levels  continue  to  rise  steadily  during  the  first  week  peaking  at  about  day 
5,  then  fall  becoming  almost  undetectable  by  the  end  of  the  second  week.  The  main 
trigger  for  the  production  and  release  of  VEGF  is  thought  to  be  wound  hypoxia  and 
nitric  oxide  production  (Nissen  NN  et  al.,  1998). 
The  exogenous  administration  of  VEGF  has  demonstrated  an  improvement  in 
granulation  tissue  formation  in  normal  and  hypoxic  experimental  wounds  (Corral  CJ 
et  al.,  1999). 
Other  cytokines  can  affect  the  production  and  effects  of  VEGF.  It  has  been  recently 
demonstrated  that  high  levels  TNFa  can  down  regulate  the  production  of  VEGF 
within  a  wound  (Patterson  C  et  al.,  1996,  Guo  DQ  et  al.,  2000). 
A  recent  study  by  Inoki  et  al,  demonstrated  that  the  angiogenic  effects  of  VEGF  can 
be  neutralised  by  adding  connective  tissue  growth  factor  to  recombinant  VEGF.  When 
this  mixture  is  injected  in  to  mice  no  neovascularisation  is  seen  (Inoki  I  et  al.,  2002). 
VEGF  may  contribute  to  the  angiogenic  stimulus  in  wounds  either  by  direct  effects  on 
the  proliferating  and  migrating  endothelial  cells  or  indirectly  by  affecting  persistent 
permeability  at  the  level  of  existing  microvessels  (Nissen  NN  et  al.,  1998).  Hence, 
VEGF  production  and  VEGF-mediated  angiogenic  activity  would  arise  in  the  early 
hypoxic  wound  and  then  fall  when  neovascularisation  is  complete  or wound  perfusion 
is  restored,  but  may  also  be  reduced  if  high  levels  of  TNFa  were  present. 
In  this  study,  VEGF  staining  was  found  to  be  distributed  in  the  peri-vascular  tissue 
with  no  staining  of  the  vascular  endothelial  lining  itself. 
Group  2  demonstrates  a  reduction  in  the  staining  intensity  at  week  6  compared  to 
week'  0.  This  may  be  because  adequate  wound  perfusion  is  restored  resulting  in  a 
larger  number  of  healed  wounds,  and  the  stimulus  for  continued  VEGF  production  is 
switched  off.  In  the  small  proportion  of  those  wounds  that  remained  unhealed  in  this 201 
group,  one  might  postulate  that  factors  other  than  perfusion  are  preventing  the  wounds 
from  achieving  closure. 
In  group  1,  DG  may  provide  a  continuous  reservoir  of  VEGF  and  no  detectable 
decrease  in  the  intensity  of  staining  is  demonstrated  within  the  week  6  samples. 
The  low  grade  in  the  intensity  of  staining  of  VEGF  in  all  groups  suggests  that  VEGF 
may  not  be  needed  in  large  concentrations  to  stimulate  angiogenesis  and  other  growth 
factors  present  in  the  wound  environment  may  also  have  angiogenic  effect. 
Basic  Fibroblast  Growth  Factor  (bFGF) 
FGF,  is  a  family  of  proteins  that  play  an  important  role  as  mediators  of  wound 
angiogenesis  and  epithelialisation.  The  most  potent  of  these  is  bFGF  (Adzich  N, 
1997).  bFGF  is  released  by  macrophages  and  endothelial  cells  and  stimulate  fibroblast 
and  keratinocytes  proliferation  and  migration  (Mustoe  TA  et  al.,  1991,  Hebda  PA  et 
al.,  1990).  It  promotes  endothelial  cell  growth  and  migration  that  is  essential  for 
angiogenesis,  prevents  wound  contraction  and  plays  an  essential  role  in  collagen 
remodelling  (Finetti  G  and  Farina  M,  1992,  Ono  I  et  al.,  1999). 
In  acute  wounds,  bFGF  levels  peak  in  the  post  wounding  period,  falling  to  near  non- 
detectable  levels  24  hours  later  (Nissen  NN  et  al.,  1996). 
It  is  believed  that  bFGF  is  stored  in  many  cells  in  the  uninjured  tissue  and  is  released 
into  the  wound  when  these  cells  become  destroyed  as  a  result  of  direct  injury  or  by 
enzymes  such  as  thrombin.  This  would  explain  the  sudden  release  of  bFGF  in 
response  to  injury  (Cordon-Cordo  C  et  al.,  1990,  Muthukrishnan  L  et  al.,  1991,  Ben- 
Ezra  M  et  al.,  1993).  This  is  further  supported  by  the  absence  of  secretory  signal 
peptides  in  the  cells  that  store  these  proteins  (Jaye  M  et  al.,  1986). 202 
In  this  study,  intense  bFGF  staining  was  visualised  in  the  area  adjacent  to  the  blood 
vessels,  and  sometimes  it  can  be  seen  to  highlight  the  endothelial  lining.  There  also 
seems  to  be  a  small  increase  in  the  staining  intensity  in  the  sections  of  the  control 
group  and  Group  3,  at  week  6  when  compared  to  the  week  0.  This  could  be  due  to  the 
continued  presence  within  the  wound  environment  products  such  as  bacterial 
degradation  products  or  proteases  which  damages  cells.  In  those  groups  that  received 
more  frequent  dosing  of  DG,  bFGF  levels  reduced  slightly.  This  could  be  due  the 
presence  of  neo-bFGF  produced  by  the  fibroblasts  in  DG. 
Transforming  Growth  Factor  "ß  (TGF(3) 
In  adults  wounded  cutaneous  tissue  heals  by  scarring.  TGF(3  is  generally 
acknowledged  to  be  the  cytokine  with  the  broadest  range  of  activities  in  the  repair  of 
injured  tissue,  as  a  variety  of  cells  produce  and  /or  respond  to  it  (Roberts  AB  and 
Sporn  MB,  1990). 
TGFß  is  the  general  name  for  the  family  of  naturally  occurring  polypeptides  which 
have  receptors  on  virtually  every  cell  and  exerts  multiple  regulatory  effects  on  cell 
proliferation  and  differentiation  (Cox  DA,  1995). 
It  is  released  in  the  form  of  a  large  latent  complex  from  the  a-granules  of  platelets, 
when  they  degranulate  in  the  presence  of  thrombin.  It  stimulates  the  migration  of 
monocytes,  lymphocytes,  neutrophils,  and  fibroblasts  in  a  dose-response  manner 
(Wahl  SM  et  al.,  1987,  Postlethwaite  AE  et  al.,  1987,  Adams  DA  et  al.,  1991,  Brandes 
ME  et  al.,  1991). 
In  rats,  injury  releases  stored  TGF(3  from  degranulating  platelets.  Subsequently,  injury 
induced  expression  of  early  genes  contributes  to  further  production  and  release  of 203 
TGFß  (Wang  JY  and  Johnson  LR,  1994).  Thus  levels  of  TGFP  remains  high  upto  14 
days,  peaking  on  days  7  to  9  post  injury  (Cromack  DT  et  al.,  1987). 
Three  isoforms  exists  in  mammals,  designated  TGFß-1,  TGFß-2,  and  TGFß-3.  It 
induces  the  production  of  procollagen  type  1  and  fibronectin,  and  inhibits 
metalloproteinases.  The  net  effect  is  an  increased  deposition  of  collagen 
(Krishnamoorthy  L  et  al.,  2001). 
Wysocki  et  al,  in  1993,  demonstrated  that  wound  fluid  obtained  from  chronic  wounds 
to  have  abnormally  raised  levels  of  metalloproteinases  and  low  levels  of  growth 
factors  such  as  TGF(3  which  aids  in  the  healing  process,  compared  to  acute 
mastectomy  wound  fluid  (Wysocki  AB  et  al.,  1993). 
In  this  study,  however  prominent  TGF3  staining  was  found  within  the  ground 
substance  that  made  up  the  granulation  tissue  and  blood  vessels  were  specifically 
negatively  stained.  There  was  a  small  increase  in  the  levels  of  TGF(3  in  response 
toDG  in  the  treatment  groups  when  compared  to  the  control  group.  This  supports  our 
initial  concept  that  once  a  wound  attains  certain  amount  of  stimulation  (in  Group  3, 
one  dose  of  DG),  it  can  trigger  a  positive  chain  reaction  that  stimulates  healing. 204 
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Knowledge  of  events  which  make  up  the  inflammatory  response  in  wound  healing  is 
still  limited.  The  inflammatory  phase  of  healing  is  the  first  and  essential  stage  in  the 
healing  process,  and  it  can  be  assumed  that  cells  that  participate  in  this  response  can 
influence  subsequent  healing.  After  neutrophils,  the  major  cellular  constituent  of 
healing  is  the  macrophage.  The  hypothesis  underlying  this  thesis  stems  from  animal 
studies  which  have  shown  that  macrophages  play  a  vital  role  in  the  orchestration  and 
execution  of  both  the  degradative  and  the  reparative  phase  of  wound  healing.  It  was 
thus  assumed  that  one  of  the  major  differences  between  acute  and  chronic  wounds 
may  involve  differences  in  the  sub-population  of  wound  macrophages  and  hence 
differences  in  the  level  of  their  activation  within  the  wounded  tissue. 
In  the  first  part  of  this  thesis,  (pilot  study),  it  has  been  shown  that  more  macrophages 
are  present  in  wounded  tissue  than  normal  skin  and  different  sub-population  of 
macrophages  are  indeed  present,  with  an  accumulation  of  early  macrophages  within 
the  acute  wound  and  an  accumulation  of  tissue  macrophages  within  the  chronic 
wounds. 
In  the  next  step  of  the  thesis,  The  DG  study  was  aimed  to  observe  the  changes  in 
chronic  wounds  in  response  to  the  application  of  DG  onto  the  wound  bed  in  a  12  week 
study  period,  and  whether  it  was  safe  to  use  in  this  sub-population  of  patients. 
This  was  a  feasibility  study,  with  63  eligible  patients  screened,  and  53  patients  being 
randomised  into  the  four  arms  of  the  study. 
It  had  been  possible  to  show  that  treating  the  wound  with  DG  12  or  4  pieces  resulted 
in  more  wounds  healing  completely  by  week  12,  compared  to  compression  therapy 
alone. 
No  major  safety  issues  were  identified  concerning  the  use  of  DG.  The  most 
commonly  reported  adverse  event  was  infection,  but  this  phenomenon  was  not 206 
uncommon  in  patients  with  venous  leg  ulcers.  There  were  no  notable  differences  in 
the  safety  profiles  of  the  four  treatment  regimens. 
Histologically,  DG  seemed  to  result  in  the  patchy  appearance  of  the  ECM,  as 
visualised  in  the  biopsies  of  those  patients  who  eventually  had  a  reduction  in  the  size 
of  their  ulcer  or  complete  closure,  but  this  appearance  did  not  seem  to  be  dose 
dependent.  The  reason  for  this  observable  trend  remains  unclear. 
DG  increased  the  level  of  collagen  and  this  correlated  with  a  reduction  in  the  ulcer 
size  and  wound  closure  in  some  patients.  In  those  patients  treated  with  4  or  more 
pieces  of  DG  showed  a  greater  number  of  blood  vessels  at  week  6  in  the  wound  when 
compared  to  controls.  It  was  also  noted  that  a  more  random  orientation  of  blood 
vessels  correlated  with  increased  ulcer  healing,  conversely,  perpendicular  alignment 
correlated  with  decreased  wound  healing,  but  DG  had  no  visible  effect  on  the 
orientation  of  the  vessels. 
Although  there  was  a  general  reduction  in  the  neutrophil  count  in  all  treatment  groups 
at  week  6  when  compared  to  week  0,  the  most  significant  reduction  in  the  mean 
neutrophil  count  was  seen  in  the  control  group.  Although  the  reason  for  this  is 
unknown,  one  can  postulate  that  DG  itself,  an  allogenic  material  may  have  stimulated 
or  produced  chemoattractants  for  neutrophils. 
There  seemed  to  be  no  significant  changes  in  the  level  of  lymphocytes  at  the  two  time 
frames  in  the  four  treatment  groups,  but  there  was  a  significant  accumulation  of  early 
stage  macrophages  and  a  significant  reduction  the  mean  count  of  tissue  macrophages 
in  those  patients  treated  with  4  pieces  of  DG. 
There  also  seemed  to  be  very  little  change  in  the  levels  of  cytokines  within  the  wound 
bed  at  the  two  time  frames.  One  may  conclude  that  the  ubiquitous  presence  of 
proteinases  within  the  wound  bed  may  have  hydrolysed  some  of  the  cytokines 207 
produced  by  the  application  of  DG  onto  the  wound,  and  a  hence  noticeable  change 
was  not  apparent. 
As  each  piece  of  DG  was  quite  expensive,  the  above  trends  seemed  to  suggest  that 
treatment  with  a  four-piece  regimen  of  DG  may  be  sufficient  to  achieve  wound 
closure  and  hence  form  the  dose  regimen  for  further  pivotal  studies.  The  pivotal  study 
utilising  a  large  patient  population  has  now  been  commenced  worldwide. 208 
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7.1  APPENDIX 257 
Reagents 
Tris  Buffered  Saline  (TBS) 
DAB  enzyme  substrate  working  solution  from  DAKO  DAB  tablet 
Preparation  of  Vectastain  working  reagents 258 
TRIS  Buffered  Saline  (TBS) 
Dissolve  80g  sodium  chloride  and  6.05g  of  TRIS  in  9  litres  distilled  water  and  adjust 
pH  to  7.6,  if  necessary  with  IM  HCI.  Make  up  volume  to  10  litres  with  distilled  water. 
DAB  enzyme  substrate  working  solution  from  DAKO  DAB  tablets 
1.  TRIS  Buffer  0.005MpH7.6 
Dissolve  1.52g  TRIS  in  50mis  distilled  water.  Add  1M  HCl  to  pH  7.6.  Make 
volume  to  250mis 
2.  Preparation  ofstock  solution 
Allow  bottle  containing  DAB  tablets  to  reach  room  temperature  from  the 
freezer.  Disslove  one  tablet  in  10ml  0.005M  TRIS.  Aliquot  in  lml  volumes 
and  store  at 
-20°C. 
3.  Preparation  of  working  substrate 
For  use,  thaw  out  lml  of  stock  solution  and  add  7.5pl  freshly  prepared  3% 
H202  (Stock  H202  30%,  so  1:  10  dilution  made  immediately  before  use). 
Preparation  of  Vectastatin  working  reagents 
Blocking  serum: 
Add  30µ1  of  stock  serum  to  2mls  TRIS 259 
Biotinylated  anti-mouse  Ia.  - 
To  I  ml  of  the  diluted  blocking  serum  add  Sµl  of  stock  biotinylated  anti-mouse  Ig 
ABC  reagent 
Add  20µl  of  reagent  A  to  Iml  of  TRIS,  mix,  and  add  20µ1  of  reagent  B.  Mix 
immediately  and  leave  to  stand  for  approximately  30  minutes  before  use. 260 
7.2  APPENDIX 261 
SOURCE  OF  TUE  EXPERIMENTAL  MATERIALS 
Poly  -L  -  lysine  Sigma-Aldrich  Ltd.,  Dorset, 
UK 
Cryo-Med  mounting  medium 
ABC  Elite  Kit 
DAB  (diaminobenzidine) 
Erlich's  Haematoxylin 
70%  alcohol 
Xylene 
DPX 
Bright  Instrument  Co.  Ltd., 
Cambridgeshire,  UK 
Sigma-Aldrich  Ltd.,  Dorset, 
UK 
Dako®  Ltd 
High  Wycombe,  UK 
BDH  Laboratory 
Supplies,  Poole,  UK 
Fisher  Scientific 
Loughborough,  UK 
Ltd., 
BDH  Laboratory  Supplies, 
Poole,  UK 
BDH  Laboratory  Supplies, 
Poole,  UK 262 
TNNmonoclonal  mouse)  Dr  WG  Jiang 
Department  of  Surgery 
University  of  Wales 
College  of  Medicine 
CD  3  (monoclonal  mouse,  clone  UCHTI)  Dako®  Ltd 
High  Wycombe,  UK 
CD4  (monoclonal  mouse,  clone  MT310)  Dako®  Ltd 
High  Wycombe,  UK 
CD8  (monoclonal  mouse,  clone  DK25)  Dako®  Ltd 
High  Wycombe,  UK 
CD19  (monoclonal  mouse,  clone  HD37)  Dako®  Ltd 
High  Wycombe,  UK 
CD45  (monoclonal  mouse,  clone  2B11)  Dako®  Ltd 
High  Wycombe,  UK 
CD68  (monoclonal  mouse,  clone  EBM11)  Dako®  Ltd 
High  Wycombe,  UK 
27e10  (mouse  monoclonal,  Clone  27e10)  BMA  Biomedical  AG®, 
Switzerland 263 
Mannose  (monoclonal  mouse) 
Sialoadhesin(monoclonal  mouse) 
Von  Willibrand  Factor  (polyclonal  rabbit) 
Dr.  P  Stahl,  St.  Louis, 
Missouri,  USA 
Dr  P  Crocker, 
University  of  Dundee 
Dundee,  UK 
Chemicon®  International 
Europe  Ltd 
Hampshire,  UK 
Neutrophil  Elastase  (monoclonal  mouse,  Clone  AHN-14)  PharMingen  International 
Cowley,  Oxford,  UK 
IL  -6  (monoclonal  rat,  clone  MQ2-6A3)  PharMingen  International 
Cowley,  Oxford,  UK 
Il  -  8(monoclonal  goat) 
11  -  10  (monoclonal  rat,  clone  JEs3-19F1) 
R&D  Systems, 
Abington,  UK 
PharMingen  International 
Cowley,  Oxford,  UK 264 
MMP9  (polyclonal  rabbit)  Calbiochem- 
Novabiochem®, 
International,  Cambridge, 
UK 
ILIA  (monoclonal  mouse,  clone  BI)  R&D  Systems, 
Abington,  UK 
bFGF  (monoclonal  mouse,  clone  3H3)  Calbiochem-NovabiochemO, 
International,  Cambridge,  UK 
TGFD  (monoclonal  rat,  clone  A75-2.1)  PharMingen  International 
Cowley,  Oxford,  UK 
VEGF  (monoclonal  mouse,  clone  G153-694)  PharMingen  International 
Cowley,  Oxford,  UK 
Anti-goat  IgG,  Anti-rabbit  IgG,  Anti-mouse  IgG  Sigma  -  Aldrich  Ltd., 
Dorset,  UK 